

AUTHOR INDEX

VOLUME 42

- Aarestrup, Frank M., 3331
 Abbott, Karen H., 813
 Abdel-Rahman, Susan M., 2706
 Abe, Kenji, 1340
 Abe, Koh, 1866
 Abe, Shigeru, 1587
 Abudullah, Noor Rain, 37
 Achour, Ammar, 2482
 Adams, John M., 409, 821
 Addis, Antonio, 1336
 Adebiyi, Antoinette-Mary A., 502
 Adrian, Peter V., 2221
 Aeschlimann, Jeffrey R., 254, 721, 981, 2188, 2710
 Agnaniet, H., 540
 Agusse-Germon, Stéphanie, 369
 Aguilar, C., 1601
 Aguilar, L., 1574
 Aguilar, Lorenzo, 1361
 Ahmad, Imran, 767
 Aihara, Miki, 1895
 Aikawa, Masamichi, 1985
 Air, Gillian M., 801
 Aitken, Ingrid A., 83
 Akasaka, Takaaki, 1284
 Akeb, Fatima, 2656
 Akiyama, Yohko, 2492
 Al-Abdely, Hail M., 2542
 Alak, Ala, 2391
 Alangaden, George J., 1295
 Alaoui-Jamali, Moulay A., 779
 Alarcón, Balbino, 2668
 Alcaide, Fernando, 2792
 Alcalá, Luis, 2452
 Alcina, Antonio, 2668
 Alder, J. D., 2385
 Alder, Jeffrey D., 2674
 Al-Hattawi, K., 2799
 Alifano, Pietro, 571
 Allan, Paula W., 1045
 Allery, A., 2125
 Allignet, Jeanine, 1794
 Alliot, Pierre, 1093
 Allococo, Alessandra, 1745
 Almela, M. J., 2863
 Al-Mohsen, Ibrahim, 2399
 Alonso, M. A., 1306
 Alós, Juan-Ignacio, 989
 Alovero, Fabiana, 1495
 Alpert, Nathaniel M., 2048
 Amano, Ken-ichi, 1895
 Ambrosetti, P., 2966
 Amicosante, Gianfranco, 1459
 Amoroso, Ana M., 228
 Amsden, Guy W., 695, 927, 1578
 Amyes, Sebastian G. B., 2221
 Anaissie, Elias, 1512
 Anaissie, Elias J., 129, 606
 Ananth, Sandya L., 801
 Anderson, Barry D., 1815
 Anderson, Jennifer, 1985
 Anderson, Kevin P., 971
 Andersson, Siv G. E., 1845
 Andes, D., 2375
 Andrei, Graciela, 216, 3285
 Andreoni, Massimo, 2017
 Andreou, Roseann, 1336
 Andrés, María T., 3022 .
- Andrews, J. M., 428
 Angarano, Gioachino, 1346
 Angus, P. W., 3130
 Annaert, Pieter, 1568
 Annis, Charles G., 2456
 Ansorg, R., 725
 Anton, K. E., 1620
 Antonakis, Kostas, 779
 Aoki, Hiroyuki, 3251
 Aoki, Miho, 1666
 Aouad, Arlette, 1295
 Appelbaum, P. C., 624, 1503
 Appelbaum, Peter C., 495, 589, 857, 953, 1253, 1263, 1269, 2002, 2459, 2914, 3028, 3032
 Appelmelk, B. J., 3073
 Aquino, A., 550
 Araki, Sei-Ichi, 1298
 Arata, Jirō, 3141
 Araujo, Fausto G., 2284
 Archer, Gordon L., 306, 1355
 Ardanuy, Carmen, 53, 1636
 Argème, Maxime, 1093
 Argenson, Jean Noel, 3086
 Arimilli, Murty N., 1568
 Ariza, Javier, 53
 Arlet, Guillaume, 464, 2352
 Arnett, Gussie, 1045
 Arnfinnsson, Jóhann, 2290
 Arpin, C., 2125
 Arranz, M. E., 618
 Asahi, Yasuko, 2267
 Asai, Masaki, 2178
 Asaka, Masahiro, 1895
 Ashton, C. H., 1256
 Astier, Alain, 2141
 Atkinson, Jill D., 682
 Aubry-Damon, Hélène, 2590
 Augustijns, Patrick, 1568
 Austria, Natasha E., 88
 Avery, Mitchell A., 1454
 Aymon, D., 2966
 Azad, Abu F., 1845
 Azad, Raana F., 971
 Azijn, Hilde, 269
 Azoulay-Dupuis, Esther, 862
 Babczynski, Peter, 2197
 Babich, John W., 2048
 Babini, Gioia S., 1168
 Babu, Y. Sudhakar, 801
 Bacchi, Cyrus J., 2718
 Bacher, John, 2399, 2700, 2898
 Bader, Augustinus, 1052
 Baillie, A. J., 2722
 Baillie, George S., 1900, 2146
 Bajaksouzian, Saralee, 3032
 Bajic, Marina, 2495
 Bajic, Miroslav, 2495
 Baker, Carol J., 1517
 Bakker-Woudenberg, Irma A. J. M., 1677, 2431, 2437
 Bala, Shukal, 2336
 Balas, Delia, 2792
 Balcabao, I. P., 1574
 Baldanti, Fausto, 444
 Balis, Frank M., 1815, 3187
 Balkovec, James M., 1985
 Ballesta, Sofia, 1850
 Ballet, Jean J., 818
 Ballow, Charles H., 521
 Ballweber, L. M., 1239, 1726
 Baltch, Aldona L., 2405, 2564, 3153
 Balzarini, J., 618
 Banach, Mary, 631
 Banerjee, Goutam, 348
 Banerjee, Partha, 1105
 Bannam, Trudi L., 1563
 Banovic, Linda, 921
 Bantia, Shanta, 801
 Baquero, F., 3279
 Baquero, Fernando, 1042
 Baragwanath Ciprofloxacin Study Group, the, 2235
 Barbaut, X., 1731
 Barbet, J. P., 1334
 Barbuch, R., 1160
 Barchiesi, Francesco J., 151
 Bard, M., 1160
 Barditch-Crovo, Patricia, 2380
 Barenholz, Yechezkel, 3092
 Barg, Neil L., 3317
 Barker, Helen, 2171
 Barnaud, Guilene, 2352
 Barone, Joseph A., 1862
 Barret, John, 2391
 Barrett, John F., 1529
 Barrow, Esther L. W., 2682
 Barrow, William W., 2682
 Barry, A. L., 945
 Barry, Arthur L., 1213, 1274, 2138, 2765
 Barthélémy, Michel, 1323
 Bartlett, Marilyn S., 934
 Bartlett, M. S., 282
 Barzilai, Asher, 473
 Basco, Leonardo K., 1811, 2347
 Bassetti, Matteo, 2017, 3014
 Basu, Indira, 206
 Basu, Mukul K., 348
 Bataille, Jean Francois, 3086
 Bateson, J. H., 436
 Battersby, Luann C., 675
 Battisti, James M., 2906
 Bauchet, Jacqueline, 862
 Bauer, Madeline, 528
 Bauerfeind, Adolf, 514, 827
 Baum, Kenneth F., 1139
 Bayer, Arnold S., 1837, 3169
 Beauchamp, Belinda, 1315
 Bébérat, C., 703
 Bébérat, Cécile M., 2024, 2304, 2474
 Bébérat, Christiane, 2024, 2304, 2474
 Bébérat, C. M., 703
 Beccani-Argème, Mireille, 1093
 Bédos, Jean-Pierre, 862
 Behn, Ingrid, 1911
 Bejaoui, Noureddine, 1966
 Bekersky, Ihor, 263, 2391
 Bekkering, Michelle, 59
 Bell, Aaron, 2898
 Benali, Karim, 942
 Benbow, John W., 339
 Bender, Brendan C., 666
 Benedi, Vicente Javier, 1636, 1850
 Benhamou, P. H., 1334
 Bennett, John E., 1695
 Bennett, L. Lee, Jr., 1045
 Bennett, P. M., 436
 Berche, Patrick, 108
 Berg, Jeanne, 2784
 Berger-Bächli, Brigitte, 564, 936
 Bergeret, M., 1334
 Bergeron, Michel G., 2527, 3309
 Bergeron, Yves, 2527, 3309
 Bergsson, Gudmundur, 2290
 Berman, Adam L., 1098
 Bermudez, Luiz E., 180
 Bernberg, Erin L., 339
 Berry, Valerie, 3193
 Bertin, Philippe, 209
 Bertino, J. S., Jr., 1842
 Bertrand, Guylène, 1068
 Beteabenner, David, 3218
 Bethel, James, 631
 Beutner, Karl R., 789
 Beveridge, Terry J., 1476
 Bhachech, Niraja, 1671
 Bhakdi, Sucharit, 2569
 Bhattacharjee, Apurba K., 583
 Bhattacharya, M. K., 206
 Bhattacharya, S. K., 206
 Bhavnani, Sujata M., 521
 Bhinderwala, Naseema S., 1447
 Biava, Mariangela, 3035
 Bickii, Jean, 2347
 Biddle, James W., 3024
 Bierbaum, Gabriele, 154
 Bierman, Robert H., 1862
 Bijsterbosch, Martin K., 1146
 Bilello, J. A., 2153
 Bilello, P. A., 2153
 Bille, J., 2966
 Bille, Jacques, 241
 Billion, Marie A., 352
 Bingen, Edouard, 942
 Biot, C., 540
 Biron, Karen K., 444
 Bischofberger, Norbert, 612, 640, 647, 1568
 Björkman, Anders, 1222
 Blagburn, Byron L., 2877
 Blampain, G., 540
 Blanton, Ronald E., 601
 Blaser, Jürg, 895
 Blázquez, Jesús, 1042
 Bleton, Rémy, 2830
 Bleyzac, N., 1731
 Blokpoel, Marian C. J., 1931
 Blondelet-Rouault, Marie-Hélène, 2612
 Bloor, Stuart, 269
 Blouin, Robert A., 2602
 Bocanegra, Rosie, 2371, 2467, 2542
 Boden, Daniel, 2775
 Bodnar, Ulana R., 734
 Boldrini, E., 2434
 Boman, Nancy L., 45
 Bonab, Ali A., 2048
 Bonacorsi, Stephane, 942
 Bonati, Maurizio, 1336
 Bonay, Pedro, 2668
 Bonino, Alessandro, 1745
 Bonmassar, E., 550
 Bonnafous, Pascale, 2066
 Bonnefoy, Alain, 1392
 Bonner, Daniel P., 313

- Bopp, Lawrence H., 2564
 Bordon, Florence, 209
 Borel, Christelle, 369
 Borg, Natalia, 2174
 Borin, Marie, 3014
 Borner, K., 459
 Borner, Klaus, 1470
 Borucki, Michael J., 1139
 Boschman, Cynthia R., 734
 Boswell, Garry, 2391
 Boswell, Garry W., 263
 Botha, P. L., 2752
 Boucher, Bradley A., 930
 Boudjadja, A., 703
 Bouffard, F. Aileen, 1985
 Bouquet, Serge, 2756
 Bouthors, A. T., 3113
 Bouvier d'Yvoire, M. Y., 1731
 Bouza, Emilio, 2452
 Bové, Joseph M., 2304
 Bové, Joseph Marie, 2024
 Bowden, Raleigh A., 2584
 Bowker, K. E., 419
 Boyaka, Prosper N., 2607
 Boyer, Paul L., 447
 Boykin, David, 2495
 Boykin, David W., 2503, 2877
 Bracchi, Valerie, 2456
 Bracey, Dani, 2160
 Bradford, Patricia A., 1671, 1980
 Bradley, Suzanne F., 1305
 Braga, Pier Carlo, 18
 Brandt, M. E., 3242
 Branzoni, Manuela, 1931
 Brasseur, Philippe, 818
 Brasseur, Robert, 209
 Bray, Patrick G., 682, 2973
 Bredberg, Anders, 1923
 Breisch, S., 114
 Breitschwerdt, Edward B., 362
 Brener, Zigman, 2549
 Brenner, M. B., 550
 Brenwald, Nigel P., 2032
 Bret, L., 1110
 Breyer, Stefan, 2417
 Bridges, Edward G., 1799, 1805
 Brien, Jo-anne E., 1370
 Brink, Douglas N., 1073
 Brinkman, A. B., 2749
 Briones, Marcelo R. S., 2731
 Brocard, J., 540
 Brockman, A., 135
 Brooks, Jason V., 3047
 Brötz, Heike, 154
 Brown, Melissa H., 475
 Brown, Scott L., 583
 Brown, S. D., 945
 Brown, Steven D., 1213, 1274, 2138, 2765
 Bruce, A. Gregory, 1133
 Brück, W., 1397
 Brueckner, Ralf P., 675, 1293
 Brummer, Elmer, 907, 2299
 Brun, Reto, 2858
 Bruni, Carmelo Bruno, 571
 Bruno, Antonella, 2232
 Brun-Pascaud, Monique, 1068
 Buzzese, T., 3012
 Bryant, Martin L., 478
 Bryskier, A., 1944
 Bryskier, André, 965, 1509
 Bu, Ming, 487
 Bucci, Cecilia, 571
 Bucke, W., 459
 Buckheit, Robert W., Jr., 487
 Buckner, Frederick S., 3245
 Budhani, R. K., 2521
 Buell, Donald, 263, 2391
 Buiting, A., 1233
 Burkinsky, Michael I., 1133
 Burch, Daniel J., 589
 Burger, Richard M., 709
 Burgmann, Heinz, 2417
 Burke, John P., 1402
 Bush, Karen, 1671
 Bushman, F., 2245
 Butters, Jenny A., 2171
 Bye, A., 2153
 Byers, Thomas J., 2144
 Byrne, William R., 675
 Cacho, Juana, 989
 Callahan, Ronald J., 2048
 Callender, Diana, 2700
 Callender, Diana P., 2898
 Callery-D'Amico, Susan V., 885
 Calvo, Raquel, 1028
 Cambau, Emmanuelle, 2084
 Camp, Mary J., 3103
 Campa, M., 2434
 Campbell, David A., 1447
 Canada, Todd W., 930
 Caniça, M. Manuela, 1323
 Cantoni, Rita, 1931
 Cao, Guoliang, 2784
 Cao, Y., 2637
 Capa, Laura, 2694
 Capobianco, John O., 389
 Capparelli, Edmund, 808
 Cappelletty, Diane M., 721
 Carattoli, Alessandra, 3053
 Carbon, C., 289
 Carbon, Claude, 468, 862, 2607, 2830, 2950
 Carias, Lenore L., 963
 Carides, A., 223
 Carlone, Nicola A., 1745
 Caroff, Nathalie, 1323
 Carosi, Giampiero, 1346
 Carothers, Lori, 2784
 Carr, Robert A., 1176
 Carrano, Lucia, 571
 Cars, O., 2739
 Cars, Otto, 2365
 Carter, K. C., 2722
 Carvalho-Oliveira, Leonardo, 2549
 Casadevall, Arturo, 1437
 Casari, Salvatore, 1346
 Casassus, Philippe, 849
 Casazza Rosetta, 3014
 Casetta, Anne, 2074, 2889
 Casin, I., 3113
 Casin, Isabelle, 209
 Cassidy, Shawna M., 1878, 3146
 Catamo, G., 3000
 Cato, Allen III, 1788
 Cavaleyra, M., 3097
 Cavanaugh, John H., 3107
 Celandroni, F., 2434
 Cenjor, Carlos, 1361
 Centrón, Daniela, 1506
 Cerami, Anthony, 1133
 Cerneau, C., 2184
 Cerceno, Emilia, 2452
 Cerwinka, S., 1088
 Cesana, Marina, 2359
 Cevini, Claudia, 2232
 Chaibi, E. B., 1110
 Chakrabarti, Debopam, 2456
 Chalkley, L. J., 2752
 Chambers, Henry F., 3325
 Chanal-Claris, C., 1110, 2184
 Chanal-Claris, Catherine, 2771
 Chandrasekar, Pranatharthi H., 3018
 Chanock, Stephen, 2391
 Chantot, Jean-François, 1392
 Chapman, S., 2637
 Chapman, Stanley W., 978
 Charleston, Bryan, 83
 Charron, Alain, 2024, 2304, 2474
 Chau, Françoise, 1068
 Chauhan, Sharda, 2299
 Chaves, J., 1524
 Chelstrom, Lisa M., 383
 Chen, Chih-Ming, 3218
 Chen, Lan Bo, 1340
 Chen, Ming S., 640, 647
 Chen, Minjun, 2633
 Chen, V., 1397
 Chen, Xiaoqi, 3218
 Cheng, Angela, 521
 Cheng, Augustine F. B., 440, 3051
 Cheng, Darwin, 3169
 Cheng, Kit L., 927, 1578
 Cheng, Yung-Chi, 369, 833, 1799, 1805
 Cherrington, J. M., 1620
 Chevallier, Michèle, 369
 Chien, Shu-Chean, 885
 Chillemi, Antoinette C., 2923
 Chioldro, Francesco, 1346
 Cho, Eun Hee, 190
 Cho, Yoon, 2206
 Chodosh, S., 114
 Choi, Myeong Jun, 2534
 Cholody, Wieslaw M., 487
 Chopra, Ian, 3282
 Choromanska, Olga, 3315
 Chou, Jenny Wen-Lin, 3146
 Chow, Andrew T., 885, 1098
 Chow, Joseph W., 1229
 Chow, J. W., 705
 Chow, Lucien L., 3325
 Christ, William J., 2824
 Christofalo, Barbara, 2295
 Christophers, Jacqueline, 868
 Chu, Chung K., 369
 Chu, Daniel, 2674
 Chu, Yiu-wai, 440, 3051
 Chuang, Yin-Ching, 1319
 Chung, Gavin A. C., 795
 Chung, Whasun O., 3022
 Church, Joseph A., 3187
 Ciferrí, Oriol, 1931
 Cihlar, Ronald L., 2342
 Cirioni, O., 3320
 Citron, Diane M., 1127
 Claeys, Geert, 3329
 Clancy, Cornelius J., 509
 Clark, J. M., 3209
 Classen, David C., 1402
 Claydon, Elizabeth, 2919
 Clayton, Julie, 868
 Cleare, Wendy, 1437
 Clemons, Karl V., 899
 Clewell, Don B., 1229
 Climo, Michael W., 306, 1355
 Cloud, Gretchen A., 1139
 Clumeck, A. N., 903
 Clumeck, N., 223
 Cockerill, Franklin R., III, 202
 Coen, Donald M., 971
 Coffin, Jill M., 1447
 Cohen, Jeffrey D., 916
 Cohn, David, 631
 Coira, A., 1524
 Colaizzi, John L., 1862
 Cole, Peter J., 772
 Coleman, David C., 1819
 Collado, I., 1524
 Collatz, E., 3113
 Collatz, Ekkehard, 209
 Colledge, Danni, 2132
 Colledge, D. L., 3130
 Collins, Jerry M., 1592
 Collins, L., 1853
 Collins, L. A., 344
 Collins, Peter, 868
 Colonno, Richard J., 3200, 3209
 Cometta, A., 2966
 Conant, Marcus, 269
 Content, Jean, 483
 Contreras, Lellys M., 1771
 Conway, Sameul C., 3179
 Cook, Gregory, 959
 Cookson, Barry D., 502
 Coote, Peter J., 2160
 Cordeiro, Carol, 2511
 Cordingley, Michael G., 1629
 Corey, E. J., 2731
 Corey, G. Ralph, 3169
 Cormet-Boyak, Estelle, 2607
 Cornaglia, Giuseppe, 1459, 2848
 Cornu, Guy, 404
 Corrado, Michael, 1098
 Correia, John A., 2048
 Corti, Emiliana, 571
 Corvaisier, S., 1731
 Cossum, Paul A., 1646
 Coster, Trinka, 1293
 Côté-Richer, Mélanie, 3309
 Cotin, Agnès, 1093
 Coudron, Philip, 596
 Couet, William, 2756
 Courtois, Philippe, 2756
 Courvalin, Patrice, 2557, 2590, 2759
 Coutrot, Anne, 209
 Cove, Jonathan H., 1702
 Cox, J., 1256
 Coyette, Jacques, 534
 Craft, J. Carl, 1176
 Craig, W. A., 2375
 Craske, John, 868
 Crellin, Paul K., 1563
 Crémieux, Anne Claude, 2830
 Creti, Roberta, 712
 Cross, Alan S., 583
 Crowder, Michael W., 921
 Cruciani, Mario, 3014
 Crumpacker, Clyde S., 1139, 2326
 Cuffini, Anna Maria, 1745
 Cundiff, Eric, 715

- Cundy, Kenneth C., 647, 687, 2380
- Cunliffe, William J., 1702
- Curvale, Georges, 3086
- Cutright, Jessica L., 3018
- Cuvelier, Catherine, 468
- Cynamon, Michael H., 462, 3315
- Czarny, Agnieszka, 2495
- Dagan, Ron, 589
- Daikoku, Tohru, 2095
- Dalhoff, A., 1397, 2060
- Dalhoff, Axel, 1868
- Dal-Ré, R., 1574
- Danel, Franck, 3117
- Daniel, Barbra E., 528
- Dankert, Jacob, 319
- Dankner, Wayne, 808
- Darby, Graham, 868
- Dardenne, Olivier, 534
- D'Argenio, D. Z., 2153
- Dargis, Michèle, 3296
- Das, I., 428
- Dautrey, S., 289
- Dautrey, Sophie, 468, 2830
- Davidson, Terry G., 3103
- Davies, Todd A., 2914
- Davis, Kelly J., 675
- Davis, Patrick J., 2405
- de Azavedo, Joyce C., 2425
- de Barbeyrac, Bertille, 2474
- de Béthune, Marie-Pierre, 269, 3123
- Debets-Ossenkopp, Y. J., 2749
- De Baere, Thierry, 3329
- De Beule, Karel, 404
- Debier, M., 223
- de Cespèdes, Gilda, 2889
- De Clercq, E., 618
- De Clercq, Erik, 170, 216, 1568, 3285
- Declercq, R., 618
- Deeks, Steven G., 2380
- Deguchi, Takashi, 433, 3293
- DeHertoghe, Deborah A., 1139
- Deidda, Delia, 3035
- De La Campa, Adela G., 2792
- de las Heras, Federico Gómez, 2694
- Delbos-Bocage, Laurence, 2950
- Delling, Ulrike, 1034
- Delon, Annie, 2756
- Del Poeta, Maurizio, 2495, 2503
- DeLuca-Flaherty, Camille R., 1447
- Delucia, Jennifer L., 2122
- Dempsey, Walla L., 2336
- den Hollander, Jan G., 377, 744, 749
- Deniau, Michele, 2141
- Denning, David W., 873, 2726
- Dennis, Suzana, 2784
- De Pascalis, Roberto, 571
- DeRemer, Mary, 409, 821
- de Repentigny, Louis, 404
- De Ridder, K., 2070
- De Rossi, Edda, 1931
- Derouin, Francis, 1068
- Derse, David, 487
- Deslauriers, Anne-Marie, 2527
- De Smet, Koen A. L., 1931
- De Smet, M., 223
- Desmyter, J., 618
- Dessus-Babus, Sophie, 2474
- Deutsch, P., 223
- Deutsch, Paul J., 332
- De Wit, S., 223, 903
- Déziel, Robert, 1629
- Diall, O., 1012
- Diamond, DeAnn M., 528
- Diarra, B., 1012
- Diaz, J. A., 618
- Diaz-Mitoma, Francisco, 2996
- Dibirdik, Ilker, 383
- Di Bonaventura, G., 3000
- Dick, Christian, 2569
- Diderot, Vimala, 1115
- Dieterich, H.-J., 2421
- Dietze, Beate, 2440
- DiFrancesco, Robin, 409
- Ding, James C., 528
- Dinh, Nhu-Nguyen, 2206
- Dionisi, Anna Maria, 3053
- Dix, Suzanne P., 3103
- Dodge, Richard K., 2630
- Doern, Gary V., 1762
- Doern, G. V., 3242
- Doit, Catherine, 942
- Doktor, Stella Z., 88
- Domagala, John, 956, 2978
- Domarle, I., 540
- Dominguez, Juan Manuel, 2274, 2279
- Dominguez, María Angeles, 1636
- Domon, Haruki, 555, 785
- Donabedian, S., 705
- Donabedian, Susan M., 1229
- D'Onfro, Jennifer, 1959
- Dong, Yuzhi, 956, 2978
- Donisi, Alessandra, 1346
- Donnelly, Samantha M., 1819
- Donnenfeld, Alan E., 1336
- Donskey, Curtis L., 963
- Dorenbaum, Alejandro, 1315
- Dornseif, Bruce, 1098
- Dorr, M. B., 2262
- Doshi, Vatsal, 3269
- Douglas, John M., Jr., 789
- Douglas, L. Julia, 1900, 2146
- Dowling, Ruth, 772
- Dowzicky, M., 1088
- Drabick, Joseph J., 583
- Drain, Kathryn L., 2877
- Drancourt, Michel, 3086, 3301
- Drlica, Karl, 709, 956, 2978
- Dropinski, James F., 1985
- Droppert, R. M., 3266
- Drusano, George L., 358, 631, 1098, 1105, 1417, 1512, 2153, 2326
- Duan, Jianmin, 1629
- Dubin, Donald T., 2122
- Duboc De Almeida, Gisele Madeira, 2630
- Dubreuil-Lemaire, Marie Laure, 2141
- Duchene, Patrick, 2602
- Dudley, Michael N., 72
- Dufresne, Julien, 1245
- Dumas, Rafaële, 298
- Dunn, J. P., 2240
- Dunn, Michael, 1290
- Duong, Michel, 3309
- du Plessis, Mignon, 2221
- Dupont, C., 1334
- Dupret, Jean-Marie, 1323
- Duran, M., 2637
- Durán-Chica, Isabel, 2668
- Durand, Remy, 2141
- Dutschman, Ginger E., 1799, 1805
- Dykstra, Christine C., 2495, 2503
- Eady, E. Anne, 1702
- Easmon, C. S. F., 2799
- Eaton, K. A., 1549
- Ecker, David J., 2113
- Edmonds, Anthony, 1176
- Ednie, Lois M., 1269, 2459
- Edwards, David I., 1973
- Edwards, J., 903
- Edwards, Kathryn M., 1375
- Eerola, Erkki, 2443
- Egron, Marie-José, 779
- Ehlers, S., 459
- Ehrhardt, A. F., 1350
- Ehrhardt, Anton F., 596
- Eiffert, H., 277
- Eisenberg, Eugene J., 647
- Eisler, M. C., 1012
- El-Farrash, Mohamed, 1340
- Elford, Howard L., 2456
- Eliopoulos, G. M., 1088, 1520
- Ellison, W., 2262
- El Menyawi, Ibrahim, 2417
- El-Shourbagy, Tawakol, 2784
- el Soh, Névine, 1794
- Endo, Masahiro, 755
- Endoh, Y. S., 3333
- Enger, Cheryl, 2240
- Engler, Michael, 1151
- Englund, Kristin, 734
- Entenza, J. M., 1889
- Erdman, Keith, 2784
- Eriksson, Staffan, 2620
- Erlandsdóttir, Helga, 1005
- Erley, C., 2421
- Ernst, Erika J., 1207, 1382, 1387
- Ernst, Michael E., 1207, 1387
- Escarpé, Paul A., 640, 647, 3234
- Esnouf, R., 618
- Esperen, Frank, 377
- Espinel-Ingróff, A., 129, 282
- Estes, Randee, 2036
- Evans, Martin E., 727
- Ewing, Patty, 2674
- Ewing, P. J., 2385
- Ezzell, John W., 675
- Faccia, Bryan, 1783
- Fairfield, Alexandra, 1959
- Falconer, Derek, 2645
- Falconer, Derek J., 1695
- Falla, Timothy J., 3282
- Fantin, Bruno, 468
- Farinotti, R., 289
- Farinotti, Robert, 468, 2950
- Farley, Maureen, 3187
- Farley, Maureen Q., 1815
- Farnet, C. M., 2245
- Farris, M. G., 1088
- Fattorini, Lanfranco, 712
- Favenec, Loïc, 818
- Fayz, Shirin, 1654
- Feldman, Charles, 772
- Feldmesser, Marta, 1437
- Fenoll, Asunción, 2768
- Ferdinando, Dudley P., 2160
- Fernandez, Marisol, 1517
- Fernández-Roblas, Ricardo, 1028
- Ferraro, M. J., 1520
- Ferreira, Ludmila R. P., 2549
- Ferrua, Bernard, 654
- Feuerstein, Erwin, 2399
- Fey, Paul D., 306
- Field, Hugh J., 1555
- Fierro, José F., 3022
- Filler, Scott G., 2645
- Finegold, Sydney M., 984
- Fingeroth, Joyce D., 2923
- Finlay, B. Brett, 2511
- Fioravanti, Rossella, 3035
- Fiori, GianPaolo, 1346
- Firsov, Alexander A., 659, 2841, 2848
- Fischman, Alan J., 2048
- Fisher, L. Mark, 2810
- Fishman, Jay Alan, 995, 1309
- Fitoussi, Frederic, 942
- Fitzgibbon, Joseph E., 2122
- Fluit, Ad, 1249
- Flynn, Pat, 3157
- Follansbee, Stephen, 631
- Fontana, Roberta, 2055
- Foote, Edward F., 456
- Ford, Clyde D., 1402
- Forman, Michael, 2240
- Forrat, Rémi, 298
- Forrest, Alan, 521
- Forsgren, Arne, 1923
- Förster, Christian, 1470
- Fortney, Kate, 2690
- Foster, Tim J., 564
- Fothergill, Annette, 147
- Fourel, Isabelle, 1045
- Fournier, Bénédicte, 121, 2109
- Fowler, Cynthia L., 885, 1098
- Fowler, Vance G., Jr., 3169
- Fox, Terry L., 789
- Frame, Bill, 1783
- Franceschini, Nicola, 1459
- François, Patrice, 564
- Franke, Mary A., 3153
- Frankenburg, Shoshana, 3092
- Franz, Renate, 3065
- Franzblau, S. G., 344
- Frech, Gabriele, 1288
- Freifeld, Alison, 2391
- French, Gary, 2771
- French, Martyn, 3038
- Fresno, Manuel, 2668
- Freys, Guy, 425
- Fridland, Arnold, 612, 1484, 2656, 3157
- Friedland, Ian R., 199, 2650
- Friedlander, Arthur M., 675
- Frimodt-Møller, Niels, 377, 1706
- Frosch, Matthias, 1052
- Frost, David J., 389
- Froyman, Robrecht, 83
- Fuchs, P. C., 945
- Fuchs, Peter C., 1213, 1274, 2138, 2765
- Fuentes, F., 414
- Fuhr, Uwe, 2359

- Fujie, Akihiko, 37
 Fujihira, Shiro, 37
 Fujii, Nobuhiro, 1895
 Fujimoto, Keisaku, 1597
 Fujioka, Hisashi, 1985
 Fujita, Naohisa, 2150
 Fujiwara, Tamio, 1340
 Fukuda, Hideyuki, 1917, 2678
 Fukuoka, Takashi, 23
 Fung-Tome, Joan C., 313
 Furr, J. R., 2151
 Furuta, Takahisa, 37
 Furuya, Nobuhiko, 555, 1858, 2853
 Fuursted, Kurt, 377, 749
- Gaillot, Olivier, 2352
 Gama, Vivian, 1990
 Gangadharam, P. R. J., 1853
 Ganoza, M. Clelia, 3251
 Gantt, Soren M., 2731
 Gao, Hong-Qiang, 447
 Garcia, Isabel, 1850
 Garcia-Bermejo, Isabel, 989
 Garcia-Bustos, José F., 2694
 Garcia-Calvo, Gloria, 1028, 1361
 Garcia-Garrote, Fernando, 2452
 Garcíá-Rodriguez, J. A., 1306
 Gardovska, Dace, 1980
 Gargallo-Viola, D., 2863
 Garry, Louis, 1068, 2830
 Gate, John J., 83
 Gates, Hiriam, 545
 Gathmann, I., 135
 Gatti, Giorgio, 2017, 3014
 Gatti, Simonetta, 2232
 Gaudreau, Christiane, 1847, 2106
 Gauthier, Jean, 1629
 Gazoili, Maria, 1259, 1281
 Gazzard, Brian G., 293
 Gazzinelli, Ricardo T., 2549
 Geber, Antonia, 1695
 Geerts, S., 1012
 Geller, Robert B., 3103
 Gemperli, B., 135
 Gendrel, D., 1334
 Genovesi, E. V., 3209
 Georges, A. J., 540
 Georgiou, Marios, 2792
 Gerardo, Sharon Hunt, 1127
 Gerckens, Lynn S., 1996
 Gerin, John L., 2804
 Gerna, Giuseppe, 444
 Geryk, Bruce, 1542
 Geslin, Pierre, 942
 Ghaffar, Faryal, 2650
 Ghannoun, M. A., 282
 Ghannoum, Mahmoud A., 2645
 Ghate, Anita A., 801
 Ghelardi, E., 2434
 Ghuysen, Jean-Marie, 534
 Giacometti, A., 3320
 Giakkoupi, Panagiota, 1281
 Giamarellou, Helen, 939
 Gibreel, Amera, 3059, 3276
 Gieffers, Jens, 2762
 Gikas, Achilleas, 2747
 Gilbert, David N., 2259
 Gilbert, Deborah, 72
 Gilbert, Huguette, 2106
- Gill, Charles J., 1996
 Gill, Martin J., 2032
 Gill, M. J., 2799
 Gillis, T. P., 1853
 Gilmore, Claire E., 3103
 Giménez, María José, 1361
 Giménez, M. J., 1574
 Girard, Pierre-Marie, 1068
 Giraud, Annick, 1093
 Giri, Neelam, 2399, 2700
 Giuliani, A., 550
 Glatman-Freedman, Aharon, 1437
 Glauer, M. P., 1889, 2966
 Glick, Dvora, 3092
 Gnann, John W., Jr., 1139
 Gniadkowski, Marek, 514, 827, 3079
 Godwin, Karen, 1815
 Gold, H. S., 1088
 Goldberg, Burt, 2718
 Goldman, David L., 1437
 Goldman, Robert C., 389
 Goldsmith, Jonathan C., 3187
 Goldstein, Beth P., 1355
 Goldstein, Ellie J. C., 1127
 Gomez De Las Heras, F., 2863
 Gomez De Las Heras, Federico, 2274
 Gómez-Garcés, Jose-Luis, 989
 Gómez-Gómez, J. M., 1042
 Gomez-Lus, M. L., 414, 1574
 Gonzalez, Corina E., 2391, 2399, 2700
 González, Irene, 2792
 Gonzalez-Torres, Concepción, 3009
 Gooch, W. Manford, 1073
 Gordon, Morris A., 2405
 Gore, Medini A., 1447
 Gorman, Sean P., 3002
 Gotoh, Naomasa, 65, 1938
 Gottfredsson, Magnus, 1005
 Gourmelen, Anne, 2612
 Gous, A. G. S., 2235
 Grabowski, Brian, 3218
 Graham, Lisa, 487
 Granneman, G. Richard, 2784, 3107, 3218
 Granneman, Richard, 1788
 Grant, Julianne, 1454
 Grasela, Thaddeus H., 409, 821
 Grasselier, Henny, 319
 Grassi, Jacques, 2656
 Gratzl, Ottmar, 2626
 Graybill, John R., 147, 151, 2371, 2467, 2542, 2938
 Graybill, J. Richard, 528
 Graziani, G., 550
 Greganti, G., 3320
 Gregis, Giampietro, 1346
 Griffin, Linda, 687
 Griffiths, Jeffrey K., 1959
 Groeneveld, Paul H. P., 739
 Groeneveld, P. H. P., 3073
 Groll, Andreas H., 2399, 2700, 2898
 Grope, Ilze, 1980
 Gropper, Michael A., 3269
 Grosse-Siestrup, Christian, 2440
 Grosset, Jacques, 1115, 2066
 Groulier, Pierre, 3086
- Grousson, Dominique, 654
 Grove, Kristie L., 833
 Grzesiowski, Paweł, 3079
 Garnieri, Joseph, 1862
 Guarro, J., 1601
 Guay, Gordon G., 88
 Guidol, Francisco, 53
 Gudmundsson, Sigurdur, 1005
 Guedj, Roger, 2656
 Gueylard, Delphine, 2950
 Guillemín, Isabelle, 2084
 Guillevin, Loïc, 849
 Guillen, Elizabeth, 1799
 Gümbel, Hermann, 3332
 Guo, Xin, 1799
 Gur, Deniz, 3117
 Gurwitz, Marc J., 606
 Gustafson, Erik A., 2923
 Gustavson, Linda E., 1176
 Guteérrez, M. N., 1306
 Gutkind, Gabriel O., 228
 Gutmann, Laurent, 173
- Hacker, Jörg, 2817
 Hadding, Ulrich, 1249
 Haddix, Heidi, 332
 Haffar, Omar K., 1133
 Hafner, Richard, 631
 Hahn, H., 459
 Haimeur, Anass, 1689
 Hajjeh, R. A., 3242
 Hak, Janneke, 2437
 Hale, Ron L., 1447
 Hall, James Edwin, 666
 Hall, Len, 2171
 Hall, Lucinda M. C., 3117
 Hallut, Séverine, 534
 Halstenson, Charles E., 456
 Hamatake, Robert K., 3200
 Hamblin, Michael R., 2595
 Hammerschlag, Margaret R., 194, 951, 1515
 Hammerum, Anette M., 3331
 Hammonds, Timothy R., 889
 Hamaoka, Masayuki, 1597
 Hanberger, Håkan, 1222
 Hancock, Susan L., 362
 Hanes, Scott D., 930
 Hannecart-Pokorni, Eleonora, 483
 Hansen, Birgit, 1249
 Hansen, Eugene B., Jr., 1121
 Hansen, M., 2245
 Hanson, Nancy D., 596
 Hanson, N. D., 1350
 Harada, Hiroshi, 1340
 Haran, M. H., 436
 Harasaki, Tamako, 23
 Harbarth, S., 2966
 Hardin, Thomas, 147
 Harrel, Lizzie J., 3169
 Harris, Stuart I., 1176
 Hasan, Tayyaba, 2595
 Hasegawa, Takaaki, 2178, 3136
 Hashida-Okado, Takashi, 755
 Hassell, Alan E., 1862
 Hastings, Kenneth L., 2336
 Hatanaka, Masakazu, 1340
 Hatch, Richard A., 974
 Hattenbach, Lars-Olof, 3332
 Hattori, Noriaki, 1406
 Hauschildt, Sunna, 1911
 Hawley, Shaun R., 682
- Hayakawa, Isao, 1284
 Hayano, Toshihide, 1597
 Hayasawa, Hirotoshi, 1587
 Hayashi, Shunji, 1895
 Hazen, Kevin C., 2961
 Hector, Richard F., 2371
 Heefner, Donald, 3256
 Hegarty, Barbara C., 362
 Heidler, Steven A., 1187
 Heifets, L. B., 1853
 Heininger, A., 2421
 Heinz, Hans-Peter, 1249
 Helbig, Jürgen H., 2870
 Hell, Wolfgang, 2817
 Hellmann, Nicholas S., 2380
 Hellmann, N. S., 1620
 Hengerer, Arne, 2870
 Hennigan, Steven H., 1375
 Henriksson, Agnethe, 1923
 Henry, D., 2262
 Henry, Daniel C., 1073
 Hernández-Allés, Santiago, 1636, 1850
 Herreros, E., 2863
 Herring, Vanessa L., 930
 Herscovici, Jean, 779
 Hertogs, Kurt, 269, 3123
 Hesney, Michael, 332
 Hess, Mary M., 930
 Hewitt, Ross G., 409, 821
 Heym, Beate, 879
 Hickerson, William L., 930
 Hickman, Melissa E., 1517
 Hidri, Nadia, 3304
 Higginbotham, Lindsey M., 2645
 Higgs, Christopher J., 293
 Hiles, Richard, 263
 Hill, S., 2956
 Hill, Shawn A., 487
 Hincenberg, Mara, 2113
 Hinuma, Yorio, 1340
 Hirai, Kei-Ichi, 700
 Hirai, Yoshikazu, 1895
 Hirakata, Yoichi, 698, 1722, 2006, 2853
 Hiramatsu, Keiichi, 1917
 Hirota, Katsuhiko, 1083
 Hishida, Akira, 1718
 Hitchcock, Christopher, 1695
 Hitchcock, Christopher A., 2645
 Hiyoshi, Suehiro, 431
 Ho, Elaine, 1336
 Hoagland, Vicki, 332
 Hoban, Daryl J., 184, 2427, 2446
 Hoch, James A., 1529
 Hoellman, Dianne B., 495, 857, 3032
 Hoepelman, I. M., 1233, 3266
 Hoffmann, E., 2421
 Hofheinz, Werner, 2602
 Hofmann, Basia, 1249
 Hogan, Patricia A., 3313
 Hoi, Annie Buu, 2889
 Holland, Kevin P., 2456
 Hollenstein, Ursula M., 2417
 Hollingshead, Melinda, 487
 Hollis, R. J., 3242
 Hollomon, Derek W., 2171
 Holmes, P., 1012
 Holt, H. A., 419

- Holtorf, Lorilynn, 3146
 Holyoak, Caroline D., 2160
 Holzgrabe, Ulrike, 1151
 Hon, H., 2235
 Hong, Sung Yu, 2534
 Hooper, David C., 121, 2109
 Hoover, David L., 583
 Hope, Michael J., 45, 2511
 Hopkins, Marlene K., 202
 Hoppe, Jörg E., 965, 1868
 Horaud, Thea, 2889
 Horgen, Lionel, 3006
 Horii, Satoshi, 1917
 Horio, Takeshi, 3141
 Hosaka, Masaki, 2678
 Hosoya, Yoshiko, 2041
 Hossain, Mohammad Ashraf, 1722
 Hostomsky, Zdenek, 140
 Houang, Elizabeth T. S., 440, 3051
 Hougham, Andrina J., 789
 Houin, René, 2141
 Houlihan, Heather H., 254, 981
 Hryniwicz, Waleria, 514, 3079
 Hsu, Ann, 1788, 2784, 3107,
 3218
 Hu, André, 971
 Huang, Kun-Yen, 1319
 Huang, Mingjun, 487
 Huang, Wan-Zhi, 2893
 Huber, O., 2966
 Huczko, Elizabeth, 313
 Hudspeth, Marie, 1127
 Huebner, Robin, 2633
 Huffman, John H., 640
 Huggins, Andrea S., 1563
 Hughes, April, 2996
 Hughes, Stephen H., 447
 Hughes, Walter, 1315
 Huletsky, Ann, 3296
 Huneau, Jean-François, 2607
 Huovinen, Pentti, 257, 1493
 Hurwitz, Selwyn J., 2804
 Hutchison, M., 2421
 Hwang, Frances, 2380
 Hyatt, Judith M., 521
- Ibrahim, Ashraf S., 2645
 Ida, Hirohisa, 431
 Iga, Tatsuiji, 691, 1738
 Igno, Felicitas R., 1295
 Ike, Yasuyoshi, 2150
 Inaba, T., 1654
 Ing, Michael, 1837
 Ingate, S. T., 618
 Inglis, Shelly, 2336
 Innaimo, S., 3209
 Inotsume, Nobuo, 453
 Ioannides-Demos, Lisa L.,
 1365, 1370
 Iona, Elisabetta, 712
 Irvin, James D., 383
 Isaka, Yoshitaka, 1340
 Ischer, Françoise, 241
 Ishida, Hiroko, 1641
 Ishida, Mariko, 325
 Ishida, Yoshihisa, 1641
 Ishiguro, Masaji, 1181
 Ishihara, Satoshi, 3293
 Ishii, Kazuhiro, 555
 Ishii, Yoshikazu, 94, 1181,
 1858, 2853
 Ishikawa, Hiroshi, 2943
 Ishimaru, M., 3333
 Ishimatsu, Yuji, 1866
 Ishizuka, Hitoshi, 1738
 Ismael, Farid, 2830
 Isogai, Emiko, 1895
 Isogai, Hiroshi, 1895
 Ison, C. A., 2799, 2919
 Isaacs, C. E., 1239
 Itoh, Akio, 2178
 Itoh, Tomoo, 325
 Itokawa, Kenichi, 1751
 Ittarat, Wanida, 2332
 Ivens, Tania, 269
 Iwashita, Tetsuji, 1866
 Iwata, Masayuki, 23
 Iwayama, Satoshi, 1666, 2095
 Izquierdo, J., 414
 Izumiakawa, Kin-Ichi, 698
 Izumikawa, Koichi, 698, 2006
 Jabs, Douglas A., 2240
 Jaccard, C., 2966
 Jackson, Jesse J., 1996
 Jacobberger, Bernadette, 425
 Jacobs, Michael R., 495, 589,
 857, 953, 1253, 1263, 1269,
 2002, 2459, 2914, 3028, 3032
 Jacobs, M. R., 624, 1503
 Jacquot, Anne, 3304
 Jacqmin, Philippe, 404
 Jaffe, Howard S., 2996
 Jafri, Hasan S., 2650
 Jahn, Andreas, 2569
 Jahn, Bernhard, 2569
 Jakeman, Kenneth J., 640, 647
 Jamard, Catherine, 369
 Jamis-Dow, Carlos, 1592
 Janoff, Andrew S., 767
 Japour, Anthony, 2784
 Japour, Anthony J., 3218
 Jaramillo, Jorge, 1629
 Jarlier, Vincent, 2084
 Jarosinski, Paul, 1815, 2391
 Jarvis, K., 2385
 Jarvis, Ken, 2674
 Jaspers, C. A. J. J., 1233
 Jayanti, Venkata, 3218
 Jelliffe, R. W., 1731
 Jenkins, John R., 889
 Jensen, Lars Boøg, 2463, 3331
 Jensen-Pergakes, K. L., 1160
 Jerome, Arnaud, 3006
 Jessen, Lois, 1862
 Jett, Bradley D., 1671
 Ji, BaoHong, 1115, 2066
 Jiménez-Valera, María, 3009
 John, Joseph F., 2122
 Johnson, Cheryl A., 3315
 Johnson, Debra, 528
 Johnson, Elizabeth M., 1412
 Johnson, M., 2956
 Johnson, Robert B., 916
 Johnson, Theresa, 1454
 Johnston, Nicole J., 2425
 Join-Lambert, Olivier, 468
 Jonckheere, H., 618
 Jones, Mark E., 1249
 Jones, R. N., 161, 3242
 Jones, Ronald N., 1762
 Jones, S., 428
 Jones, Susan, 2495
 Jones, Susan K., 666, 2503
 Jorgensen, James H., 2312
 Joseph, W. Patrick, 1139
 Ju, William D., 332
 Jueneman, Shane A., 2914
 Jung, Louis, 425
 Jungheim, Louis N., 916
 Jungwirth, Renate, 514, 827
 Jura, Heike, 1052
 Justice, Steven J., 332
 Kaatz, Glenn W., 197, 254, 721,
 981
 Kabani, Amin M., 184, 2427
 Kabayashi, Intetsu, 579
 Kadota, Jun-Ichi, 1866
 Kadurugamuwa, Jagath L.,
 1476
 Kageruka, P., 1012
 Kahn, James O., 2380
 Kaijser, Bertil, 3276
 Kaiser, Allen B., 545, 2449
 Kakeya, Hiroshi, 1722
 Kaku, Mitsuo, 698, 2006
 Kalach, N., 1334
 Kamai, Yasuki, 23
 Kamali, F., 1256
 Kamihira, Shimeru, 698, 2006
 Kaminsky, Ronald, 2858
 Kampf, Günter, 2440
 Kanamaru, Mitsutaka, 1433,
 1718
 Kaneki, Toshimichi, 1597
 Kanematsu, Emiko, 433, 3293
 Kapel, Nathalie, 818
 Karkhanis, Yashwant, 1985
 Karlovsky, James A., 184,
 2427, 2446
 Karlsson, Sigfus M., 2290
 Karp, Matti, 1906
 Kasama, Tsuyoshi, 1499
 Kashuba, A. D. M., 1842
 Kataja, Janne, 1493
 Kataoka, Atsuko, 1778
 Katayama, Koichi, 2824
 Kati, Warren, 3218
 Kato, Ikuoshin, 755
 Kato, Tamamo, 1666
 Kauffman, Carol A., 1305
 Kaul, Sanjeev, 2295
 Kaw, Pamela, 1105
 Kawada, Harumi, 23
 Kawada, Yukimichi, 433, 3293
 Kawahara, Yukinori, 1738
 Kawakami, Jun-Ichi, 691
 Kawamura, Takeshi, 433, 3293
 Kawasaki, Shin, 1499
 Kawata, Tsutomu, 2824
 Kazempour, Kazem, 2336
 Kearns, Gregory L., 2706
 Kehrenberg, Corinna, 2116
 Keller, Amy, 3187
 Keller, M. R., 2637
 Kellner, James D., 2425
 Kelly, Diane E., 1756, 3065
 Kelly, Steven L., 1756, 3065
 Kelly, Valerie A., 2274
 Kemp, Sharon, 269
 Kemp, Dale J., 3218
 Kennedy, Allison, 3146
 Kennedy, M. A., 1160
 Kern, Winfried V., 2089
 Kernodle, Douglas S., 545,
 1375, 2449, 3163
 Kerrigan, John E., 666
 Keyserling, Constance H., 1073
 Khan, Anis A., 1713, 2284
 Khan, Ikhlas A., 1454
 Khetarpal, Minoo, 1295
 Kieft, H., 1233
 Kikuchi, Mikio, 1895, 2943
 Kim, Choung, 612
 Kim, Choung U., 640, 647,
 1568, 3234
 Kim, Hak Yeop, 190
 Kim, Jeong Hoon, 190
 Kim, Kwang Seo, 190
 Kim, So H., 1217
 Kim, Won B., 1217
 Kim, Young Min, 190
 Kim, Young S., 3325
 Kimura, Akifumi, 2824
 Kinard, Rachel G., 2877
 King, Peter J., 140
 King, Robert W., 2128, 3179
 King, Stephen R., 930
 Kinsman, Oonagh S., 2274
 Kinzig, Martina, 1659
 Kinzig-Schippers, Martina,
 2012, 2359
 Kippenberger, Stefan, 3332
 Kirikae, Fumiko, 1015
 Kirikae, Teruo, 1015
 Kirkpatrick, Iain D. C., 2427
 Kirkpatrick, William R., 2932,
 2938
 Kirst, Herbert A., 1303
 Kishi, Yoshito, 2824
 Kitada, Ayako, 1718
 Kitahara, Shigeo, 1200
 Kitaichi, Kiyouki, 3136
 Kitano, Megumi, 2492
 Kitayama, Akiko, 23
 Kitzis, Marie-Dominique, 173
 Klaus, Sidney, 3092
 Klecker, Raymond W., 1592
 Klein, Larry L., 389
 Klepser, Michael E., 1207,
 1382, 1387
 Kline, Bruce, 202
 Klugman, Keith, 2633
 Klugman, Keith P., 1329, 2221
 Knaebel, David, 911
 Knapp, Joan S., 2103
 Knott, Sarah J., 1973, 3193
 Knowles, M., 2637
 Knudsen, Jenny Dahl, 377
 Knudsen, Jenny Dahl, 1706
 Ko, Wen-Chien, 1319
 Kobayashi, Hiroyuki, 1641
 Kobayashi, Kazuo, 1499
 Kobayashi, Nobumichi, 717
 Kobayashi, Seiichi, 2824
 Kobayashi, Toshio, 1597
 Koher, Astrid, 3123
 Kodama, Hiroki, 967
 Kodama, Kazuyoshi, 1778
 Kodama, Makoto, 1340
 Koegel, C., 1160
 Koffel, Jean Claude, 425
 Kofterithis, Diamantis, 2747
 Koga, Tetsufumi, 23
 Kohlhepp, Sue J., 2259
 Kohlsdorfer, C., 1397
 Kohner, Peggy, 202
 Kohno, Shigeru, 40, 698, 1722,
 1866, 2006

- Köhler, Karl, 1249
 Kohyama, Tadashi, 1499
 Koivisto, Leeni, 1906
 Koizumi, Tomonobu, 1597
 Kojima, Saori, 3136
 Kojima, Somei, 37
 Koller, Klaus-Peter, 2817
 Kolonoski, Peter, 180
 Komatsuzawa, Hitoshi, 1278
 Komori, Toshiaki, 2150
 Kon, Tatiana, 65
 Korba, Brent E., 2804
 Korda, Anna, 339
 Koren, Gideon, 1336
 Korneyeva, Marina, 3218
 Kosuge, Kazuhiro, 1298
 Kotra, Lakshmi P., 1542
 Kourea, Helen P., 840
 Kovach, Danuta, 1290
 Koyama, Junko, 700
 Koyano, Shinichi, 325
 Koymans, Luc, 241
 Kozawa, Osamu, 1433
 Kozel, Thomas R., 1437
 Krakowka, Steven, 1549
 Kreiswirth, Barry N., 1295
 Krishnamoorthy, Rajagopal, 1323
 Kropp, Helmut, 1996
 Krueger, W. A., 2421
 Kubar, Joanna, 654
 Kubitz, D., 2060
 Kubo, Keishi, 1597
 Kubota, Mikie, 23
 Kubota, Satoshi, 1200
 Kugler, Kari, 1762
 Kuipers, E. J., 2749
 Kukhanova, Marina, 1799
 Kumar, Arvind, 2495, 2503
 Kumar, Gondi N., 3218
 Kumar, Princy, 631
 Kumazawa, Joichi, 579
 Kumon, Hiromi, 1083
 Kuo, Chih-Feng, 1319
 Kurahashi, Kiyoyasu, 3269
 Kuritzkes, D. R., 2637
 Kurosaka, Seiko, 1284
 Kurosaka, Yuichi, 1641
 Kusano, Nobuchika, 2193
 Kusters, J. G., 2749
 Kuwahara, Shogo, 23
 Kuzuhara, Naoki, 967
 Kwappenberg, Kitty M. C., 739
 Kwon, Mi-yun, 2534
 Labia, R., 1110, 2184
 Labia, Roger, 879, 1323, 2771
 Labro, M. T., 1944
 Lacy, Steven A., 640
 Ladner, Stephanie K., 2128, 3179
 Lagrange, Philippe H., 464, 2352
 Lakey, David L., 1375
 Lakshminarayanan, S., 114
 Lal, Ritu, 3218
 Lalezari, Jacob P., 1139
 Lalkin, Arieh, 1336
 Lamb, David C., 3065
 Lamb, L., 3209
 Lambert, Michelle, 1629
 Lambert, Thierry, 2557, 2759
 Lambros, Chris, 147
 Lamm, Janet E., 3107
 Lamp, Kenneth C., 231
 Lampe, M. F., 1239, 1726
 Lampis, Giorgio, 3035
 Lamy, P. D., 1620
 Lancaster, Danny, 2656
 Lancaster, M. V., 282
 Land, Tracey M., 2877
 Landay, Alan L., 2326
 Landry, Bernard, 631
 Landureau, Jean-Charles, 2482
 Laneury, Jean Paul, 2602
 Lang, Jean, 298
 Langaae, Taimour Yousef, 3296
 Langlie, Mridula-Chandan, 383
 Lant, Ariel F., 293
 Laouari, D., 289
 Larder, Brendan, 269
 Larrick, James W., 3269
 Larsen, Robert A., 528
 Larrete, Paul A., 389
 Lassek, Christoph, 2012
 Lavandera, José L., 2694
 Lavitola, Alfredo, 571
 Lawetz, Carol, 1629
 Leal, Mary Ann E., 528
 Lebib, J., 540
 LeBlanc, Donald J., 2312
 Le Blancq, Sylvie M., 843
 Leclerc, Jean-Marie, 404
 Leclercq, Roland, 1392
 Lecoublet, Sophie, 818
 Ledee, Dolena R., 2144
 Lee, Bok Luel, 2534
 Lee, Chang-Kwon, 2985
 Lee, Ji Hye, 2534
 Lee, Keun Heyeung, 2534
 Lee, Linda N., 2312, 2932
 Lee, Mark, 762
 Lee, Myung G., 1217
 Lee, William A., 687
 Leeds, Janet M., 2113
 Lees, N. D., 1160
 Le Fichoux, Yves, 654
 Legakis, Nicholas J., 1281
 Leggett, James E., 2259
 Lehr, Karl H., 199
 Lehrer, Robert I., 2206, 2690
 Leitner, Ingrid, 1057
 Leitzke, S., 459
 Lelièvre, Alain, 654
 Lemesre, J. L., 3097
 Lemmouchi, Y., 1012
 Lendvai, Nikoletta, 1437
 Lenfant, Bernard, 199
 Leonard, John, 1788
 Leonardo, John M., 2784, 3107, 3218
 Leopold, Klaus, 154
 Leotard, Sophie, 3304
 Lerner, Stephen A., 1295, 1542
 Lessard, I. A. D., 2215
 Leunk, Robert D., 1549
 Levesque, Roger C., 1245, 1966, 2319, 2576
 Levy, Benjamin, 1788
 Levy, Stuart B., 2089, 3050
 Lew, D., 2966
 Lew, Daniel P., 564
 Lew, Willard, 640, 647, 3234
 Lewin, Alfred, 509
 Lewis, Linda L., 3187
 Lewis, Russell E., 1207, 1382
 Li, Cong, 1837
 Li, Leping, 389
 Li, Tsai-Kun, 1022
 Li, Wei Dong, 2731
 Li, Weixing, 640, 647
 Li, W.-X., 1620
 Li, Xian-Zhi, 399, 1682, 2225
 Li, Yongjun, 712
 Li, Yu-Feng, 2989
 Li, Yuzhou, 911
 Li, Zhiyu, 3293
 Liassine, Nadia, 1794
 Libby, Jeffrey M., 78
 Liberator, Paul, 1985
 Liendo, Andreina, 1771
 Lienhardt, Christian, 1115
 Lietman, Paul S., 2380
 Ligozzi, Marco, 2055
 Lin, Enjarn, 2132
 Lin, Gengrong, 1253, 3032
 Lin, Lillian S., 3103
 Lináres, Josefina, 53, 1636, 2792
 Lindsay, David S., 2877
 Ling, Baodong, 936
 Ling, Julia M., 440
 Linquist-Stepps, Valerie, 2113
 Liolios, Lisa L., 1365, 1370
 Lipford, J. R., 2245
 Lipman, J., 2235
 Lister, Philip D., 1610
 Liu, Jien-Wei, 1319
 Liu, Leroy F., 1022
 Liu, Qing-Feng, 1105, 1417, 1512
 Liu, Quingxiang, 3325
 Liu, Shwu-Huey, 369, 833, 1799, 1805
 Liu, Weigu, 1105, 1417, 1512
 Liu, Wenqiu, 911
 Liu, Xuejun, 911
 Luzzi, Michel, 1629
 Livermore, David M., 1168, 3117
 Lloyd, D., 1195
 Locarnini, S. A., 3130
 Locarnini, Stephen, 2132
 Lo Cascio, Giuliana, 2055
 Locke, Charles S., 1176
 Loebenberg, David, 1771, 2467
 Loebstein, Ronen, 1336
 Logan, Patricia, 45
 Loimaranta, Vuokko, 1906
 Loiseau, Philippe M., 352
 Lomovskaya, Olga, 2225
 Looraceeuwan, S., 135
 Looareesuwan, Sornchai, 2332
 Look, Gary C., 1447
 Lopez-Ribot, Jose L., 2932
 Lortholary, Olivier, 849
 Louie, Arnold, 1105, 1417, 1512, 2405
 Louie, Lisa, 762
 Louie, Marie, 762
 Lounis, Nacer, 2066
 Low, Donald E., 2425
 Löwdin, E., 2739
 Löwdin, Elisabeth, 2365
 Lozano-Chiu, Mario, 129
 Lu, Amy T., 1447
 Luck, Linda, 911
 Lück, P. Christian, 2870
 Lückefahr, Marc, 1249
 Lucumi, Armando, 1990
 Lührmann, Anja, 1911
 Lund, Brian C., 1382
 Lupetti, A., 2434
 Lurain, Nell S., 2326
 Luscombe, Carolyn, 2132
 Luther, Michael F., 151, 2371, 2938
 Luther, Mike F., 2467
 Lutsan, Irja, 2650
 Lutsch, Charles, 298
 Lütticken, Rudolf, 1509
 Lutwyche, Peter, 2511
 Luxemburger, C., 135
 Luzzi, Ida, 3053
 Lynch, Geoffrey R., 687
 Lyon, Donald J., 440
 Lyons, Christopher N., 2584
 Lyras, Dena, 1563
 Ma, Ling, 1181
 Maass, Matthias, 2762
 MacGowan, A. P., 419, 436
 Maciejewski, L., 540
 Mack, Douglas, 2036
 Maclean, Derek, 1447
 Macleod, Catherine M., 2295
 Madaio, R., 550
 Madaras-Kelly, Karl J., 1266
 Madders, Helen, 2919
 Mäder, M., 277
 Madu, Assumpta, 1417
 Maesaki, Shigeumi, 40, 698, 1722, 2006
 Magambo, Japheth K., 601
 Magnaval, Jean-François, 2770
 Magner, D. J., 2262
 Maillard, J.-Y., 2151
 Mainardi, Jean-Luc, 468
 Maire, P. H., 1731
 Malena, Marina, 3014
 Mallet, Marie-Noëlle, 1093
 Mamelok, Richard D., 606
 Manavathu, Elias K., 1295, 3018
 Manna, Filomena, 571
 Manning, Nigel J., 1756
 Mansfield, D. L., 2262
 Manteau, Michel, 2830
 Manzo, Ruben H., 1495
 Mao, Chen, 3225
 Maquaire, S., 3097
 Marchese, Anna, 464
 Marchetti, O., 1889
 Marco, F., 161
 Markowitz, M., 2637
 Markowitz, Martin, 2775
 Marone, Piero, 2017
 Marotti, Keith R., 947
 Marr, Kieren A., 2584
 Marriott, Michael S., 2274
 Marriott, M. S., 2863
 Marsden, Katherine, 1695
 Marsh, Kennan C., 3218
 Marsh, V. R., 1256
 Marshall, C. G., 2215
 Martin, Claude, 1093
 Martín, J. Julio, 2274, 2279
 Martín, M. M., 414
 Martínez, C. M., 2863
 Martínez, J. A., 1306
 Martínez-Bueno, Manuel, 534

- Martínez-Martínez, Luis, 1636, 1850, 3290
 Martin-Munley, Sarah, 293
 Martiny, Heike, 2440
 Marttila, Harri J., 2443
 Maruyama, Kazuo, 40
 Maslo, Caroline, 2066
 Mason, William S., 1045
 Massias, Laurent, 2830
 Massova, Irina, 1
 Matlow, Anne, 1290
 Matsubara, Yuichi, 1866
 Matsuda, Izumi, 2178
 Matsuda, Junichi, 2006
 Matsumoto, Makoto, 2943
 Matsumoto, Syouzou, 1433
 Matsumoto, Tetsuro, 579
 Matsumoto, Tetsuya, 555, 1858, 2853
 Matsumura, Naoki, 176
 Matsuno, Hiroyuki, 1298, 1433
 Matsuo, Hirotami, 691, 1738
 Matsuo, Takashi, 1083
 Matsuzawa, Hiroshi, 1181
 Mattei, Maurizio, 712
 Matthews, C., 223
 Mattie, Herman, 739
 Mattuzzi, Gloria N., 606
 Maurin, M., 1537
 Maxwell, Anthony, 889
 Mayers, Martin, 1417, 1512
 Mazabel, E., 2637
 Mazière, Bernard, 2830
 Mazière, Jean-Claude, 2482
 Mazzariol, Annarita, 1459
 Mazzieri, Maria Rosa, 1495
 Mberu, E. K., 164
 Mbongo, Nicolas, 352
 McAtee, Robert K., 2932
 McCaffrey, Ronald P., 1424
 McClelland, R. Scott, 3169
 McCoig, Cynthia C., 2650
 McCracken, George H., Jr., 2650
 McCrea, J., 223
 McCully, Cindy L., 1815
 McCune, Joseph M., 2113
 McCutchan, Thomas F., 715
 McDonald, Edith, 3218
 McDougal, Linda K., 2312, 3024
 McDougall, Brenda, 140
 McDowell, J., 2153
 McElhaney-Feser, Gail E., 2342
 McEvoy, Maureen, 2391
 McFadden, Diane, 1985
 McGuire, Brian, 2996
 McLean, A. J., 1365
 McLeod, Rima, 2036
 McMahon, J., 705
 McMillian, Carl L., 2898
 McMurray, Walter J., 1076
 McMurry, Laura M., 3050
 McNamara, James, 1315
 McSharry, James J., 2326
 Mead, Jan R., 339
 Medda, Swapna, 348
 Medina, I., 3209
 Mégraud, Francis, 2836
 Melby, Peter C., 2542
 Melnick, Laurence, 3256
 Mendel, Dirk B., 640, 647, 3234
 Mendoza, Alfonso, 2694
 Menzies, Barbara E., 1375
 Mercier, Renee-Claude, 981, 254
 Merker, Hans Joachim, 1470
 Merriam, C. Vreni, 1127
 Merson, James, 640, 647
 Mertz, Gregory J., 1139
 Merz, Michael, 298
 Meshnick, Steven R., 934, 1454, 2332
 Messer, S., 161
 Messer, S. A., 3242
 Messer, Shawn A., 1387
 Meulbroek, Jon, 2674
 Meyers, W. M., 2070
 Mian, Umar, 1417
 Michailowsky, Vladimir, 2549
 Michejda, Christopher J., 487
 Michelena, Phyllis B., 3153
 Middlemas, David, 3157
 Miki, Shigeru, 1340
 Mikiewicz, Barbara, 827
 Miller, Carole B., 606
 Miller, Kenneth, 2405
 Miller, L. P., 1853
 Miller, M. D., 1620
 Miller, Michael H., 1105, 1417, 1512
 Miller, Thomas J., 2128, 3179
 Miller, Veronica, 269, 3123
 Millet, P., 540
 Mills, John, 3038
 Mimoz, Olivier, 3304
 Minami, Rumiko, 453
 Minami, Shinzaburo, 176
 Minamoto, Masahiko, 1433
 Minassian, Beatrice, 313
 Mindermann, Thomas, 2626
 Mine, Tomoyuki, 1778
 Minnick, Michael F., 2906
 Miriagou, Vivi, 1281
 Mirochnick, Mark, 808
 Mistry, Anita, 2225
 Mitchell, Bernadette A., 475
 Mitsuhashi, Susumu, 176
 Mitsuya, Hiroaki, 1815
 Mitten, M., 2385
 Mitten, Mike, 2674
 Miyahara, Takayuki, 1597
 Miyake, Yoichiro, 1083
 Miyama, Tetsuo, 1738
 Miyamae, Shin, 2119
 Miyamoto, Kaname, 2824
 Miyazaki, Haruko, 1695
 Miyazaki, Shuichi, 94, 555, 785, 1858, 2853
 Miyazaki, Tsuneko, 967
 Miyazaki, Yoshitsugu, 40, 1695
 Mizen, Linda W., 813
 Mizuoka, Keiji, 431
 Mizushima, Tohru, 1778
 Moshaberry, Shahriar, I., 1542
 Moellering, R. C., Jr., 1088, 1520
 Moesker, H. L., 3266
 Moghazeh, Soraya L., 1295
 Moland, E. S., 1350
 Moldovan, Tabitha, 721
 Mole, Larry, 631
 Molina, Judith, 1771
 Molitoris, Denise, 984
 Molitoris, Eric, 984
 Molla, Akhteruzammen, 3218
 Möller, Lieke V. M., 319
 Montalbo, Eleanor, 2542, 2938
 Montalbo, Eleanor M., 151
 Montgomerie, J. Z., 188
 Monzillo, Vincenza, 564
 Moon, Hong Mo, 2534
 Moore, Caroline B., 2726
 Moore, P. Hutton, 2877
 Morales, Vivian E., 583
 Moran, Gary P., 1819
 Mordrelle, Agnès, 2607
 Moreillon, P., 1889
 Moreno, Encarnación, 3009
 Moreno, Mary Beth, 2113
 Moretti, Myla, 1336
 Moribe, Kunikazu, 40
 Morita, Yuji, 1778
 Morita, Yutaka, 1499
 Morosini, María-Isabel, 1042
 Morrissey, Graham, 873
 Morrissey, Jacqui, 873
 Morschhäuser, Joachim, 3065
 Morse, Gene D., 409, 821
 Morton, Teresa M., 1305
 Moskowitz, Bruce L., 1862
 Moss, Neil, 1629
 Mouton, Johan W., 377, 744, 749
 Move, John, 1315
 Mueller, Brigitte U., 1815, 3187
 Muffat-Joly, Martine, 862
 Mugnier, P., 3113
 Mugnier, Pierre, 108
 Mukherjee, Jean, 1437
 Mukhopadhyay, Asish Kumar, 206
 Mulamba, Gilbert B., 971
 Mulato, A. S., 1620
 Muli, F., 1428
 Mullen, A. B., 2722
 Müller, Carola, 2359
 Müller, R., 459
 Munghin, Mathirut, 682, 2973
 Muñoz, J. L., 1306
 Murakami, Kinya, 1083
 Muramatsu, Hideyuki, 37, 2041
 Murphy, Philip G., 3002
 Murphy, Robert, 1815
 Murray, Barbara E., 2883
 Murray, Robert W., 947
 Murta, Silvane M. F., 2549
 Musafija, Albert, 473
 Mushatt, David, 631
 Myers, Dorothea E., 383
 Myung, Joon Mo, 2731
 Naas, Thierry, 2074
 Naber, Kurt, 1659
 Nabeshima, Toshitaka, 2178, 3136
 Nadai, Masayuki, 2178, 3136
 Nadler, H. L., 1088
 Nadler, Steven G., 1133
 Naesens, Lieve, 1568
 Naftziger, Anne N., 695, 927, 1578, 1842
 Nagahara, Naoki, 2492
 Nagashima, Satoru, 1433, 1718
 Nagata, Aya, 691
 Nagata, Kumiko, 700
 Nair, G. Balakrish, 206
 Naito, Mikihiko, 1738
 Najvar, Laura, 528
 Najvar, Laura K., 147, 151, 2371, 2467, 2542
 Nakahara, Kazuhiko, 1499
 Nakahashi, Masaaki, 1938
 Nakajima, Moto-O, 1406
 Nakamura, Chizuko, 453
 Nakamura, Hidenori, 1499
 Nakano, Masahiro, 453
 Nakano, Masayasu, 1015
 Nakano, Michiko, 2006
 Nakao, Masafumi, 2492
 Nakashima, Mitsuyoshi, 1298
 Nakayama, Issei, 431
 Nakazawa, Harumi, 1666, 2095
 Naruhashi, Kazumasa, 2178
 Nash, Theodore, 1488
 Nasr, Mohamed, 2284
 Natarajan, Jaya, 1098
 Nau, R., 277, 1397
 Nau, Roland, 2012
 Nauta, J. J. P., 3266
 Navre, Marc, 1447
 Nayak, Ramchandra, 885
 Negri, María-Cristina, 1042
 Nelson, Gene O., 675
 Nelson, M., 729
 Nelson, Page W., 129
 Nemoto, Ken, 1083
 Neuhardt, Jan, 2620
 Neville, W. A., 436
 Neysts, Johan, 170, 216, 3285
 Ng, Samson P., 1646
 Ng, Tak-keung, 440
 Ng, Winston, 2650
 Nguyen, M. Hong, 471, 509
 Nicas, Thalia I., 1303
 Nichols, Brian P., 88
 Nicola, Federico G., 3024
 Nicolas-Chanoine, Marie-Hélène, 879
 Nicolau, David P., 840, 991
 Nicoll, A. J., 3130
 Nie, Lin, 840
 Nieto, Eva, 1361
 Nieto, Marcelo, 1495
 Nightingale, Charles H., 840, 991
 Nihsira, Takuya, 2985
 Niida, Yoshito, 1433
 Nikaido, Hiroshi, 2119
 Niki, Yoshihito, 1751
 Nilius, A. M., 2385
 Nilsson, Lennart E., 1222
 Nilsson, Maud, 1222
 Nishino, Takeshi, 1938
 Nishino, Yoshinori, 433, 3293
 Nishiyama, Yukihiro, 1666, 2095
 Niu, Ping, 3218
 Niwa, Masayuki, 1433
 Niwano, Yoshimi, 967
 Nixon, James R., 3002
 Njoroge, Ernest M., 601
 Noda, Tetsuhiro, 1722
 Nomura, Atsuko, 1938
 Nonomiya, Tomoko, 431
 Noormohamed, Faruq H., 293
 Norbeck, Daniel W., 3218
 Nordmann, Patrice, 2074, 3304
 Noskin, Gary A., 606, 734

- Nosten, F., 135
 Notka, Mostafa, 2326
 Nouaille-Degorce, B., 289
 Nukkula, Mike, 2674
 Nussenweig, Victor, 2731
 Nzadiyabi, T., 540
 Nzila-Mounda, A., 164
- Oakley, Karen L., 873, 2726
 Obara, Masao, 1718
 Obias, Arlene A., 734
 Occhialini, Alessandra, 2836
 Ochi, Kozo, 2041
 Odds, F. C., 282
 Odenholt, I., 2739
 Odenholt, Inga, 2365
 O'Doherty, E., 903
 Oethinger, Margret, 2089
 Ogawa, Atsuko, 755
 Ogawa, Yasuyuki, 2492
 O'Gorman, Maurice R. G., 2326
 Oguma, Keiji, 1895
 Oh, Jong Eun, 2534
 Ohara, Kenji, 3141
 O'Hara, Koji, 431, 1406
 Ohara, Maria, 3269
 Ohashi, Kyoichi, 1298
 Ohishi, Kazuhisa, 1718
 Ohlsen, Knut, 2817
 Ohmura, Yuko, 1666
 Ohno, Akira, 94, 555, 1858, 2853
 Ohta, Kouji, 1278
 Ohtoshi, Takayuki, 1499
 Ohya, Satoshi, 23
 Oikawa, Miki, 1666
 Ojwang, Joshua O., 1412, 1646
 Okada, Kazuyoshi, 1597
 Okamoto, Kiyomi, 1938
 Okamoto, Susumu, 2041
 Okazaki, Osamu, 1751
 Okonogi, Kenji, 2630
 Okunishi, Masahiko, 1666, 2095
 Oleksijew, A., 2385
 Oleksijew, Andy, 2674
 Olink, A. G., 1233
 Olivier, Martin, 2527
 Olson, Jcl E., 2254
 Omura, Satoshi, 2731
 O'Neill, Paul M., 682
 O'Neill, P. M., 2410
 Ono, Nobukazu, 1666, 2095
 Ono, Tsuneko, 1083
 Onodera, Yoshikuni, 3044
 Oomori, Yasuo, 2678
 Orani, Anna, 1346
 Orden, Beatriz, 989
 Orefici, Graziella, 712
 Orme, Ian M., 3047
 Orozco, Alison S., 2645
 Ortiz, G., 1306
 Osborne, Barbara, 332
 Østergaard, Christian, 1706
 Osterling, M. Clayton, 487
 Otani, Tsuyoshi, 1641
 Otsubo, Takakazu, 40
 Otten, Tatjana F., 2443
 Otto, Michael J., 3179
 Ouassis, A., 3097
 Ouellet, Daniele, 3107
 Ouellet, Nathalie, 2527, 3309
 Ouellette, Marc, 1689
- Owens, Mary L., 789
- Padoin, C., 1463
 Paetznick, Victor L., 129
 Paige, L., 2385
 Paige, Lenette, 2674
 Palamone, Carla, 487
 Palarchio, Angela Ianni, 1745
 Palepu, Marie-France L., 502
 Pallares, Roman, 53
 Palmer, Michael, 2569
 Palmer, Robert, 1176
 Palucha, Andrzej, 3079, 827
 Palzikl, Timothy, 2319, 2576, 2893
 Pan, Xiao-Su, 2810
 Pankuch, G. A., 624, 1503
 Pankuch, Glenn A., 1263, 2914, 3028, 3032
 Pannecouque, C., 618
 Papa, Pietro, 2017
 Paradise, Michael R., 959
 Pariat, Claudine, 2756
 Paris, William, 1629
 Park, B. K., 2410
 Park, Chang, 3218
 Park, I.-S., 2215
 Parker, William B., 1045
 Parkinson, Tanya, 1695, 2645
 Parra, Araceli, 1361
 Parrott, Steven C., 1646
 Pascual, Alvaro, 1850, 3290
 Pastuszak, Anne, 1336
 Patel, Robin, 202
 Paterson, Jesse, 779
 Patrick, A. K., 2637
 Patrick, Donald A., 666, 2877
 Patrick, Sheila, 3002
 Patron, Roberto L., 1355
 Patterson, Jan E., 1305, 2312
 Patterson, Thomas F., 2932, 2938
 Patton, D. L., 1239
 Paul, Gérard, 1323
 Paul, Muriel, 2141
 Pauwels, Rudi, 269, 3123
 Payares, Gilberto, 1771
 Payne, D. J., 436
 Pearce, James A., 2160
 Peeters, Frank, 269
 Pelak, Barbara A., 1996
 Peloquin, Charles A., 927, 1578
 Peña, Carmen, 53
 Penso, Gabriella, 2232
 Perani, Evelyne, 1115
 Perez, Evelio J., 3290
 Pereira, Maria E. S., 2549
 Perez, Norma, 1771
 Perfect, John R., 2495, 2503, 2630
 Perilli, Mariagrazia, 1459
 Perkins, Margaret E., 843
 Perkins, Ruth, 1417
 Perkins, Walter R., 767
 Perni, Robert B., 3179
 Pernodet, Jean-Luc, 2612
 Perret, G., 1463
 Perri, M. B., 705
 Peterson, Lance R., 734
 Petitjean, O., 1463
 Petitjean, Olivier, 849, 3304
 Petraitienė, Ruta, 2700, 2898
 Petraitis, Vidas, 2700
- Petraitis, Vidmantas, 2898
 Petrofsky, Mary, 180
 Petrosino, Joseph, 2893
 Petrucca, Andrea, 3053
 Pettit, George R., 2961
 Pettit, Margaret, 921
 Pettit, Robin K., 2961
 Pezzella, Cristina, 3053
 Pfaller, M. A., 161, 282, 3242
 Pfaller, Michael A., 1207, 1382, 1387, 1762
 Pfrunder, Dietmar, 1868
 Philippon, Alain, 464, 2352
 Piccolomini, R., 3000
 Pichoud, Christian, 369
 Piddock, Laura J. V., 795, 2956
 Pietrelli, Larry A., 606
 Pinkerton, Frank H., Jr., 2656
 Piper, James R., 3315
 Piras, Marta, 1771
 Piras, Romano, 1771
 Pirofski, Liise-Anne, 1437
 Piscitelli, Stephen, 2399, 2700
 Pitout, J. D. D., 1350
 Pitout, Johann D. D., 596
 Pitt, M. Louise, 675
 Pizzo, Philip A., 1815, 3187
 Plattner, Jacob J., 3218
 Plowe, C. V., 164
 Ploy, Marie-Cécile, 2557
 Podglajen, Isabelle, 209, 2089
 Poggio, Antonio, 1346, 2017
 Pomerantz, Roger J., 1200
 Pompei, Raffaello, 3035
 Ponte, Carmen, 1361
 Poole, Keith, 65, 399, 1682, 2225
 Poole, Robert K., 959
 Pootrakul, Pensri, 2332
 Popov, Serguei, 1133
 Porcelli, S. A., 550
 Porretta, Giulio Cesare, 3035
 Portaels, F., 2070
 Portillo, A., 3279
 Portnoy, Yury A., 2841, 2848
 Posho, Leta, 2950
 Postelnick, Michael A., 734
 Pottecher, Thierry, 425
 Potts, Karen E., 478
 Pouedras, P., 2184
 Power, Maureen, 631
 Powles, Mary Ann, 1985
 Poyart, Claire, 108
 Prange, Hilmar W., 2012
 Pratlong, Francine, 2141
 Praz, G., 2966
 Preira, A., 1944
 Preston, Sandra L., 1098
 Prieto, J., 414, 1574
 Pritchard, P. Haydn, 3146
 Psaroulaki, Anna, 2747
 Pujol, I., 1601
 Pujol, Miquel, 53
 Purdue, Lynette, 1315
 Purimetta, Nayantara, 907
- Qian, Jiang, 1788, 3107
 Qin, Xiang, 2883
 Quarta, M., 3320
 Quenelle, Debra C., 2682
 Quentin, C., 2125
 Quesne, Gilles, 108
 Quinn, Patricia, 1290
- Quintiliani, Richard, 991
 Raasch, Ralph, 631
 Rabin, Linda, 2113
 Radding, Jeffrey A., 1187
 Radulovic, Suzana, 1845
 Rafai, Fatemeh, 1121
 Rainey, Petrie M., 1076
 Rajacic, Zarko, 895
 Rajagopalan-Levasseur, Premavathy, 1068
 Rama, Paolo, 2232
 Ramachandran, Kishore, 666
 Ramage, Gordon, 3002
 Ramaswamy, Manisha, 1646, 3146
 Ramon, Jaco, 473
 Rampp, Albert, 2569
 Ramsey, Mary A., 1305
 Ranieri, Sergio, 1346
 Raoult, D., 1537
 Raoult, Didier, 3086
 Rasheed, J. Kamile, 2312
 Rastogi, Nalin, 3006
 Ratelle, Johanne, 404
 Ratheiser, Klaus, 2417
 Rather, Philip N., 959
 Rattendi, Donna, 2718
 Rauli, Robert E., 2342
 Ravensbergen, E., 3073
 Raymond, J., 1334
 Raymond, Martine, 1034
 Raymond, Ralph H., 2295
 Rayner, Craig R., 1370
 Raze, Dominique, 534
 Reagan, David R., 1305
 Reeves, D. S., 419
 Regelink, Annette G., 319
 Regen, Steven L., 147, 2542
 Reichelderfer, Patricia S., 2326
 Rechl, Veronica, 1098
 Reilly, William, 1402
 Reinecke, Manfred G., 140
 Reinert, Ralf René, 1509
 Remington, Jack S., 1713
 Renaudin, H., 703
 Renaudin, Hélène, 2304
 Renaudin, Joel, 2024, 2304
 Revankar, Sanjay G., 2938
 Rex, J. H., 282
 Rex, John H., 129
 Reynolds, Peter E., 154
 Reynolds, Robert C., 3315
 Ricart, Asumpta, 53
 Riccardi, Giovanna, 1931
 Ricci, Davide, 18
 Ricci, Maria Luisa, 712
 Ricci, V., 2956
 Rice, Louis B., 963, 1871
 Rice, William G., 487, 1488
 Richards, David M., 1266
 Ricou, B., 2966
 Ridley, Robert G., 2973
 Ridoux, Olivier, 3301
 Riesbeck, Kristian, 1923
 Rietbroek, S., 2359
 Rieux, Véronique, 862
 Rimaroli, C., 3012
 Rinaldi, M. G., 282
 Rinaldi, Michael G., 147, 151, 978
 Ringertz, Signe, 1062
 Ringwald, Pascal, 1811, 2347

- Ritz, William J., 2564
 Rivera, Johanna, 1437
 Rivollet, Daniele, 2141
 Robbins, Brian L., 612, 2656
 Robert-Gero, Malka, 352
 Roberts, Marilyn C., 257, 3022
 Roberts, Patricia, 767
 Roberts, William L., 1076
 Robertson, B. D., 2799
 Robinson, W. E., Jr., 2245
 Robinson, W. Edward, Jr., 140
 Robledo, Sara, 1990
 Roblin, Patricia M., 194, 951,
 1515
 Rogers, Michael, 1315
 Rogers, M. John, 715
 Rogers, P. David, 978
 Rolain, J. M., 1537
 Romand, J., 2966
 Romanha, Alvaro J., 2549
 Rood, Julian I., 1563
 Rooney, James F., 2380
 Rosas, Angel L., 1437
 Rosato, Adriana, 1392
 Rosen, H., 1996
 Rosenkranz, Alexander R.,
 2417
 Rosenthal, Philip J., 2254
 Ross, Jeremy I., 1702
 Rossi, Rick, 3256
 Rossignol, Daniel P., 2824
 Rossignol, Jean François, 2836
 Rousseau, Déborah, 654
 Roy, Paul H., 1506
 Royce, C., 135
 Rubin, Marc, 3187
 Rubin, Robert H., 2048
 Rubinstein, Ethan, 473, 2607
 Rudant, Eric, 2759
 Rudin, Susan D., 963
 Rudy, Jeff, 2996
 Ruette, Sandrine, 654
 Ruhnke, Markus, 3065
 Ruiz, F., 3279
 Ruiz, Joaquin, 2768
 Ruiz-Bravo, Alfonso, 3009
 Ruscoe, J. E., 2410
 Rusing, Guido, 1151
 Russell, A. D., 2151
 Rustad, Tiger, 2584
 Rutman, Andrew, 772
 Ruys, G. J. H. M., 1233
 Rybak, Michael J., 254, 721,
 981, 2188, 2710
 Ryder, Neil S., 1057
 Ryu, Miwako, 691
 Sabbagh, Yves, 2319
 Sacks, Stephen L., 2996
 Sadler, B., 2153
 Sadler, Brian, 1315
 Sacnz, Y., 3279
 Safrin, Sharon, 2380, 2996
 Sage, David R., 2923
 Sage, Suzanne, 1336
 Sahl, Hans-Georg, 154
 Sahm, Daniel, 1980
 Sahm, Daniel F., 1229, 1671
 Saika, Takeshi, 579
 Saito, Shinji, 1015
 Sakamoto, Misao, 579
 Sala, J., 1601
 Saldivar, Ayda, 3218
 Saleh Mghir, Azzam, 2830
 Salerno-Concalves, Rosangela,
 2482
 Sales, Nicole, 2830
 Salvadó, M., 1524
 Samii, Kamran, 3304
 Samuels, D. Scott, 2906
 Sanders, C. C., 1350
 Sanders, Christine C., 596, 1610
 Sanders, W. Eugene, Jr., 1610
 Sandul, Amy L., 2103
 Sanglard, Dominique, 241,
 1819, 2932
 Sanjoa, Cristina, 1771
 Sanschagrin, Francois, 2576,
 1245, 1966, 2319
 Sarasini, Antonella, 444
 Saravia, Nancy G., 1990
 Sarkkinen, Hannu, 1493
 Sasaki, Eisuke, 1722
 Sato, Akihiko, 1340
 Sato, Kenichi, 236, 1284, 1641,
 3044
 Saunders, Marilyn H., 184
 Savov, Orlin, 1659
 Sawa, Teiji, 3269
 Sawada, Yasufumi, 691, 1738
 Sawai, Tetsuo, 431, 1406
 Saxon, Dawn, 45
 Scagliola, Massimo, 2232
 Seafuse, G., 3320
 Schaad, Ronda D., 947
 Schacht, E., 1012
 Schaefer, Catherine A., 487
 Schantz, Peter M., 601
 Scharf, Matthew D., 1437
 Schaufele, Robert L., 2898
 Schel, Patricia, 269
 Schell, Wiley A., 2495, 2503,
 2630
 Schenk, Peter, 2417
 Schentag, Jerome J., 521
 Scheuring, Sibylle, 1249
 Schick, Betsy, 1336
 Schick, D. G., 188
 Schiller, Neal L., 974
 Schinazi, Raymond F., 2804
 Schito, Gian Carlo, 464
 Schlüter, Gerhard, 1831
 Schmatz, Dennis, 1985
 Schmid, E. N., 725
 Schmidt, H., 277, 1397
 Schmit, J.-C., 618
 Schmitt, Jürgen W., 2870
 Schmitt, Kathy A., 789
 Schmitz, Franz-Josef, 1249
 Schmuck, Gabriele, 1831
 Schneider, Ines, 514, 827
 Schneider, O., 1397
 Schneider, R., 2966
 Scholten, P. C., 3266
 Schönfeld, Wolfgang, 2197
 Schrijver, I. A., 3073
 Schroeder, T. H., 2421
 Schühly, U., 2060
 Schülin, T., 1088, 1520
 Schultz, Marc J., 1605
 Schumann, Jens, 1911
 Schürmann, Anja, 1831
 Schurr, Erwin, 1034
 Schuster, Brian G., 1293
 Schuster, Sheldon M., 2456
 Schwabe, Rudolf, 1470
 Schwank, Silvia, 895
 Schwarz, Stefan, 1288, 2116
 Schweizer, Herbert P., 394
 Scribante, J., 2235
 Seal, David V., 2144
 Segatore, Bernardetta, 1459
 Segovia, M., 1306
 Segura, C., 1524
 Seibel, Nita L., 2391
 Seiberling, Michael, 298
 Seifer, Maria, 3200, 3209
 Sein, Tin, 2399, 2700, 2898
 Sekiguchi, Morie, 1597
 Sekiyama, Takaaki, 2095
 Semaoun, Rémi, 849
 Semenov, Andrey, 2254
 Sempere, Marco, 2768
 Senesi, S., 2434
 Seo, Susan M., 197, 254, 981
 Seppälä, Helena, 257, 1493
 Sereno, D., 3097
 Setacci, Domenico, 1459
 Seytre, Delphine, 849
 Shafran, Stephen D., 2996
 Shah, Nikil H., 1447
 Shakibaei, Mehdi, 1470
 Sham, Hing L., 3218
 Shanley, Diarmuid B., 1819
 Shannon, Kevin, 2771
 Shapiro, Howard M., 2326
 Shaw, Jeng-Pyng, 687
 Shaw, Margaret M., 934
 Shayegan, Mehdi, 1105
 Shealy, Y. Fulmer, 1045
 Shedlofsky, Steve, 2602
 Sheehan, Daniel J., 3313
 Shelton, Mark J., 409, 821
 Sherrill, Lanette C., 1139
 Shetty, Daiva, 2399
 Shetty, Shubhra, 1200
 Shevchenko, Alexander A., 659,
 2841, 2848
 Shewach, Donna S., 1045
 Shi, Harry, 1176
 Shigenobu, Fritz, 431
 Shigeri, Yasushi, 2745
 Shim, Hyun J., 1217
 Shimada, Hideyo, 325
 Shimizu, Masaki, 431
 Shimizu, Mayumi, 2745
 Shinabarger, Dean L., 3251
 Shioota, Sumiko, 1778
 Shirai, Chiharu, 1278
 Shmuklarsky, Moshe, 1293
 Shoen, Carolyn M., 3315
 Shugarts, D., 2637
 Sibbald, R. Gary, 2996
 Siber, George E., 583
 Sibley, C. H., 164
 Sidorenko, Sergei V., 1259
 Sidwell, Robert W., 640, 3234
 Siegel, J., 2245
 Sieradzki, Krzysztof, 100
 Sifaoui, Farid, 173
 Sigfusson, Ásbjörn, 1005
 Silen, Joy L., 1447
 Simard, Marie, 2527, 3309
 Simarro, Encarnación, 2768
 Simjee, S., 2799
 Simoncini, Lavinia, 444
 Simor, Andrew E., 762
 Singh, Kavindra V., 2883
 Sinnis, Photini, 2731
 Sirot, D., 1110, 2184
 Sirot, Danielle, 2771
 Sirot, J., 1110, 2184
 Sjögren, Eva, 3276
 Sköld, Ola, 1062, 3059, 3276
 Skurnik, Mikael, 257, 1493
 Skurray, Ronald A., 475
 Slifer, Teri R., 1713
 Slight, Thra, 135
 Slocombe, Brian, 813
 Smallwood, R. A., 3130
 Smeijsters, Louis J. J. W., 1146
 Smidt, Mary L., 478
 Smith, Anthony M., 1329
 Smith, Gillian M., 813
 Smith, James W., 934
 Smith, Jean A., 1139
 Smith, Raymond P., 2405, 2564,
 3153
 Smith, R. P., 903
 Smitherman, Laura S., 2906
 Smithgall, Molly D., 1133
 Snijders, Susan V., 1677, 2431
 Socransky, Sigmund S., 2595
 Soejima, Rinzo, 3141
 Soini, Hanna, 257, 2443
 Sokal, Etienne M., 404
 Solas, Caroline, 2989
 Solas, Dennis W., 1447
 Solbach, Werner, 2762
 Sommadossi, Jean-Pierre, 2989
 Soong, Seng-jaw, 1139
 Sörberg, Mikael, 1222
 Sörensen, Tina Klitmøller, 1706
 Sörgel, Fritz, 1151, 1659, 2012,
 2359
 Soriano, Francisco, 1028, 1361
 Sougakoff, Wladimir, 2074
 Soukos, Nikolaos S., 2595
 Souli, M., 1088
 Souli, Maria, 939
 Soussy, Claude-James, 2590
 Sow, Samba, 1115
 Spangler, Sheila K., 495, 1253
 Sparfloxacin Multicenter UTI
 Study Group for the, 2262
 Spector, Stephen A., 808
 Spielberg, B., 1233
 Speelman, Peter, 1605
 Speirs, Robert J., 462
 Speldooien, Valérie, 879
 Speneer, James, 921
 Speranza, Filippo, 1346
 Sperling, Rhoda S., 808
 Spicer, W. John, 1365, 1370
 Spinola, Stanley M., 2690
 Spring, L., 1853
 Spruance, Spotswood, 789
 Spyridaki, Ioanna, 2747
 Sri Kumar, Ramakrishnan, 65,
 399, 1682, 2225
 Srinivas, Ranga V., 612, 1484,
 3157
 Staas, Jay K., 2682
 Stähle, Lars, 2174
 Stahlmann, Ralf, 1470
 Staib, A. Horst, 2359
 Stamm, W. E., 1239, 1726
 Standiford, Harold C., 631
 Standing, David N., 3200, 3209
 Stanko, Jason P., 666
 Stapleton, Paul, 2771
 Stass, H., 2060

- Staszewski, Schlomo, 269, 3123
 Steckelberg, James M., 202
 Steigbigel, Roy T., 1139
 Stein, Andreas, 3086
 Stein, Daniel S., 358
 Steingrimsson, Olafur, 2290
 Stephan, Bernd, 83
 Sterrett, Andrew T., 332
 Stevens, David A., 767, 899,
 907, 2299
 Stevens, Dennis L., 1266
 Stevens, Rachel, 767
 Steward, Christine D., 2661
 Stewart, Kent, 3218
 Stewart, Michael B., 2295
 Stiebel, Thomas R., Jr., 478
 St-Louis, Maryse, 2511
 Stoberingh, Ellen E., 3331
 Stoddart, Cheryl A., 2113
 Stoeckel, Klaus, 2602
 Stoffels, Paul, 3123
 Stone, J., 223
 Stone, Julie A., 332
 Storch, Gregory, 1980
 Storie, Christine, 1563
 Strobel, Frank W., 1878
 Struthers, J. K., 1428, 2521
 Struwig, M. C., 2752
 Stuerz, K., 277, 1397
 Stürmer, Martin, 3123
 Suárez, Ana Isabel, 3290
 Sudbeck, Elise A., 3225
 Sueoka, Cathy, 687
 Sugai, Motoyuki, 1278
 Sugar, Alan M., 1424
 Sugimoto, Hirohiko, 1340
 Suginaka, Hidekazu, 1278
 Suginaka, M., 3333
 Sugita, M., 550
 Sugiyama, Toshiro, 1895
 Sulavik, Mark C., 3317
 Suller, M. T. E., 1195
 Sullivan, Derek J., 1819
 Sullivan, Donna C., 978
 Sullivan, J., 2262
 Sultan, Eric, 199
 Sumpunsirikul, Petchmanee,
 2332
 Sun, Eugene, 2784, 3218
 Sundelof, Jon G., 1996
 Sunder-Plassmann, Gere, 2417
 Suriano, Terra, 734
 Sutton, Kym, 45
 Suzuki, Katsuya, 1666, 2095
 Suzuki, Naoyoshi, 2985
 Swaney, Steve M., 3251
 Swarz, H., 114
 Swedberg, Göte, 1062
 Sweet, Clive, 640, 647
 Swenson, Christine E., 767
 Symonds, W., 2153
 Szekely, Adrien, 1412
 Taba, Hideki, 2193
 Taber, Harry, 1105
 Tachedjian, Gilda, 3038
 Taek, Kenneth J., 1073
 Tada, Mayumi, 2492
 Tahar, Rachida, 1811
 Tai, Chun Y., 640, 3234
 Tailor, Sandra A. N., 762
 Takahashi, Koichi, 579
 Takanaga, Hitomi, 1738
 Takei, Masaya, 2678
 Takekura, Hiromu, 698, 2006
 Takesako, Kazutoh, 755
 Takeuchi, Naonobu, 1499
 Takiguchi, Yoshiharu, 1433
 Takizawa, Hajime, 1499
 Takizawa, Tomoko, 40
 Talarico, Christine L., 444
 Talbot, G. H., 1088, 2262
 Tamaoka, Hisashi, 2943
 Tamura, Hirohi, 1015
 Tamura, Shinobu, 1858
 Tamura, Toshihide, 700
 Tanaka, Eitaro, 40
 Tanaka, Hironori, 698, 2006
 Tanaka, Masatoshi, 579
 Tanaka, Mayumi, 236, 1284,
 3044
 Tanaka, S. K. T., 2385
 Tanaka, Yoshinobu, 2119
 Taniguchi, Koki, 717
 Tanimoto, Koichi, 2150
 Tashiro, Takayoshi, 40, 1722
 Tateda, Kazuhiro, 555, 1858,
 2853
 Tatsu, Yoshiro, 2745
 Tattawasart, Unchalee, 2151
 Täuber, Martin G., 3235
 Tavanti, A., 2434
 Taylor, D., 3209
 Taylor, Diane E., 59, 1952
 ten Kate, Marian T., 1677
 Tennant, Bud C., 2804
 Tenorio, C., 3279
 Tenover, Fred C., 2312, 2661,
 3024
 Tenovuo, Jorma, 1906
 Tentori, L., 550
 Teraguchi, Susumu, 1587
 Tessier, F., 2125
 Tessier, Pamela R., 840, 991
 Thackray, Alana M., 1555
 Thal, L. A., 705
 Thalhammer, Florian, 2417
 Then, Rudolf, 1495
 Theodos, Cynthia M., 1959
 Thériault, Esther, 2319
 Therrien, Christian, 2576
 Theuretbacher, Ursula, 1659
 Thiel, Andreas, 2012
 Th'ng, Cecilia, 1290
 Thölke, Jürgen, 1911
 Thomas, Ann M., 528
 Thomas, Jennifer K., 521
 Thompson, Diane G., 1303
 Thompson, Randall K., 1996
 Thomson, Kenneth S., 596
 Thomson, K. S., 1350
 Thorburn, Christine E., 1973,
 3193
 Thoresen, Ove Fredrik, 712
 Thormar, Halldor, 2290
 Tidwell, Richard R., 666, 2495,
 2503, 2877
 Tiegs, Gisa, 1911
 Tingle, M. D., 2410
 Titlow, William B., 727
 Tod, M., 289, 1463
 Tod, Michel, 849
 Tolson, D., 436
 Tomasz, Alexander, 100
 Tomé, Daniel, 2607
 Tominaga, Kaoru, 1015
 Tomono, Kazunori, 40, 698,
 1722, 2006
 Toole, J. J., 3130
 Tornatore, Michelle A., 734
 Toro, D., 1574
 Torre, Donato, 1346, 2017
 Tornero, M. N., 344
 Torres, C., 3279
 Tosini, Fabio, 3053
 Totten, Patricia A., 2690
 Tovciak, A., 2385
 Tran, Thu T., 2656
 Traore, H., 2070
 Trapnell, Carol Braun, 1592
 Trees, David L., 2103
 Tremblay, Carole, 1847
 Trépanier, Eric F., 695
 Trépo, Christian, 369
 Trescher, Gudrun, 59
 Triebel, Catharine A., 59
 Triessenberg, Steve, 1783
 Trieu-Cuot, Patrick, 108
 Trofatter, Kenneth F., Jr., 789
 Troillet, N., 2966
 Trostdorf, F., 1397
 Trottier, Sylvie, 2996
 Trowbridge, Martin, 868
 Troyer, Jill Michelle, 1845
 Truffot-Pernot, Chantal, 2066
 Truong, Lo Anne, 2113
 Tsai, Shane F., 1229
 Tsclentis, Yannis, 2747
 Tshukutsoane, S., 2235
 Tsuboi, Isami, 431
 Tsuchiya, Tomofusa, 1778
 Tsuda, Masataka, 1938
 Tsuda, Yasuyuki, 325
 Tsuji, Masakatsu, 94
 Tsuji, Takashi, 2095
 Tsujimoto, Hideto, 1938
 Tsunoi, Tomoko, 325
 Tsuruo, Takashi, 755, 1738
 Tsutsui, Ken T., 1447
 Tucker, Simon T., 478
 Tuel-Ahlgren, Lisa, 383, 3225
 Tullio, Vivian, 1745
 Tunney, Michael M., 3002
 Turik, Michael A., 2446
 Turner, Jeffrey, 2206
 Turner, William W., 1187
 Turpin, Jim A., 487
 Tyring, Stephen K., 789, 1139
 Tzelepi, Eva, 1259, 1281
 Tziori, Saul, 1959
 Tzouvelekis, Leonidas S., 1259,
 1281
 Ubeaud, Geneviève, 425
 Ubukata, Kimiko, 2267
 Uchida, Takahiro, 691
 Uchida, Yoko, 1284, 3044
 Uckun, Faith M., 383
 Uckun, Fatih M., 3225
 Uematsu, Toshihiko, 1298,
 1433
 Uemura, Yayoi, 1015
 Uh, Mitchell, 2511
 Uhl, Jim R., 202
 Ulrich, Peter, 1133
 Underwood, Mark R., 444
 Unertl, K., 2421
 Urasawa, Shozo, 717
 Urbina, Julio A., 1771
 Uriel, Clara, 779
 Uzzan, Bernard, 849
 Vaccaro, Joseph R., 675
 Vakulenko, Sergei B., 1542
 Valadon, Philippe, 1437
 van Alphen, Loek, 319
 van Berkel, Theo J. C., 1146
 van Boxtel, René A. J., 3173
 Van Cauwenberge, Anja, 269
 Vandamme, A.-M., 618
 van de Klundert, Jos A. M.,
 3173
 Vandenbroucke-Grauls,
 C. M. J. E., 2749
 van den Bogaard, Anthony E.,
 3331
 Van den Eynde, Christel, 269
 Van Den Mooter, Guy, 1568
 van der Poll, Tom, 1605
 van Deventer, Sander J. H.,
 1605
 van Dissel, Jaap T., 739
 van Dissel, J. T., 3073
 van Dyke, Russ, 808
 van Dyke, Russell, 1315
 Vanechoute, Mario, 3329
 van Etten, Els W. M., 1677,
 2431, 2437
 Van Gerven, F., 282
 van Gerwen, Veerle, 269
 Vanhoof, Raymond, 483
 van Houtte, Margriet, 269
 van Langevelde, P., 3073
 van Langevelde, Petra, 739
 van Marwijk Kooij, M., 1233
 Van Meervelt, L., 618
 van Vianen, Wim, 2431, 2437
 Van Voorhis, Wesley C., 3245
 van Vugt, M., 135
 Vargas, Marcus, 2718
 Varon, Emmanuel, 173
 Vasavanonda, Suditha, 3218
 Vasilyef, Alexandre V., 2443
 Vattanavibool, Phantip, 2332
 Vaudaux, Pierre E., 564
 Vazifeh, D., 1944
 Veau, C., 289
 Vedantam, Gayatri, 88
 Vega, S., 618
 Venkatachalam, T. K., 3225
 Venkateswarlu, K., 1756
 Venzon, David J., 3187
 Verbrugh, Henri A., 377, 744,
 749
 Verdet, Charlotte, 2352
 Verhoeven, Jan, 1249
 Vermeulen, M. C. A., 1233
 Verschraegen, Gerda, 3329
 Verweij, Paul E., 873
 Vestris, G., 1537
 Vicarini, Hubert, 1392
 Vickers, Mary K., 231
 Vig, Rakesh, 3225
 Viljanen, Matti K., 2443
 Villari, Paolo, 100
 Villarreal, Elecira C., 916
 Vincent, H. H., 1233
 Vincent, John, 2048
 Visalli, M. A., 624
 Visalli, Melissa A., 857, 953,
 2002

- Visca, Paolo, 3053
 Vogel, Nicolas, 2036
 Voladri, Rama Kishan R., 1375, 3163
 Vollmer, A., 725
 von Recklinghausen, G., 725
 Vora, Shefali, 907, 2299
 Vostrov, Sergey N., 659, 2841, 2848
 Voyer, Normand, 2319
 Vyshnevskaya, Elena, 2443
 Vyshnevskiy, Boris I., 2443
 Wachira, Timothy M., 601
 Wada, Takaomi, 1938
 Wada, Yasunao, 700
 Wagner, Sonja, 1057
 Wakabayashi, Hiroyuki, 1587
 Waldman, Scott, 332
 Walker, Scott, 762
 Wallace, Thomas, 1646
 Wallace, Thomas L., 1412
 Walsh, Gerald M., 801
 Walsh, Thomas J., 263, 2391, 2399, 2700, 2898
 Walsh, Timothy R., 921
 Walsh, T. J., 282
 Walsh, T. R., 436
 Wandtschneider, Heidi L., 930
 Wang, B., 2245
 Wang, Elaine, 1290
 Wang, Ge, 1952
 Wang, Hui, 2633
 Wang, Jianghai, 2620
 Wang, Jian-Ying, 709, 956
 Wang, Li, 2178, 3136
 Wang, Q. May, 916
 Wang, Shan-Tair, 1319
 Wang, Tong, 236
 Wang, Yan Yan, 2132
 Wang, Yongwen, 1447
 Ward, Douglas J., 1695
 Ward, Rosemary, 868
 Ward, S. A., 2410
 Ward, Stephen A., 682, 2973
 Waring, Alan J., 2206
 Warnock, David W., 1412
 Wasan, Kishor M., 1646, 1878, 3146
 Watanabe, Naoko, 325
 Watkins, W. M., 164
 Webb, Murray S., 45, 2511
 Wehrle, A., 2421
 Weigel, Linda M., 2661
 Weinberg, Adriana, 2326
 Weinstock, George M., 2883
 Welch, John T., 462
 Welkos, Susan L., 675
 Welton, L. A., 705
 Wendt, Constanze, 2440
 Wennenstern, C. B., 1088, 1520
 Werckenthin, Christiane, 2116
 Wesche, David L., 1293
 Westin, Katherine, 1437
 Wexler, Hannah M., 984
 Whitcomb, Patricia O., 2391
 White, N. J., 135
 White, Theodore C., 2584, 2932, 3245
 Whitley, Richard J., 1139
 Whittington, William L., 2103
 Wichelhaus, Thomas A., 2817
 Wideburg, Norm, 3218
 Wiener-Kronish, Jeanine P., 3269
 Williams, Byron K., 528
 Williams, D. L., 1853
 Williams, Kerstin J., 795
 Williams, Matt, 647
 Williams, Matthew A., 640, 3234
 Williams, R. Rex, 885
 Williamson, Karen, 487
 Wills, Peter, 772
 Wilson, Aaron J., 3245
 Wilson, Robert, 772
 Wilson, Wyndham, 2391
 Winchester, Gary A., 2682
 Wincker, Patrick, 1771
 Wingard, John R., 3103
 Winstanley, P. A., 164
 Wise, R., 428
 Wise, Richard, 2032
 Wiseman, David J., 45, 2511
 Witvrouw, M., 618
 Wolfe, Joyce N., 184
 Wolff, M., 28
 Wong, Frank A., 885
 Wong, Frankie A., 1098
 Wong, Kim F., 45
 Wong, Wesley, 1646
 Wood, John, 1402
 Wood, P., 1365
 Woodford, Neil, 502
 Woodford, Patricia J., 2919
 Woodnutt, Gary, 3193
 Woolf, Eric, 332
 Wootton, M., 419
 Wretlind, Bengt, 3276
 Wright, G. D., 2215
 Wu, Bor Wen, 140
 Wu, Huiwei, 3234
 Wu, Juinn-Jong, 1319
 Wu, Teresa W., 843
 Wu, Yaming, 1340
 Wubbels, Loretta, 2650
 Wyatt, J. R., 2113
 Xiao, Yan, 712
 Xie, Meng-Yu, 2989
 Ximenez-Fyvie, Laurie Ann, 2595
 Xu, Chen, 956, 2978
 Xu, Jing, 1315
 Xu, Yi, 2883
 Yamada, Hideo, 325
 Yamada, Yasuaki, 2006
 Yamada, Yasuhiro, 2985
 Yamaguchi, Hideyo, 967, 1587
 Yamaguchi, Keizo, 94, 555, 785, 1181, 1858, 2853
 Yamaguchi, Toshiyuki, 698, 2006
 Yamaji, Emiko, 431
 Yamakido, Michio, 1278
 Yamamoto, Hiroshi, 1597
 Yamamoto, Kazuhiko, 1499
 Yamamoto, Koujirou, 691, 1738
 Yamanishi, Koichi, 1666
 Yamano, Katsuhiro, 1738
 Yamatani, S., 3333
 Yamatsut, Isao, 2824
 Yanagihara, Katsumori, 1722
 Yang, Shio-w-Shong, 3256
 Yang, Youjun, 1671, 1980
 Yasuda, Hiroshi, 23
 Yasuda, Mitsuru, 433, 3293
 Yasue, Tokutaro, 2678
 Yates, R., 903
 Yeaman, Michael R., 3169
 Yeh, Kuang C., 332
 Yeldandi, Vijay, 2391
 Yoge, Ram, 1315
 Yokochi, Takashi, 1015
 Yokokawa, Masahiro, 1433
 Yokota, Kenji, 1895
 Yoshida, Masanori, 967
 Yoshida, Ryoji, 698, 2006
 Yoshikawa, Eiji, 431
 Yoshikawa, Susumu, 2745
 Yoshimura, Fuminobu, 2119
 Yoshimura, H., 3333
 Yoshimura, Manabu, 2150
 Yoshihaga, Michiko, 1866
 Yoshioka, Hirofumi, 755
 Yoshizumi, Satoshi, 785
 Youle, Michael S., 293
 Young, Douglas B., 1931
 Young, Lowell S., 180
 Young, Lynnette D., 583
 Yu, Christine Y., 471
 Yu, Yue C., 509
 Yuan, Meifang, 1168
 Yuen, Geoffrey J., 3187
 Yumoto, Noboru, 2745
 Zaai, Sebastian, 1605
 Zagury, Daniel, 2482
 Zafert, Katie, 3179
 Zukula, Dorothy, 389
 Zalkow, L., 2245
 Zanetti, G., 2966
 Zanetti, Stefania, 3035
 Zarazaga, M., 3279
 Zelenitsky, Sheryl A., 2446
 Zemzoumi, K., 3097
 Zepp, Charlie, 3256
 Zervos, M., 729
 Zervos, Marcus J., 1229, 2710
 Zervos, M. J., 705
 Zeyhle, Eberhard E., 601
 Zhan, Giorgio G., 184, 2427, 2446
 Zhang, Huizhong, 1200
 Zhang, Li, 399, 2225
 Zhang, Lijun, 640, 647
 Zhao, Qixun, 1682, 2225
 Zhao, Xilin, 956, 2978
 Zhong, Zhaojing, 1437
 Zhou, Jianfeng, 956
 Zhou, Weicheng, 2718
 Zhou, Xiao-Jian, 2989
 Zhu, Yong-Lian, 1805
 Ziebuhr, Wilma, 2817
 Ziegelbauer, Karl, 1581, 2197
 Zimmerli, Werner, 895, 2626
 Zinner, Stephen H., 72, 659, 2841, 2848
 Zippel, Uta, 1470
 Zoulim, Fabien, 369
 Zuckerman, Judy, 1815
 Zurenko, Gary E., 947
 Zwinkels, M. G. J., 3266

SUBJECT INDEX

VOLUME 42

- 2-Oxazepems
 E. faecalis, 2943
OPC-20011, 2943
S. aureus, 2943
S. pneumoniae, 2943
- 2-Pyridones
 ABT-255, 2674
 M. tuberculosis, 2674
- 3TC
 AT-61, 3179
hepatitis B virus, 2128, 3179
HIV, 2989
PBMC, 2989
pharmacodynamics, 2804
woodechuck hepatitis virus, 2804
- 141W94
 HIV, 2153
synergy with 1592U89, 2153
- 1592U89
 HIV, 2153
synergy with 141W94, 2153
- 23S RNA
clarithromycin, 2749
H. pylori, 2749
- A-5021
herpes simplex virus, 2095
herpesvirus
 antiviral activity in cell culture, comparative evaluation, 1666
varicella-zoster virus, 2095
- aacC3*
 E. coli, 3173
 P. aeruginosa, 3173
- aac(6')-Ij*
 Acinetobacter sp. 13, 2759
- aac(6')-Iq*
 K. pneumoniae
 characterization of, 1506
- Abelcet
 L. donovani, 2722
versus sodium stibogluconate, 2722
- ABT-255
 M. tuberculosis, 2674
- ABT-378
 HIV protease, 3218
ritonavir, 3218
- Acanthamoeba*
povidone-iodine, 2232
propamidine, 2144
- Acanthamoeba castellanii*, 2870
uptake of *L. pneumophila*, 2870
- Acinetobacter* sp. 13
 aac(6')-Ij, 2759
 IS18, 2759
- Acne vulgaris
peroxides, organic, water soluble
synthesis and antibacterial evaluation, 911
- Actinobacillus actinomycetemcomitans*
clarithromycin, 3000
erythromycin, 3000
- Actinomyces viscosus*
photochemotherapy, 2595
- Acylovir
dermatomal herpes zoster
 human immunodeficiency virus-infected patients, 1139
sorivudine, comparative evaluation, 1139
- EBV TK, 2923
- herpes simplex virus resistance
 northwest England, survey of, 868
HSV-1 TK, 2923
- mycophenolate mofetil
 potentiation of antiherpesvirus activity, 216
- Adefovir dipivoxil
human immunodeficiency virus variants
 from AIDS patients after prolonged therapy
 genotypic and phenotypic characterization, 1620
- Acromonas veronii*
metallo-β-lactamase
 ImiS, nucleotide and amino acid sequences, 436
- Albendazole
microsporidia, 3301
- All-trans-retinoic acid
lipoprotein distribution
 differences in human, dog, and rat plasma, 1646
- Alpha-toxin
 S. aureus, 2817
- Aluminum hydroxide
pharmacokinetics
 effects on fosfloxacin bioavailability in healthy volunteers, 453
- AmBisome
 C. albicans, 2437
 L. donovani, 2722
versus liposomal amphotericin B, 2437
versus sodium stibogluconate, 2722
- Amikacin
cefeprime, 3304
ceftazidime, 3304
E. cloacae, 3304
imipenem, 3304
M. avium, 3006
 liposome encapsulated, prolonged-interval treatment, rationale for and efficacy of, 459
- M. tuberculosis* resistance
mechanism of, 1295
- pharmacokinetics
 population pharmacokinetic study in febrile, severely neutropenic adults, 849
- Y. enterocolitica*, 3009
- Aminoglycoside acetyltransferases
aac(6')-Iq
 characterization of, 1506
- E. cloacae*
altered substrate profile, 209
- Aminoglycoside phosphotransferases
chromogenic detection, 228
- Aminoglycoside-modifying enzymes
nomenclature of genes encoding letter to the editor, 483
- Aminoglycosides
 E. cloacae and *C. freundii* resistance
 aminoglycoside 6'-N-acetyltransferase variants, altered substrate profile, 209
- P. aeruginosa*, mucoid
diffusion through extracellular polysaccharide, promotion by alginate lyase, 974
- P. stuartii* resistance
 mutations, 959
- pharmacodynamics
- dosing to obtain pharmacodynamic goals in patients with pneumonia, 1892
- pharmacokinetics
 tobramycin MIC changes alter responses of *P. aeruginosa*, 1365
- resistance
 aminoglycoside phosphotransferases, chromogenic detection of, 228
- Amoxicillin
combination with clavulanate, 2375
H. pylori, 2492
infection in gnotobiotic piglets, 1549
- H. pylori* resistance
risk of development, 1222
- microspheres, 2492
- otitis media, acute
cefuroxime, comparative evaluation, 1361
- S. pneumoniae*, penicillin resistant, 1361
- S. pneumoniae*, 2375
- synergy
 cefotaxime, critical importance of concentrations, 468
- experimental *E. faecalis* endocarditis, 468
- Amoxicillin-clavulanate
 H. influenzae, 3193
 S. pneumoniae, 3193
 S. pneumoniae, penicillin resistant activity in experimental respiratory infection model in rats, 813
- AmpC
 P. aeruginosa, 3296
- AmpD
 P. aeruginosa, 3296
- Amphocil
 L. donovani, 2722
versus sodium stibogluconate, 2722
- Amphotericin B
 A. fumigatus, 2569
aspergillosis
 invasive pulmonary, in mice, 40
- Aspergillus*, 3018
- Aspergillus* and *Fusarium* spp.
synergy with rifabutin, 509
- Aspergillus* spp., 2726
- C. albicans*, 2431
- Candida*, 3018
- cholesterol, 3146
- colloidal dispersion
 invasive fungal infections in really impaired patients, 606
- combinations
 flucytosine with or without fluconazole, 528
- murine cryptococcal meningitis, 528
- cryptococcal meningitis
alone and with flucytosine with or without fluconazole, 528
- cryptococcosis, systemic murine
- Fungizone, Amphotec, AmBisome, and Abelcet, comparative evaluation, 899
- dopamine, 3103
- immunoliposomal
 aspergillosis, invasive pulmonary, in mice, 40
- in macrophages, 2569
- L. donovani*, 2722
- L. donovani* promastigotes, resistance in

- mechanism of resistance, 352
L. infantum, 2141
L. major, 3092
leukemia patients, 3103
lipid complex
antifungal activity in vitro and in vivo,
role of phospholipases, 767
lipid emulsion
stability, compatibility, and in vitro anti-fungal activity, 762
lipid nanosphere encapsulated
C. neoformans, activity against, 1722
liposomal, 2431, 2437
liposomes
blood clearance capacity of the mono-nuclear phagocyte system, 1677
nephrotoxicity, 3103
neutropenia, 2391
Paecilomyces spp.
antifungal susceptibilities, 1601
pharmacodynamics
assessment of activity against *C. albicans* by dynamic in vitro mycotic infection model, 1382
pharmacokinetics, 2391, 3146
distribution in lung tissue after injection and inhalation, 1597
unilamellar liposomal vesicle formulation, rats, 263
polyene analog KY-62
murine candidiasis, treatment of, 147
synergy
Aspergillus and *Fusarium* spp., 509
rifabutin, 509
transplant patients, 3103
unilamellar liposomal vesicle formulation
pharmacokinetics and toxicological profile in rats, 263
versus itraconazole, 3018
versus LY303,366, 2726
versus sodium stibogluconate, 2722
versus voriconazole, 3018
Ampicillin
combination with LY333328, 2564
E. faecium, 2564
Ampicillin-sulbactam
concentrations in tissues
bolus injections versus bolus plus continuous infusion, 1093
pharmacodynamics
in vitro infection model against resistant *E. coli*, 231
S. aureus, 3325
Anaerobes
cefminox
comparative in vitro activity, 495
gatifloxacin, 2459
skin and soft tissue infections
levofloxacin, in vitro activities, 984
Y-688
in vitro activities, 419
Antibiotic resistance determinants
E. hirae penicillin-binding protein 3 β
gene is borne on plasmid carrying other antibiotic resistance determinants, 534
Antidiotetoxin reagents
polymyxin B-immunoglobulin G conjugate, 583
Antifungal agents
cordycepin
candidiasis, invasive, antifungal activity, 1424
nystatin, liposome encapsulated
four amphotericin B formulations, comparative evaluation, 1412
time-kill tests
influence of test conditions on results, 1207
Antifungal testing
filamentous fungi
in vitro susceptibilities, possible correlation with outcomes in animal models, 282
Antimalarial agents
quinoline-ring containing
S. cerevisiae drug resistance genes, identification of, 1034
Antimony
L. infantum, 3097
pentavalent, 3097
Antimycobacterial agents
fluorescent protein reporter microplate assay
high-throughput screening of compounds, 344
AP-1
ciprofloxacin, 1923
Artemether-benflumetol
falciparum malaria, multidrug resistant artesunate-mefloquine, comparative evaluation, 135
Artesunate
P. falciparum, 2332
pharmacokinetics, 2332
thalassemia, 2332
Artesunate-mefloquine
falciparum malaria, multidrug resistant artemether-benflumetol, comparative evaluation, 135
Aspartic protease inhibition
cysteine, 2254
P. falciparum, 2254
Aspergillosis
A. fumigatus, amphotericin B susceptible and resistant
LY303366, efficacy in murine model, 873
amphotericin B
immunoliposomal, 40
pulmonary, invasive
amphotericin B, immunoliposomal, 40
Aspergillus
amphotericin B, 2726, 3018
itraconazole, 2726, 3018
LY303,366, 2726
voriconazole, 3018
Aspergillus fumigatus
amphotericin B, 2569
immunoliposomal, 40
invasive pulmonary aspergillosis in mice, 40
amphotericin B susceptible and resistant
LY303366, efficacy in murine model of invasive aspergillosis, 873
G-CSF, 2299, 2467
GM-CSF, 2299
LY303366, 2898
efficacy in murine model of invasive aspergillosis, 873
monocytes, 2299
neutrophils, 2299
rabbits, 2898
triazoles, 2467
voriconazole, 2299
Aspergillus spp.
rifabutin-amphotericin B synergy, 509
AT-61
3TC, 3179
hepatitis B virus, 3179
Atherosclerosis
C. pneumoniae, 2762
Atomic force microscopy
E. coli morphology
before and after exposure to cefodizime, use to investigate, 18
Atovaquone
3'-azido-3'-deoxythymidine
glucuronidation by human liver microsomes, inhibition by, 1592
cefotaxime
alone or in combination with minocycline, 1319
experimental murine infection, treatment of, 1319
minocycline
alone or in combination with cefotaxime, 1319
experimental murine infection, treatment of, 1319
pharmacokinetics
zidovudine, glucuronidation by human liver microsomes, inhibition by, 1592
pharmacokinetics and phase I safety
human immunodeficiency virus-infected infants and children, 1315
ATP-bioluminescence susceptibility testing
filamentous cell treatment
novel test using, 1406
Aureobasidin A
S. cerevisiae resistance
role of ABC transporters, 755
Autolysins
E. faecalis, 2883
Avoparcin
chickens, 3333
Enterococcus, 3333
letter to the editor, 3333
AY 9944
HIV, 2482
3'-Azido-3'-deoxythymidine
azido-reductase
activation by ethacrynic acid, dipyridamole, and indomethacin, 1654
inhibition by human immunodeficiency virus protease inhibitors, 1654
glucuronidation by human liver microsomes
inhibition by atovaquone, fluconazole, methadone, and valproic acid, 1592
human immunodeficiency virus-infected patients, 1788
pharmacokinetics
alone and in combination with ritonavir, 1788
Azithromycin
E. coli
postantibiotic and sub-MIC effects, 414
H. influenzae, 2385, 3193, 3313
pharmacodynamics
in vitro and in vivo, comparison with those of erythromycin, 377
pharmacokinetics, 2385
bronchopulmonary, letter to the editor, 481
S. aureus

- postantibiotic and sub-MIC effects, 414
S. pneumoniae, 2914, 3193
- Azoles
C. albicans resistance
 cytochrome P-450 lanosterol 14 α -demethylase, amino acid substitutions, 241
 lactoferrin-triazole combinations, synergy, 1587
Candida, 2342
Candida resistance
 13-year evolution and prevalence in cancer patients at a large medical center, 734
 synergy with nitric oxide, 2342
L. cruzi, 3245
- Aztroconam
 combinations
cefpime, 1610
P. aeruginosa, 1610
P. stuartii resistance
 TEM-60 β -lactamase, 1459
- pharmacodynamics
P. aeruginosa, activity alone and with *cefpime*, 1610
- Babesia divergens*
 drug susceptibilities
 in vitro evaluation, 818
- Bacillus circulans*
 vancomycin, 2055
- Bacteremia
 bacterial pathogens from frequencies of occurrence and antimicrobial susceptibility patterns, 1762 SUNTRY antimicrobial surveillance program, 1762
- Bacterial resistance
 development in acutely ill patients during therapy
 factors associated with, pharmacodynamic evaluation of, 521
- Bacteroides fragilis*
 norfloxacin efflux, 2119
- Bartonella bacilliformis*
 coumermycin A₁, 2906
grvB, 2906
- BAY 10-8888
C. albicans, 2197
 decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
 mechanism of action, 1581
- C. tropicalis*
 decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
 mechanism of action, 1581
- BAY 12-8039
 antimycoplasmal activities in vitro, 703
- B. parapertussis*
 susceptibilities to, letter to the editor, 1868
- B. pertussis*
 susceptibilities to, letter to the editor, 1868
- C. pneumoniae*
 in vitro activity, 951
- BEA005
 pharmacokinetics, 2174
- Benflumetol
P. falciparum, 2347
- Benzimidazoles
 β -tubulin, 2171
C. albicans, 2495, 2503
C. neoformans, 2495, 2503
E. multilocularis metacestodes
 in vitro activities, 1052
 structure-activity relationships, 2495
- Benznidazole
 IL-12, 2549
T. cruzi, 2549
- β -Lactamase inhibitors
P. aeruginosa multidrug efflux pumps substrates for, 399
 resistant TEM-1 mutants
 selection and characterization of, 1542
- β -Lactamas
A. veronii ImiS
 nucleotide and amino acid sequences, 436
- AmpC type
P. mirabilis, chromosomally encoded, 1110
bla_{IMP}, 2006
 BLIP, 2893
 carbenicillin-hydrolyzing, 1966
Caz-hi, 3329
 cefotaxime-hydrolyzing, 1980
 cefotaxime-resistant *Enterobacteriaceae*
 identification of new CTX-M-3 cefotaxime-hydrolyzing enzyme, 827
 ceftazidime, 2576
 class A, cefotaxime hydrolyzing, plasmid mediated
 CTX-M-4, sequence of gene encoding, 1259
 involvement of serine 237 in cephalosporin hydrolysis, 1259
 CTX-M-3, cefotaxime hydrolyzing identification of, 827
 DHA-1, 2352
E. coli
 resistance to expanded-spectrum cephalosporins, 1350
 TEM-43, biochemical and genetic properties, 1671
 Toho-2, cloning and sequencing, 1181
- Enterobacteriaceae*, ceftazidime resistant novel TEM and SHV-5 type, isolates from Polish hospitals, 514
- extended spectrum, TEM and SHV-5 type ceftazidime resistant *Enterobacteriaceae* isolates from Polish hospitals, 514
- extended spectrum, TEM type A237T as a modulating mutation, 1042
- FOX-3
 AmpC type, plasmid mediated, characterization of, 464
- H. influenzae*, 3313
 inhibitor resistant *E. coli*
 discriminatory detection by single-strand conformation polymorphism-PCR, 879
 inhibitor-resistant mutants
 selection and characterization of, 1542
- K. oxytoca*, 2184
 AmpC type, plasmid mediated, characterization of, 464
- K. pneumoniae*, 3079
 association with decreased susceptibility to moxalactam, 108
 novel, extended spectrum, TEM type, 108
 outbreak of, epidemiology and success-
- ful control, 53
 resistance to expanded-spectrum cephalosporins, 1350
 TEM-43, biochemical and genetic properties, 1671
- L-1 metallo- family
 overexpression, purification, and characterization, 921
- S. maltophilia*, molecular heterogeneity, 1245
- letter to the editor, 3329
- M13, 2893
- M. catarrhalis*, 2521
- M. morganii*, 2125
- M. morganii* ampR, 2352
- M. tuberculosis*
 β -lactam susceptibilities, contribution to, 1524
 recombinant expression and characterization of, 1375
- minireview
 kinship and diversification, 1
- OXA-16, 3117
- OXA-19, 3113
- OXA-20, 2074
- OXY-2, 2184
- P. aeruginosa*, 2074, 3113, 3117
- P. aeruginosa* AmpC, 3296
- P. mirabilis*
 AmpC type, chromosomally encoded, 1110
 resistance to expanded-spectrum cephalosporins, 1350
- P. stuartii*
 TEM-60, characterization of, 1459
- PSE-4, 2319, 2576
- S. aureus* blaZ, 3163
- S. enteritidis*, 2352
- S. maltophilia* metallo- β -lactamase L1 molecular heterogeneity, 1245
 overexpression, purification, and characterization, 921
- S. marcescens*
 sequences of, 176
 sanfetinim, interaction with comparison with interactions with imipenem and oral β -lactams, 1168
- SHV-5, 3079
 mutants constructed by substitutions at position 69, properties of, 1281
- sulbactam, 2319
- tazobactam, 2319
- tazobactam, preferential inhibition by Toho-2, cloning and sequencing, 1181
- TEM-1, inhibitor resistant natural variation and site-directed substitution at Asp276, 1323
- TEM-21, 2125
- TEM-41, 2771
- TEM-47, 3079
- TEM-60
P. stuartii, characterization of, 1459
- TEM-61, 3329
- Toho-2
 cloning and sequencing, 1181
- β -Lactams
E. coli hipA, 3282
- M. tuberculosis* susceptibilities
 β -lactamases, contribution to, 1524
- N. gonorrhoeae* penB, 2799
- S. pneumoniae*, 1973, 2914
 release of lipoteichoic and teichoic acids as a result of exposure, 277

- β-Tubulin**
benzimidazoles, 2171
phenylcarbamates, 2171
- Biapenem**
pharmacokinetics and safety
elderly subjects, 1433
- Bicyclomycin**
transcription termination factor Rho
effects on RNA- and ATP-binding activities, 571
- BILD 1633**
herpes simplex virus type 1
acyclovir resistant, 1629
- Bioavailability**
cephalosporin prodrug esters, 2602
effect of food, 2295
stavudine, 2295
- Biocide resistance**
letter to the editor, 2151
- Biofilms**
antibiotic activity
in vitro and in vivo, impact on, 895
- C. albicans*, 1900, 2146
- interaction of *S. pneumoniae* and *M. catarrhalis*, 2521
- P. aeruginosa*
levofloxacin, in vitro and in vivo activities, 1641
- S. epidermidis* slime production
effect on activities of various agents, 939
- Bioluminescence**
S. mutans, 1906
- Biosynthesis**
streptomycin, 2041
- Bis(isopropoxycarbonyloxymethyl)PMPA**
human immunodeficiency virus, drug resistant
activity against, 1484
- Bis(isopropoxycarbonyloxymethyl)-PMPA**
antiretroviral efficacy
mice, 1568
- pharmacokinetics
mice, 1568
- Bite wound isolates**
HMR 3004 (RU 64004)
aerobic and anaerobic human and animal bite pathogens, comparative evaluation, 1127
- HMR 3647 (RU 66647)
aerobic and anaerobic human and animal bite pathogens, comparative evaluation, 1127
- bla_{IMP}*
P. aeruginosa, 2006
S. marcescens, 2006
- Blastomyces dermatitidis**
fluconazole
susceptibilities of clinical and laboratory isolates, 978
- itraconazole**
susceptibilities of clinical and laboratory isolates, 978
- ketoconazole**
susceptibilities of clinical and laboratory isolates, 978
- BLIP**
M13, 2893
- Blood-brain barrier**
BEA005, 2174
zalcitabine, 2174
- BM212**
M. tuberculosis, 3035
- BM2716**
aac(6')-Ij, 2759
IS8, 2759
- BMS 181184**
A. fumigatus, 2399
neutropenia, 2399
- BMS 181884**
effect of food, 2706
oral solution, 2706
pharmacokinetics, 2706
- BMS-200475**
hepatitis viruses, 3200, 3209
hepatitis B virus, 3209
triphosphate form, 3200
- BMS-207147**
in vitro antifungal activity, 313
- Bordetella parapertussis**
HMR 3004 (RU 64004)
in vitro activity, comparative evaluation, 965
- HMR 3647 (RU 66647)
in vitro activity, comparative evaluation, 965
- susceptibilities to, letter to the editor, 1868
- Bordetella pertussis**
HMR 3004 (RU 64004)
in vitro activity, comparative evaluation, 965
- HMR 3647 (RU 66647)
in vitro activity, comparative evaluation, 965
- susceptibilities to, letter to the editor, 1868
- Brain**
rifampin concentrations, 2626
- Bronchitis**
grepafloxacin
ciprofloxacin, comparative evaluation, 114
efficacy and safety for treatment of acute bacterial exacerbations, 114
- Broth microdilution**
penicillin-clindamycin
S. pyogenes, antimicrobial effect, 1266
- Burn patients**
fluconazole pharmacokinetics in, 930
- Caco-2 cells**
sparfloxacin, 2607
- Caco-2/TC-7 cells**
glucose metabolism, 2950
glutamine metabolism, 2950
ofloxacin, 2950
S. typhimurium, 2950
- Campylobacter fetus**
subsp. *fetus*
susceptibility testing, 1847
- Campylobacter jejuni**
ciprofloxacin, 2106, 3276
dfr, 3059
erythromycin, 2106
nalidixic acid, 2106
QRDR, 3276
tetracycline, 2106
trimethoprim, 3059
- Candida**
amphotericin B, 3018
azoles, 2342
EF-2, 2279
itraconazole, 3018
LY303366, 2446
nitric oxide, 2342
- sordarins, 2274, 2279
- SPA-S-843**, 3012
- voriconazole**, 3018
- Candida albicans**
AmBisome, 2431, 2437
amphotericin B, 2146, 2431, 2437
assessment by dynamic in vitro mycotic infection model, 1382
azole resistance
cytochrome P-450 lanosterol 14α-demethylase, amino acid substitutions, 241
azole resistant
inhibition of hyphal growth by triazoles in presence of lactoferrin, 1587
- BAY 10-8888**, 2197
decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
mechanism of action, 1581
- benzimidazoles**, 2495, 2503
- biofilms**, 1900, 2146
- carbazoles**, 2503
- CDR**, 2584, 2923
- combinatorial chemistry**, 2534
- cyclopeptamines**
A172013, cellular accumulation, localization, and activity, 389
- decapeptides**, 2534
- erg6* mutants
susceptibility studies, 1160
- ERG16**, 2923
- fluconazole**, 2584, 2645, 2923, 2938, 3065
assessment by dynamic in vitro mycotic infection model, 1382
pharmacodynamics in murine model of systemic candidiasis, 1105
- Fungizone**, 2431, 2437
- growth rate**, 1900
- HIV**, 2923
- KY-62**
murine candidiasis, treatment of, 147
- LY303366 photoaffinity analog**
identification of targets, 1187
- MDRI**, 2923
- murine peritoneal macrophages, 2437
- murine vaginitis, 2434
- neuropeptide Y, 2745
- pentamidine analogues, 2495
- pentoxifylline, 2405
- polycarbophil-econazole, 2434
- SPI-ARGENT II**, 2440
- sterol methyltransferase gene sequencing, disruption, and characterization, 1160
- terbinafine**
in vitro activities, 1057
- voriconazole**
neutrophils or monocytes, combination with, 907
- Candida dubliniensis**
fluconazole resistant
multidrug transporters, identification and expression of, 1819
- Candida glabrata**
fluconazole resistance
association with drug efflux and a drug transporter gene, *PDHI*, 1695
- Candida krusei**
fluconazole, 2645
- Candida spp.**
amphotericin B
lipid complex, role of phospholipases in

- antifungal activity, 767
lipid emulsion, 762
azole resistance
13-year evolution and prevalence in cancer patients at a large medical center, 734
- time-kill tests
influence of test conditions on results, 1207
- voriconazole
comparative in vitro activity, 161
- Candida tropicalis*
BAY 10-8888
decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
mechanism of action, 1581
- Candidiasis
antifungal activity, 1424
fluconazole
optimizing correlation between in vitro results and therapeutic outcome, 129
pharmacodynamics in murine model of systemic candidiasis, 1105
- KY-62
treatment of, 147
- CAP18
P. aeruginosa, 3269
- Carbapenems
biapenem
pharmacokinetics and safety in elderly subjects, 1433
- CS-834
in vitro and in vivo activities, 555
pneumonia in mice, 23
S. pneumoniae, penicillin susceptible and resistant, 23
- DA-1131
pharmacokinetics in rats with uranyl nitrate-induced acute renal failure, 1217
- K. pneumoniae* resistance
outer membrane protein profiles, association with, 1636
- panipenem, 3136
- S-4661
in vitro and in vivo activities, 94
S. aureus, 1996
- Carbazoles
C. albicans, 2503
C. neoformans, 2503
C. parvum, 2877
- Carbenicillin
hydrolyzing β -lactamases, 1966
- Cathelicidins
LL-37, 2206
- Caz-hi β -lactamase
letter to the editor, 3329
- cDNA integration
HIV, 2245
- CDR
C. albicans, 2584
fluconazole resistance, 2584
- Cefazolin
S. aureus, 2449
S. epidermidis, 2449
synergism with PGG-glucan, 2449
- Cefdinir
pharmacokinetics
hemodialysis patients, 1718
- S. pyogenes* pharyngitis
5-day treatment, efficacy of, 1073
- Cefepime
amikacin, 3304
combinations
aztreonam, 1610
P. aeruginosa, 1610
E. cloacae, 3304
pharmacodynamics
P. aeruginosa, activity alone and with aztreonam, 1610
pneumonia, community acquired ceftiaxone, comparative evaluation, 729
- Cefminox
anaerobic bacteria
comparative in vitro activity, 495
- Cefodizime
S. pneumoniae, 2527
- Cefoperazone
biliary excretion, 2178
combinations with quinolones, 2002
G-CSF, 2178
S. maltophilia, 2002
- Cefotaxime
Enterobacteriaceae
hospital in Warsaw, identification of new CTX-M-3 cefotaxime-hydrolyzing β -lactamase, 827
hydrolyzing β -lactamase, 1980
S. pneumoniae, 2768
bactericidal activity, letter to the editor, 1869
synergy
amoxicillin, critical importance of concentrations, 468
experimental *E. faecalis* endocarditis, 468
V. vulnificus
alone or in combination with minocycline, 1319
experimental murine infection, treatment of, 1319
- Cefpirome
combinations with quinolones, 2002
comparative evaluation
ceftazidime, 28
pneumonia in intensive care patients, empiric treatment of, 28
- pharmacokinetics
concentrations in cerebrospinal fluid of children with bacterial meningitis, 199
- pneumonia
ceftazidime, comparative evaluation, 28
S. maltophilia, 2002
- Ceftazidime
amikacin, 3304
 β -lactamase PSE-4, 2576
combinations with quinolones, 2002
comparative evaluation
cefpirome, 28
pneumonia in intensive care patients, empiric treatment of, 28
- E. cloacae*, 3304
K. pneumoniae, 3079
lipopolysaccharide release, antibiotic induced
S. typhi, delay between killing and release, 739
- P. stuartii* resistance
TEM-60 β -lactamase, 1459
pneumonia
cefpirome, comparative evaluation, 28
S. maltophilia, 2002
S. typhi
- lipopolysaccharide release, antibiotic induced, delay between killing and release, 739
- Ceftizoxime
pharmacokinetics
continuous infusion in clinically ill adults, 1783
- S. pneumoniae*
bactericidal activity, letter to the editor, 1869
- Ceftriaxone
assays, 2259
concentration in serum, 2259
pneumonia, community acquired ceftiaxone, comparative evaluation, 729
S. pneumoniae, penicillin resistant meropenem, imipenem, and ceftriaxone-vancomycin, comparative activities, 942
versus L-749,345, 2365
Y. enterocolitica, 3009
- Cefuroxime
otitis media, acute
amoxicillin, comparative evaluation, 1361
- S. pneumoniae*, penicillin resistant, 1361
- Cephalexin
pharmacokinetics
interaction with quinapril, analysis by a nonlinear mixed-effect model, 1463
- Cephalosporins
 β -lactamase CTX-M-4
involvement of serine 237 in cephalosporin hydrolysis, 1259
- bioavailability, 2602
- E. aerogenes* resistance
plasmid mediated, 596
expanded spectrum
 β -lactamase responsible for resistance, characterization of, 1350
- K. pneumoniae*, *P. mirabilis*, and *E. coli* resistance, 1350
- K. pneumoniae* resistance
outer membrane protein profiles, association with, 1636
- prodrug esters, 2602
- S. pneumoniae*, 2650
- Cercopin P1, 3320
- Cerulenin
P. aeruginosa resistance
role of efflux systems, novel technique for study, 395
- Children
HIV, 3187
lamivudine, 3187
- China
S. pneumoniae susceptibilities, 2633
- Chlamydia pneumoniae*
atherosclerosis, 2762
azithromycin
microbiologic efficacy, 194
susceptibilities of isolates from patients with community-acquired pneumonia, 194
- BAY 12-8039
in vitro activity, 951
- HMR 3647 (RU 66647)
activity in vitro, 1515
susceptibilities, 2762
- Chlamydia trachomatis*
chlorhexidine gluconate gel
susceptibility to, 1726
- fatty acids, 2290

- gyrase, 2474
 monoglycerides, 2290
 QRDR, 2474
 synthetic lipids adapted from compounds
 in human breast milk
 killing by, 1239
 topoisomerase IV, 2474
- Chloramphenicol**
C. difficile resistance
 Tn4453 transposon, 1563
- Chlorecloguanil**
P. falciparum
 in vitro activity, correlation with point
 mutations in the dihydrofolate re-
 ductase domain, 164
- Chlorhexidine gluconate**
C. trachomatis
 susceptibility to, 1726
 gel
 C. trachomatis, susceptibility to, 1726
- 5-Chloropyrazinamide
Mycobacterium spp.
 in vitro activity, 462
- Cholera toxin**
 ciprofloxacin pharmacokinetics
 effect on intestinal elimination in rab-
 bits, 473
- Cholesterol**
 amphotericin B, 3146
- Cidofovir**
 cytomegalovirus retinitis, 2240
 herpes simplex virus, 2996
- Cimetidine**
 clarithromycin
 interaction with, 1578
 pharmacokinetics
 ofloxacin, effects on renal disposition in
 rats, 456
- Ciprofloxacin**
 AP-1, 1923
B. pertussis
 susceptibilities to, letter to the editor,
 1868
B. pertussis
 susceptibilities to, letter to the editor,
 1868
C. jejuni, 3276
 chloramphenicol acetyltransferase, 1923
 combination with gentamicin, 2002
 combinations
 fenbufen, effects on central nervous sys-
 tem, assessment by electroencephalo-
 graphy, 1256
 combinations with cephalosporins, 2002
 fosfomycin, interaction with
 neurotoxicodynamics of, 691
H. pylori
 infection in gnotobiotic piglets, 1549
 high-dose pharmacokinetics, 2235
 IL-2, 1923
 liposomal encapsulation
 pharmacokinetics, effect on, 45
S. typhimurium infection in mice, effect
 on antibacterial efficacy, 45
 Marvelon contraceptive, 3266
N. gonorrhoeae, 2919
N. gonorrhoeae parC, 2103
 NF- κ B, 1923
 orthopedic implants, 3002
 pharmacokinetics, 2841
 cholera toxin, effect on intestinal elimi-
 nation in rabbits, 473
 effects of combination therapy with fen-
- bufen on central nervous system,
 1256
 liposomal encapsulation, effect on, 45
 renal failure in rats, influence on, 289
 prediction of effect, 2848
 prophylaxis in bone marrow transplant
 recipients
 alone and in combination with vanco-
 mycin, comparative evaluation,
 1402
S. aureus *grlA*, *grlB*, *gyrA*, and *gyrB* muta-
 tions
 characterization of and effect on MIC,
 1249
S. maltophilia, 2002
S. typhimurium
 liposomal encapsulation, effect on infec-
 tion in mice, 45
 severe sepsis, 2235
 viridans streptococci, 2792
Y. enterocolitica, 3009
- Citrobacter freundii**
 aminoglycoside 6'-N-acetyltransferase
 variants
 altered substrate profile, 209
 cefotaxime resistant
 hospital in Warsaw, identification of
 new CTX-M-3 cefotaxime-hydro-
 lyzing β -lactamase, 827
- Clarithromycin**
A. actinomycetemcomitans, 3000
 electrocardiographic pharmacodynamics
 after individual or concomitant adminis-
 tration with loratadine, 1176
H. influenzae, 2385, 3193, 3313
H. pylori, 2749
 infection in gnotobiotic piglets, 1549
H. pylori resistance
 risk of development, 1222
Legionella spp.
 activity in vitro, 1520
M. avium, 3006
M. ulcerans, 2070
 pharmacokinetic interactions with rifabu-
 tin
 human immunodeficiency virus-infected
 volunteers, 631
- pharmacokinetics, 2385
 after individual or concomitant adminis-
 tration with loratadine, 1176
 bronchopulmonary, letter to the editor,
 481
 grapefruit juice, effect on, 927
 oral cimetidine prolongs absorption,
 1578
S. pneumoniae, 3193
 tolerance
 human immunodeficiency virus-infected
 volunteers, 631
- clarithromycin and loratadine
 individual or concomitant administration,
 1176
- Clavulanate**
 combination with amoxicillin, 2375
S. pneumoniae, 2375
- Clinafloxacin**
 bacterial isolates from 10 North American
 centers
 disk diffusion interpretive zone dia-
 meter criteria, 1274
 susceptibility to, 1274
- gram-positive and gram-negative bacteria
 comparative evaluation, 1269
- M. tuberculosis*, 2066
 pharmacokinetics
 inflammatory fluid penetration, 428
S. pneumoniae, 2810
 susceptibility testing
 disk diffusion interpretive zone dia-
 meter criteria, 1274
- Clindamycin**
 coryneform bacteria, 3290
 HIV, 3014
 penetration, 3014
S. pneumoniae
 HMR 3647, quinupristin-dalfopristin,
 and erythromycin, comparative ac-
 tivities of and cross-resistance to,
 945
S. pyogenes
 in vitro activity of combinations with
 penicillin, 1266
- Clofazimine**
M. avium, 3006
- Clostridium difficile**
 chloramphenicol resistance
 Tn4453 transposon, 1563
- Clostridium** spp.
 nitrofurantoin resistant, nitroreductase
 producing
 isolation from human intestinal tract,
 1121
- Clostridium tetani**
 new pasteurized human tetanus immuno-
 globulin
 safety and pharmacokinetic profile, 298
- CNI-H0294**
 human immunodeficiency virus
 inhibition of virus replication in in-
 fected peripheral blood mono-
 nuclear cells, 1133
- Co-amoxiclav**
S. aureus, heteroresistant
 in vitro activities at concentrations
 achieved in human serum, 1574
- Combinatorial chemistry**
C. albicans, 2534
 decapeptides, 2534
- Combinatorial library screening**
 two-dimensional agar format, 1447
- Comparative molecular field analysis**
 sulfa drugs
 inhibitors of *P. carinii*, 1454
- Contraceptives**
 interaction with ciprofloxacin, 3266
- Cordycepin**
 antifungal activity, 1424
- Coryneform bacteria**
 clindamycin, 3290
 HMR3647, 3290
 macrolides, 3290
- Co-trimoxazole**
Staphylococcus, 3086
- Coumarins**
grlA, 2109
S. aureus, 2109
S. aureus resistance
 mutations in topoisomerase IV and
 DNA gyrase, effect on, 121
- Coumermycin A₁**, 2906
B. bacilliformis *gyrB*, 2906
- Coxiella burnetii**
 trovaflloxacin, 2747
- Cryptococcosis**
 amphotericin B
 Fungizone, Amphotec, Ambisome, and

- Abeel et al., comparative evaluation, 899
Cryptococcus
SPA-S-843, 3012
Cryptococcus neoformans
amphotericin B
alone and with flucytosine with or without fluconazole, 528
lipid nanosphere encapsulated, activity of, 1722
Fungizone, Amphotec, AmBisome, and Abeel, comparative evaluation, 899
dolastatin 10, 2961
fluconazole susceptible and resistant voriconazole versus itraconazole, 471
furans, 2503
monoclonal antibody to capsular polysaccharide candidate for human therapeutic studies, 1437
pentamidine analogues, 2495
triazole TAK-187, 2630
Cryptosporidiosis
dinitroanilines synthesis and evaluation for treatment, 339
Cryptosporidium parvum
carbazoles, 2877
cyclosporin analogs inhibition of in vitro growth, 843
dinitroanilines synthesis and evaluation for treatment, 339
nitazoxanide, 1959, 2877
paromomycin, 1959, 2877
CS-834 in vitro and in vivo activities, 555
S. pneumoniae penicillin susceptible and resistant, 23 pneumonia in mice, 23
CTX-M-5 cefotaxime, 1980
S. typhimurium, 1980
Cyclopeptamines A172013 fungi, cellular accumulation, localization, and activity, 389
fungi A172013, cellular accumulation, localization, and activity, 389
Cyclosporin analogs *C. parvum*, inhibition of in vitro growth, 843
C. parvum inhibition of in vitro growth, 843
cysC *E. coli*, 3173
P. aeruginosa, 3173
Cysteine inhibition aspartic protease, 2254
P. falciparum, 2254
Cytochrome P-450 ketocomazole, effect on susceptibility, 1756
Cytokines production induced by heat-killed *S. pneumoniae*
- effect of erythromycin and penicillin, 1605
trovafloxacin production by human monocytes, effect on, 1713
Cytomegalovirus cidofovir, 2240 flow cytometry, 2326 fomivirsen resistance sequence dependent, 971 foscamet, 2240 ganciclovir, 2326 ganciclovir resistance Cys607→Tyr change in UL97 phosphotransferase, 444 retinitis, 2240
- D0870 pharmacokinetics two multiple-dosing regimens in human immunodeficiency virus-positive patients, 903
- DA-1131 pharmacokinetics rats with uranyl nitrate-induced acute renal failure, 1217
- DABO HIV reverse transcriptase, 3225
- Dalfopristin-quinupristin *E. faecium*, vancomycin resistant in vitro susceptibility, 1088
- Defensins conjunctiva, 3328 letter to the editor, 3328
- Delivery systems liposomal novel, peptide grafted, 348
- 3'-Deoxyadenosine candidiasis, invasive antifungal activity, 1424
- 2'-Deoxyguanosine D and L enantiomers metabolism in human cells, 1045
- Deoxyribonucleoside salvage *E. coli*, 2620
- Dermaseptin s3 *S. cerevisiae*, 2160
- Dermatomal herpes zoster acyclovir human immunodeficiency virus-infected patients, 1139 sorivudine, comparative evaluation, 1139
- sorivudine acyclovir, comparative evaluation, 1139 human immunodeficiency virus-infected patients, 1139
- Dextran 70 PMX-622, 2765
- DHA-1 *M. morganii ampR*, 2352 *S. enteritidis*, 2352
- Diamidoximes prodrugs of anti-*Pneumocystis* activities, 666
- Diaminomethylpyridopyrimidines *M. avium* complex, 3315
- Dicaffeoylquinic acid human immunodeficiency virus type 1 selective inhibition of integrase, 140
- Dicaffeoyltartaric acid human immunodeficiency virus type 1 selective inhibition of integrase, 140
- Diclofenac panipenem, 3136
- Didanosine pharmacokinetics human immunodeficiency virus-infected outpatients, 821 relationship between didanosine exposure and surrogate marker response, 821
- 2',3'-Dideoxy-2',3'-dihydro-β-L(-)-5-fluorocytidine [$L(-)Fd4C$] human immunodeficiency virus type 1 antiviral activity in combination with β-D(+)-nucleoside analogs, 1799
- pharmacokinetics metabolism, 1799, 1805
- Dihydrofolate reductase diaminomethylpyridopyrimidines, 3315 *M. avium* complex, 3315 trimethoprim, 2221
- Dihydrofolate reductases *C. jejuni*, 3059 trimethoprim, 3059
- Dinitroanilines cryptosporidiosis evaluation for treatment, 339 synthesis of, 339
- Dipyridamole zidovudine azido-reductase activation by, 1654
- Dirithromycin *H. influenzae* effect on infection of the respiratory mucosa, 772
- Disulfiram *G. lamblia* efficacy of, 1488
- DNA gyrase *S. aureus* mutations, novel pleiotropic effects on quinolone and coumarin activity, 121
- DNA gyrases cleavage and cell killing modulation by ATP, 1022
- E. faecalis* resistance alterations in GyrA subunit, association with, 433
- S. marcescens* cloning and nucleotide sequence, 190 mutations in quinolone-resistant isolates, characterization of, 190
- Dolastatin 10 *C. neoformans*, 2961
- Dopamine amphotericin B nephrotoxicity, 3103
- Doxycycline combination with quinupristin-dalfopristin, 2710 *E. faecium*, 2710 rickettsiae in vitro susceptibilities, 1537
- Doxycycline hydlate *E. canis* experimental canine ehrlichiosis, 362 ehrlichioses canine, experimental, 362
- DU-6859a theophylline metabolism effect on, 1751
- E5531 murine endotoxin response, 2824

- E test
penicillin-clindamycin
S. pyogenes, antimicrobial effect, 1266
- Echinocandins
A. fumigatus, 2898
Aspergillus spp., 2726
Candida, 2446
LY303366, 2446, 2726, 2898
LY303366 photoaffinity analog
C. albicans, identification of targets in, 1187
water soluble
Pneumocystis pneumonia in mice, 37
- Echinococcus granulosus*
oxendazole
naturally infected animals, treatment of, 601
- Echinococcus multilocularis*
benzimidazoles
metacestodes, activity against, 1052
- Econazole
C. albicans, 2434
combination with polycarbophil, 2434
- EF2
S. cerevisiae, 2694
- Efflux
B. fragilis, 2119
norfloxacin, 2119
P. aeruginosa, 1938, 2225
S. pneumoniae, 2032
- Ehrlichia canis*
doxycycline hydiate
experimental canine ehrlichiosis, 362
- Ehrlichiosis
canine
doxycycline hydiate, 362
- E. canis*
doxycycline hydiate, 362
- Elderly patients
bacterial infections, serious
meropenem versus cefuroxime-gentamicin, comparative evaluation, 1233
- Encephalitis
T. gondii
trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine, 1346
- Encephalitozoon
albendazole, 3301
- Endocarditis
E. faecalis
amoxicillin-ceftaxime synergy, critical importance of concentrations, 468
- S. aureus*
experimental, efficacy of trovafloxacin, 254
- S. aureus*, methicillin resistant
LY333328, efficacy against, 981
lysostaphin, treatment of, 1335
trovafloxacin, activity against, 1837
- Endotoxin
P. aeruginosa and *E. coli*, antibiotic treated
biological characterization, 1015
- Enterobacter aerogenes*
BM2688, 2557
cephalosporins, expanded spectrum, resistance to
plasmid mediated, 596
- In40, 2557
- Enterobacter cloacae*
amikacin, 3304
aminoglycoside 6'-N-acetyltransferase variants
- altered substrate profile, 209
cefpipime, 3304
ceftazidime, 3304
imipenem, 3304
- Enterobacteriaceae*
β-lactamases
novel TEM and SHV-5 type, isolates from Polish hospitals, 514
fluoroquinolone resistance, 2661
gyrA, 2661
- Enterococcus faecalis*
aacB-aph2, 2889
autolysin, 2883
β-lactamase inhibitor combinations
activities and time-kill studies, 857
- endocarditis
amoxicillin-ceftaxime synergy, critical importance of concentrations, 468
- eperezolid and linezolid
comparative activity and postantibiotic effect, 721
- gentamicin, 2889
glycopeptides
activities and time-kill studies, 857
- OG1RF, 2883
- OPC-20011, 2943
- penicillin
activities and time-kill studies, 857
- quinolone resistance
alterations in GyrA subunit of DNA gyrase and ParC subunit of DNA topoisomerase IV, 433
- Enterococcus faecium*
doxycycline, 2710
eperezolid and linezolid
comparative activity and postantibiotic effect, 721
- glycopeptide resistance
transferable, plasmid mediated, VanB type, 963
- letter to the editor, 3331
LY333328, 2564
quinupristin-dalfopristin, 2188, 2710
- satA, 3331
vancomycin, 2150
vancomycin resistance, 2564
vancomycin resistant, 2710
characterization of isolates from United States, 1088
dalfopristin-quinupristin susceptibility in vitro, 1088
- vgb, 3331
- Enterococcus hirae*
penicillin-binding protein 3r
gene is borne on plasmid carrying other antibiotic resistance determinants, 534
- Enterococcus* spp.
antimicrobial resistance
turkey flocks fed virginiamycin, 705
- avoparcin, 3333
chickens, 3333
gentamicin resistance, high level
aph(2')-Id, 1229
glycopeptides, 2215
HMR3647, 3279
letter to the editor, 2463, 3333
pyelonephritis
trovafloxacin-rifampin, contrast with in vitro and in vivo results, 188
- South Africa, 2752
susceptibilities, 2752
- trovafloxacin
- in vitro dynamic model of infection, 72
- VanA glycopeptide resistance elements diversity, human and nonhuman sources, 502
- vanA*, *vanB*, *vanC-1*, and *vanC-2/3*
DNA sequence variation, 202
- vancomycin, 2215
vancomycin resistance, 2463
- Eperezolid
S. aureus, coagulase-negative staphylococci, *E. faecalis*, and *E. faecium*
comparative activity and postantibiotic effect, 721
- Epileptogenic potential
norfloxacin, 2756
pefloxacin, 2756
- Epstein-Barr virus
acyclovir, 2923
ganciclovir, 2923
thymidine kinase, 2923
- erg6
C. albicans
sequencing, disruption, and characterization, 1160
- Erythromycin
A. actinomycetemcomitans, 3000
C. jejuni, 2106
cytokine production induced by heat-killed *S. pneumoniae*
effect on, 1605
- H. influenzae*, 3193, 3313
inhibitory effect on superoxide anion production by human neutrophils
letter to the editor, 1866
- L. pneumophila*, 3153
- pharmacodynamics
in vitro and in vivo, comparison with those of azithromycin, 377
- S. aureus*, 3024
- S. pneumoniae*, 2312, 3193
quinupristin-dalfopristin, HMR 3647, and clindamycin, comparative activities of and cross-resistance to, 945
- S. pyogenes* resistance
emergence in Madrid, letter to the editor, 989
novel methylase gene (*ermTR*), 257
- streptococci, group C and G, resistance analysis of different mechanisms of, 1493
- Escherichia coli*
aacC3, 3173
ampicillin-sulbactam
in vitro infection model against strains with various levels of resistance, 231
- aztreonam
postantibiotic and sub-MIC effects, 414
- β-lactamase
resistance to expanded-spectrum cephalosporins, 1350
tazobactam, preferential inhibition by, 1181
- TEM-43, biochemical and genetic properties, 1671
- Toho-2, cloning and sequencing, 1181
- β-lactamase, extended spectrum, TEM type
A237T as a modulating mutation, 1042
- β-lactams, 3282
- cefotaxime resistant hospital in Warsaw, identification of

- new CTX-M-3 cephalosporinase-hydrolyzing β -lactamase, 827
- cephalosporins, expanded spectrum, resistance to
 β -lactamase, characterization of, 1350
- cycC, 3173
- deoxyribonucleoside salvage enzymes, 2620
- DNA gyrase-mediated cleavage and cell killing
 modulation by ATP, 1022
- endotoxins released after antibiotic treatment
 biological characterization, 1015
- enterohemorrhagic O157:H7
 outbreak in Japan, antibiotic susceptibility, 431
- fluoroquinolone resistance, 2089
- fluoroquinolones, 3282
 comparative efficacies, 83
 continuous or pulsed administration in water, 83
- hipA, 3282
- isepamicin
 postantibiotic and sub-MIC effects, 414
- linezolid, 3251
- marA, 2089
- nucleoside analogs, 2620
- postantibiotic effect
 cefotaxime and piperacillin, 78
 determination with real-time metabolic monitoring, 78
- physical and biochemical characteristics and dynamics, determination by flow cytometry, 1005
- screen for HIV variants, 3256
- soxS, 2089
- SPI-ARGENT II, 2440
- sulfathiazole resistance
 mutations contributing to, characterization of, 88
- Ethacrynic acid
 zidovudine azido-reductase activation by, 1654
- Famciclovir
 herpes simplex virus type 1
 latency, prevention of, quantitative comparison with valacyclovir, 1555
- Famotidine
 pharmacokinetics
 effects on tosufloxacin bioavailability in healthy volunteers, 453
- Fatty acids
C. trachomatis, 2290
- Fenbufen
 combinations
 ciprofloxacin, effects on central nervous system, assessment by electroencephalography, 1256
- pharmacokinetics
 effects of combination therapy with ciprofloxacin on central nervous system, 1256
- Ferrocene-chloroquine
P. falciparum
 in vitro activity, 540
- Fleroxacin
 bactericidal activity
 pefloxacin, comparative evaluation, 1659
- pharmacokinetics
 urinary excretion in healthy volunteers, comparative evaluation, 1659
- Flow cytometry
 postantibiotic effect of methicillin
S. aureus, 1195
- Fluconazole
 3'-azido-3'-deoxythymidine
 glucuronidation by human liver microsomes, inhibition by, 1592
- B. dermatitidis*
 susceptibilities of clinical and laboratory isolates, 978
- C. albicans*, 2645, 2923, 2938, 3065
- C. albicans CDR*, 2584
- C. dubliniensis* resistance
 multidrug transporters, identification and expression of, 1819
- C. glabrata* resistance
 association with drug efflux and a drug transporter gene, *PDHI*, 1695
- C. krusei*, 2645
- Candida* resistance
 13-year evolution and prevalence in cancer patients at a large medical center, 734
- candidiasis, invasive
 optimizing correlation between in vitro results and therapeutic outcome, 129
- Paecilomyces* spp.
 antifungal susceptibilities, 1601
- pharmacodynamics
 assessment of activity against *C. albicans* by dynamic in vitro mycotic infection model, 1382
- murine model of systemic candidiasis, 1105
- pharmacokinetics
 burn patients, 930
 rabbits and humans, correlation of AUC and peak levels, 1512
- zidovudine, glucuronidation by human liver microsomes, inhibition by, 1592
- pharmacokinetics of indinavir
 human immunodeficiency virus-infected patients, effect on, 223
- Flucytosine
Paecilomyces spp.
 antifungal susceptibilities, 1601
- 2'-Fluoro-5-methyl- β -L-arabinofuranosyluracil (L-FMAU)
 duck hepatitis B virus
 inhibition of replication, 369
- unique metabolism
 substrate for both thymidine kinase and deoxycytidine kinase, 833
- Fluoroquinolones
 BAY 12-8039
 antimycoplasmal activities in vitro, 703
- C-8 substituents, 2978
- C-8-methoxy
S. aureus, killing by, 956
- E. coli*, 2089
- E. coli* hipA, 3282
- E. coli* infection in chickens
 comparative efficacies, 83
 continuous or pulsed administration in water, 83
- efflux, 2032
- Enterobacteriaceae*, 2661
- excitatory potencies in central nervous system
 in vitro model, 1831
- gestational exposure, pregnancy outcome following
 multicenter prospective controlled study, 1336
- gyrA, 2661
- Haemophilus* spp., 2956
- HSR-903
 respiratory pathogens, in vivo activity, 785
- K. pneumoniae*, quinolone resistant energy-dependent accumulation, 1850
- marA, 2089
- mycobacteria, 2978
- P. aeruginosa*, 2956
- rickettsiae
 in vitro susceptibilities, 1537
- S. aureus* resistance
 letter to the editor, 727
 selection with ciprofloxacin and trovafloxacin, 727
- S. pneumoniae*, 2032, 2956
- soxS, 2089
- sulfanilyl
 mode of action, 1495
- V. cholerae* resistance
 letter to the editor, 206
 patients with acute diarrhea in Calcutta, India, 206
- Y-688
 anaerobic bacteria, 419
- Fluoxetine
 ritonavir pharmacokinetics, 3107
- Fomivirsen
 cytomegalovirus resistance
 sequence dependent, 971
- Food
 pliconaril pharmacokinetics, 2706
- Food and Drug Administration approvals 1997, 987
- Foscarnet
 ciprofloxacin, interaction with neurotoxicodynamics of, 691
 cytomegalovirus retinitis, 2240
 HIV, 3038
- pharmacokinetics
 absolute bioavailability, 293
 human immunodeficiency virus-seropositive patients, 293
- zidovudine coresistance, 3038
- Fosfomycin
S. pyogenes CD15s-related antigen expression
 reduction of, 1083
- Fungal infections
 amphotericin B colloidal dispersion
 really impaired patients, 606
- Fungi
 amphotericin B
 lipid emulsion, 762
 BMS-207147
 in vitro activity, 313
 cyclopeptamines
 A172013, cellular accumulation, localization, and activity, 389
- filamentous
 in vitro susceptibilities, possible correlation with outcomes in animal models, 282
- furanonaphthoquinone analogs
 antimicrobial activities, 700
- Fungizone
C. albicans, 2437
 versus liposomal amphotericin B, 2437

- Furanonaphthoquinones
analog
antimicrobial activities, 700
- Furans
C. albicans, 2503
C. neoformans, 2503
- Fusarium* spp.
rifabutin-amphotericin B
synergy, 509
- γ -Glutamylcysteine ethyl ester
human immunodeficiency virus type I
production and propagation, inhibition
of, 1200
- Ganciclovir
cytomegalovirus, 2326
cytomegalovirus resistance
Cys607 \rightarrow Tyr change in UL97 phospho-
transferase, 444
- EBV TK, 2923
- flow cytometry, 2326
- HSV-1 TK, 2923
- mycophenolate mofetil
potentiation of antiherpesvirus activity,
216
- Gardnerella vaginalis*
susceptibility testing
continuous-culture biofilm system, 1428
- Gatifloxacin
anaerobes, 2459
E. coli DNA gyrase, 2678
- HeLa topoisomerase II, 2678
pharmacodynamics, 2650
- S. aureus*, 1917
- S. aureus* topoisomerase IV, 2678
- S. pneumoniae*, 2650
- G-CSF
A. fumigatus, 2299, 2467
- cefoperazone, 2178
- voriconazole, 907, 2299
- Genital warts
imiquimod
efficacy and safety in infected patients,
789
- Gentamicin
combinations with quinolones, 2002
delivery into mammalian cells
S. flexneri membrane vesicles, 1476
- E. faecalis*, 2889
- Enterococcus* resistance, high level
aph(2')-Ia, 1229
- L. monocytogenes*, 2511
- liposomes, 2511
- pharmacokinetics
initial concentration-time profile deter-
mines efficacy against *E. cloacae*,
1370
- S. maltophilia*, 2002
- S. typhimurium*, 2511
- Giardia lamblia*
zinc-finger-active drugs
efficacies of, 1488
- ginA*
glycosyl transferase inactivation, 2612
- S. ambofaciens*, 2612
- spiramycin, 2612
- Glucose metabolism
Caco-2/TC-7 cells, 2950
- ofloxacin, 2950
- S. typhimurium*, 2950
- Glutamine metabolism
Caco-2/TC-7 cells, 2950
- ofloxacin, 2950
- S. typhimurium*, 2950
- Glutathione prodrugs
 γ -glutamylcysteine ethyl ester
human immunodeficiency virus, inhibi-
tion of production and propaga-
tion, 1200
- Glycopeptides
E. faecalis
activities and time-kill studies, 857
- E. faecium* resistance
transferable, plasmid mediated, VanB
type, 963
- enterococcal resistance
VanA, diversity of, human and nonhu-
man sources, 502
- enterococci, 2215
- staphylococci, coagulase negative, methi-
cillin resistant
decreased susceptibilities to teicoplanin
and vancomycin, 100
- vancomycin, 2215
- Glycosyl transferase
S. ambofaciens *ginA*, 2612
- spiramycin, 2612
- GM-CSF
A. fumigatus, 2299
- voriconazole, 907, 2299
- Golgi
megalomicin, 2668
- Gonorrhoea
pazufloxacin, reduced clinical efficacy
against
high prevalence of quinolone-resistant
isolates with GyrA mutation, 579
- Gram-negative
clinafloxacin
comparative evaluation, 1269
- Gram-negative organisms
furanonaphthoquinone analogs
antimicrobial activities, 700
- Gram-positive
clinafloxacin
comparative evaluation, 1269
- Gram-positive bacteria
tetracycline resistance
16S rRNA mutation, association with,
1702
- Gram-positive organisms
furanonaphthoquinone analogs
antimicrobial activities, 700
- HMR 3647 (RU 66647)
in vitro activity, comparative evaluation,
1028
- Grepafloxacin
antipneumococcal activity
comparative evaluation by time-kill
methodology, 1263
- chronic bronchitis, acute bacterial exacer-
bations of
ciprofloxacin, comparative evaluation,
114
- efficacy and safety, 114
- gyrA*
coumarins, 2109
- quinolones, 2109
- S. aureus*, 236, 1249, 1306, 2109
- gyrB*
S. aureus
characterization of mutations and effect
on ciprofloxacin MIC, 1249
- GS 4071
- GS 4104 prodrug
influenza virus, protection against infec-
tion in mice and ferrets, 640
- oral bioavailability, 647
- influenza virus neuraminidase, 3234
- GS 4104
influenza virus
protection against infection in mice and
ferrets, 640
- oral bioavailability
comparison with that of GS 4116, 647
- gyrA*
Enterobacteriaceae, 2061
- S. aureus*
characterization of mutations and effect
on ciprofloxacin MIC, 1249
- mutations in, detection in 344 strains,
236
- S. pneumoniae*, 2193
- sparfloxacin, 2193
- Gyrases
B. bacilliformis *gyrB*, 2906
- C. trachomatis*, 2474
- clinafloxacin, 2810
- coumermycin A₁, 2906
- E. coli*, 2678
- gatifloxacin, 2678
- letter to the editor, 3051
- M. hominis*, 2304
- mycobacteria, 2084
- Mycobacterium* sp. *gyrA*, 2978
- QRDR, 2474
- quinolone resistance, 2084
- S. flexneri*, 3051
- S. pneumoniae*, 2810
- gyrB*
S. aureus
characterization of mutations and effect
on ciprofloxacin MIC, 1249
- H2G
herpesvirus, 3285
- mycophenolate mofetil, 3285
- Haemophilus*
fluoroquinolones, 2956
- Haemophilus ducreyi*
protegrin, 2690
- Haemophilus influenzae*
amoxicillin-clavulanate, 3193
- antimicrobial susceptibility
isolates from respiratory tracts of pa-
tients with cystic fibrosis, 319
- azithromycin, 2385, 3193
- β -lactamase production, 3313
- clarithromycin, 2385, 3193
- dirithromycin
effect on infection of the respiratory
mucosa, 772
- erythromycin, 3193
- HMR 3647, 2138, 3032
- macrolide susceptibility, 3313
- HeLa cells
gatifloxacin, 2678
- topoisomerase II, 2678
- Helicobacter pylori*
23S RNA, 1952
- amoxicillin, 2492
- clarithromycin, 2749
- infection in gnotobiotic piglets
antimicrobial therapies, 1549
- model for the identification of novel
antimicrobials for treatment, 1549
- metronidazole, 2836
- metronidazole resistance
effect on bacterial eradication in in-

- fected children, 1334
miconazole
 letter to the editor, 725
 morphological effects of, 725
MLS resistance, 1952
nitazoxanide, 2836
rebamipide, 1889
 resistance to amoxicillin, clarithromycin, and metronidazole
 risk of development, 1222
Hemofiltration
 meropenem, 2417, 2421
Hemoglobin degradation
 4-aminoquinolines, 2973
P. falciparum, 2973
 phenanthrene methanols, 2973
 quinoline methanols, 2973
Hepatitis
 3TC, 2804
 woodchucks, 2804
Hepatitis B virus
 3TC, 3179
 AT-61, 3179
 BMS-200475, 3209
 duck
 2'-fluoro-5-methyl-β-D-arabinofuranosyluracil, 369
 2'-fluoro-5-methyl-β-D-arabinofuranosyluracil
 inhibition of replication, 369
L(-)Fd4C
 antiviral activity, comparative evaluation, 1805
 PMEA, 3130
 woodchucks, 3209
Hepatitis viruses
 BMS-200475, 3200, 3209
 lobucavir, 3200
Hepatitis B virus
 3TC, 2128
 M539V, 2128
 penciclovir, 2132
Herpes simplex virus
 A-5021, 2095
 acyclovir resistance
 northwest England, survey of, 868
 cidofovir, 2996
Herpes simplex virus type 1
 acyclovir resistant
 BILD 1633, antiviral activity of, 1629
 latency, prevention of
 famciclovir and valaciclovir, quantitative comparison, 1555
 prevention of latency, quantitative comparison, 1555
Herpesvirus
 A-5021
 antiviral activity in cell culture, comparative evaluation, 1666
 H2G, 3285
mycophenolate mofetil, 3285
 potentiation of activity of acyclovir, ganciclovir, and penciclovir, 216
Hexadecylphosphocholine
L. infantum infection in mice
 short- and long-term efficacy, 654
hipA
E. coli, 3282
Histoplasma capsulatum
 MK-991 (L-743,872)
 treatment of, 151
nikkomycin Z, 2371
Histoplasmosis
 MK-991 (L-743,872)
 treatment of, 151
HIV
 141W94, 2153
 1592U89, 2153
 3TC, 2989
 ABT-378, 3218
 AY 9944, 2482
 bioavailability of stavudine, 2295
C. albicans, 2923
 children, 3187
 clindamycin, 3014
 DABO derivatives, 3225
 detection of resistance to protease and reverse transcriptase inhibitors
 rapid method for, 269
 diflucloxacillin and dicloxacillartaric acids
 selective inhibition of integrase, 140
E. coli screen, 3256
 foscarnet, 3038
γ-glutamylcysteine ethyl ester
 inhibition of production and propagation, 1200
 indinavir, 3157, 3256
 integrase inhibitors, 2245
 ISIS 5320, 2113
L(-)Fd4C
 antiviral activity in combination with β-D(+)-nucleoside analogs, 1799
 lamivudine, 3187
 lamivudine triphosphate, 2656
 lovoviride, 3123
 MDR1, 3157
 minireview, 2775
 MRPI, 3157
 nelfinavir, 2637, 3157
 nuclear importation inhibitors
 CNI-H0294, inhibition of virus replication in infected peripheral blood mononuclear cells, 1133
 PBMC, 2989
 PMPA, 612, 1484, 2380
 protease, 3157, 3218, 3256
 protease inhibitors, 478, 2775
 reverse transcriptase, 447, 618, 3038, 3123, 3225
 rifabutin, 2017
 ritonavir, 3157, 3218
 saquinavir, 3157
 S-1153, 1340
 temacrazine
 selective inhibition of replication, 487
 1,1,3-trioxa-2*H,4H*-thieno[3,4-*e*][1,2,4]thiadiazine derivatives
 in vitro activity, 618
TXU (anti-CD7)-pokeweed antiviral protein
 potent inhibition, comparative evaluation, 383
 variants from AIDS patients after prolonged adefovir dipivoxil therapy
 genotypic and phenotypic characterization, 1620
 zidovudine, 2656, 3038
HMR 3004
 aerobic and anaerobic human and animal bite pathogens
 comparative evaluation, especially macrolides, 1127
B. pertussis and *B. parapertussis*
 in vitro activity, comparative evaluation, 965
S. pneumoniae
 German isolates, activity against, 1509
 streptococci inducibly resistant to erythromycin
 activity against, 1392
HMR 3647
 aerobic and anaerobic human and animal bite pathogens
 comparative evaluation, especially macrolides, 1127
 aerobic and facultative non-spore-forming gram-positive bacilli
 in vitro activity, comparative evaluation, 1028
B. pertussis and *B. parapertussis*
 in vitro activity, comparative evaluation, 965
C. pneumoniae
 activity in vitro, 1515
H. influenzae, 2138, 3032
Legionella spp.
 activity in vitro, 1520
M. catarrhalis, 3032
 polymorphonuclear neutrophils, 1944
 pneumococci, penicillin and erythromycin susceptible and resistant
 comparative activity, 624
S. pneumoniae
 German isolates, activity against, 1509
 quinupristin-dalfopristin, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
HMR3647
 coryneform bacteria, 3290
Enterococcus, 3279
Homophthalimides
 human rhinovirus
 2A and 3C proteases, dual inhibition of, 916
HSR-903
 respiratory pathogens
 in vivo activity, 785
Human papillomavirus
 imiquimod
 efficacy and safety in patients with external genital warts, 789
Human rhinovirus
 homophthalimides
 2A and 3C proteases, dual inhibition of, 916
Hydatid disease
 oxfendazole
 naturally infected animals, treatment of, 601
Hydrocephalus
 meropenem, 2012
Hydroxamate
P. falciparum, 2456
 (S)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]
 pharmacokinetics
 disposition in liver, 1146
Hydroxynaphthoquinones
T. gondii, 2284
Imidazoles
NND-502
Trychophyton spp., in vitro and in vivo activities, comparative evaluation, 967
S-1153
 human immunodeficiency virus, inhibi-

- tion of replication of drug-resistant strains, 1340
- Imipenem**
amikacin, 3304
E. cloacae, 3304
lipopolysaccharide release, antibiotic induced
S. typhi, delay between killing and release, 739
S. pneumoniae, penicillin resistant meropenem, ceftazidime, and ceftriaxone-vancomycin, comparative activities, 942
S. typhi
lipopolysaccharide release, antibiotic induced, delay between killing and release, 739
versus L-749,345, 2365
- Imipenem-cilastatin**
versus piperacillin-tazobactam, 2966
- Imiquimod**
genital warts, external
efficacy and safety in infected patients, 789
- human papillomavirus
efficacy and safety in patients with external genital warts, 789
- Implants**
orthopedic, 3086
Staphylococcus, 3086
- In40**
E. aerogenes In40, 2557
- Indinavir**
CD4 lymphocyte count and viral load changes
mathematical modeling of interrelationship, 358
HIV, 3157
HIV protease, 3256
interaction with ritonavir, 2784
- MDR1**, 3157
- MRP1**, 3157
- pharmacokinetics**
fluconazole, effect on, human immunodeficiency virus-infected patients, 223
single dose, effect of food, 332
- Indofincin**, 3320
- Indomethacin**
zidovudine azido-reductase activation by, 1654
- Influenza A virus**
neuraminidase inhibitor BCX-140 resistant
generation and characterization of mutant, 801
- Influenza virus**
GS 4071, 3234
GS 4104
protection against infection in mice and ferrets, 640
- neuraminidase**, 3234
- neuraminidase inhibitors**
GS 4104, protection against infection in mice and ferrets, 640
- Integrase inhibitors**
HIV, 2245
- Integrins**
S. enterica, 3053
- Interleukin-2**
ciprofloxacin, 1923
- Interleukin-10**
P. aeruginosa, 2853
- Interleukin-12**
benznidazole, 2549
T. cruzi, 2549
- Intracellular delivery**
gentamicin
delivery into mammalian cells by *S. flexneri* membrane vesicles, 1476
- IS18**
Acinetobacter sp., 13, 2759
- Isepamicin**
E. coli
postantibiotic and sub-MIC effects, 414
S. aureus
postantibiotic and sub-MIC effects, 414
- ISIS 5320**
HIV, 2113
- Isometamidium**
trypanosomiasis in cattle
sustained-release device, prophylactic effect, 1012
- Isoniazid**
combination with rifalizol, 3047
combination with rifapentine, 3047
M. avium
activity in beige mice, 712
amikacin and/or clarithromycin, activity in beige mice, 712
- M. tuberculosis*, 3047
- M. tuberculosis katG*, 2443
- mycobacteria**
intracellular activation, role of superoxide, 709
- Itraconazole**
Aspergillus, 3018
Aspergillus spp., 2726
- B. dermatitidis*
susceptibilities of clinical and laboratory isolates, 978
- blood-brain barrier, transport across P glycoprotein, mediation by, 1738
- C. neoformans*, fluconazole susceptible and resistant
comparative efficacy, itraconazole, 471
- Candida*, 3018
- Paeciliomyces* spp.
antifungal susceptibilities, 1601
- pharmacokinetics**
blood-brain barrier, transport across, mediation by P glycoprotein, 1738
enhanced bioavailability in hydroxypropyl-β-cyclodextrin solution, 1858
- C. neoformans*, fluconazole susceptible and resistant
repeated dose, infants and children, 404
- versus amphotericin B, 3018
- versus LY303,366, 2726
- versus voriconazole, 3018
- Ivermectin**
letter to the editor, 2770
toxicosis, 2770
- Kanamycin**
M. tuberculosis resistance mechanism of, 1295
- katG*
isoniazid, 2443
- M. tuberculosis*, 2443
- rifampin**, 2443
- Keto-C-glycosides**
non-small-cell lung cancer cells
antiproliferative and apoptotic activities, 779
- Ketoconazole**
B. dermatitidis
susceptibilities of clinical and laboratory isolates, 978
- NADPH cytochrome P-450 oxidoreductase**
effect on susceptibility, 1756
- Paeciliomyces* spp.
antifungal susceptibilities, 1601
- Ketolides**
aerobic and facultative non-spore-forming gram-positive bacilli
in vitro activity, comparative evaluation, 1028
- HMR 3004, 3309
- HMR 3004 (RU 64004)
aerobic and anaerobic human and animal bite pathogens, comparative evaluation, 1127
- B. pertussis* and *B. parapertussis*, in vitro activity, comparative evaluation, 965
- S. pneumoniae*, activity against, 1509
- streptococci inducibly resistant to erythromycin, activity against, 1392
- HMR 3647, 1944, 2138
- HMR 3647 (RU 66647)
aerobic and anaerobic human and animal bite pathogens, comparative evaluation, 1127
- B. pertussis* and *B. parapertussis*, in vitro activity, comparative evaluation, 965
- C. pneumoniae*, in vitro activity, 1515
- gram-positive organisms, comparative evaluation, 1028
- pneumococci, penicillin and erythromycin susceptible and resistant, 624
- S. pneumoniae*, activity against, 1509
- HMR 3647, 3279
- pneumococci, penicillin and erythromycin susceptible and resistant
HMR 3647 (RU 66647), 624
- Ketonucleosides**
non-small-cell lung cancer cells
antiproliferative and apoptotic activities, 779
- Klebsiella oxytoca*
β-lactamase
AmpC type, plasmid mediated, characterization of, 464
- OXY-2, 2184
- Klebsiella pneumoniae*
antimicrobial resistance
outer membrane protein profiles, association with, 1636
- β-lactamase
association with decreased susceptibility to moxalactam, 108
- novel, extended spectrum, TEM type, 108
- resistance to expanded-spectrum cephalosporins, 1350
- TEM-43, biochemical and genetic properties, 1671
- ceftazidime, 3079
- cephalosporins, expanded spectrum, resistance to
β-lactamase, characterization of, 1350
- extended-spectrum β-lactamase producing outbreaks, epidemiology and successful control, 53
- fluoroquinolones**
energy-dependent accumulation in quinolone-resistant strains, 1850
- outer membrane protein profiles

- antimicrobial resistance, association with, 1636
SHV-5 β -lactamase, 3079
TEM-47 β -lactamase, 3079
KNI-272
pharmacokinetics
human immunodeficiency virus-infected children after intravenous and oral dosing, 1815
nonhuman primates after intravenous dosing, 1815
KY-62
candidiasis
murine, treatment of, 147
L. amazonensis, 2542
L. donovani, 2542
L-743,872
histoplasmosis
disseminated, murine model, treatment of, 151
L-749,345
versus imipenem, 2365
versus ceftriaxone, 2365
Lactacystin
Plasmodium spp., 2731
Lactobacillus acidophilus
susceptibility testing
continuous-culture biofilm system, 1428
Lactoferrin
C. albicans, azole resistant
inhibition of hyphal growth, 1587
synergy with triazoles, 1587
Lamivudine
children, 3187
HIV, 3187
pharmacokinetics, 3187
Lamivudine triphosphate
HIV, 2656
in PBMC, 2656
Lantibiotics
mersacidin
peptidoglycan synthesis, inhibition by targeting lipid II, 154
Legionella pneumophila
A. castellanii, 2870
ampicillin, 2870
ciprofloxacin, 2870
erythromycin, 2870, 3153
imipenem, 2870
levofloxacin, 3153
monocytes, 3153
rifampin, 3153
U937 cells, 2870
Legionella spp.
newer antimicrobial agents
activity in vitro, 1520
Leishmania amazonensis
KY62, 2542
Leishmania donovani
amphotericin B, 2722
amphotericin B resistance
promastigotes, mechanism of, 352
KY62, 2542
megalomicin, 2668
sodium stibogluconate, 2722
Leishmania infantum
amphotericin B, 2141
hexadecylphosphocholine
established infection in mice, short- and long-term efficacy, 654
pentavalent antimony, 3097
Leishmania major
amphotericin B, 3092
megalomicin, 2668
Leishmania spp.
meglumine antimonate
characterization of, 1076
Leishmania tarentolae
sodium stibogluconate resistant gene amplification, 1689
Leishmania viannia panamensis
pentavalent antimony, 1990
Leishmaniasis
hexadecylphosphocholine
established infection in mice, short- and long-term efficacy, 654
liposomal delivery system, peptide grafted macrophages, targeting to, 348
Leprosy
ofloxacin-minocycline, with or without rifampin
bactericidal activity in mice and lepromatous patients, 1115
Letters to the Editor
aminoglycoside-modifying enzymes
nomenclature of genes encoding, 483
avoparcin, 3333
B. parapertussis
BAY 12-8039, trovafloxacin, and ciprofloxacin, susceptibilities to, 1868
B. pertussis
BAY 12-8039, trovafloxacin, and ciprofloxacin, susceptibilities to, 1868
beta-defensins, 3328
biocide resistance, 2151
Caz-hi β -lactamase, 3329
cefotaxime
S. pneumoniae, activity against, 1869
cefotizoxime
S. pneumoniae, activity against, 1869
E. faecium
satB, 3331
vgb, 3331
Enterococcus, 3333
erythromycin
inhibitory effect on superoxide anion production by human neutrophils, 1866
glycopeptide usage
Europe, 3049
U.S., 3049
H. pylori
miconazole, morphological effects of, 725
ivermectin, 2770
M. leprae, 3334
miconazole
H. pylori, morphological effects on, 725
pharmacokinetics
azithromycin and clarithromycin, bronchopulmonary, 481
S. aureus, fluoroquinolone and methicillin resistant selection with ciprofloxacin and trovafloxacin, 727
S. aureus, mupirocin resistant isolates from different geographic areas, characterization of, 1305
S. aureus, quinolone resistant *grlA* mutations, analysis of, 1306
S. pneumoniae
ceftizoxime and cefotaxime, activities against, 1869
synergistic activity of trovafloxacin and ceftriaxone or vancomycin, 991
S. pyogenes, erythromycin resistant, clindamycin susceptible
emergence in Madrid, letter to the editor, 989
S. rimosus OtrB, 3050
TEM-41, 2771
toxocariasis, 2770
V. cholerae fluoroquinolone resistance patients with acute diarrhea in Calcutta, India, 206
vancomycin
historical yearly usage, 1303
vancomycin resistance, 3049
vancomycin-resistant *E. faecium*, 2150
vancomycin-resistant enterococci, 2463
Leukemia
amphotericin B nephrotoxicity, 3103
Levofoxacin
anaerobes from skin and soft tissue infections
in vitro activities, 984
combination with gentamicin, 2002
combinations with cephalosporins, 2002
L. pneumophila, 3153
P. aeruginosa
determination of activities by checkerboard and time-kill methodology, 953
synergy, 953
P. aeruginosa, biofilm producing in vitro and in vivo activities, 1641
pharmacokinetics
double-blind evaluation in healthy volunteers, 885
population pharmacokinetics and demographic model for prediction of individual drug clearance, 1098
pneumococci
postantibiotic effect and postantibiotic sub-MIC effect, comparative evaluation, 1253
postantibiotic effect and postantibiotic sub-MIC effect pneumococci, comparative evaluation, 1253
S. maltophilia, 2002
safety
double-blind evaluation in healthy volunteers, 885
L-FMAU
duck hepatitis B virus
inhibition of replication, 369
Linezolid
E. coli, 3251
inhibition of protein synthesis, 3251
S. aureus, 3251
S. aureus, coagulase-negative staphylococci, *E. faecalis*, and *E. faecium* comparative activity and postantibiotic effect, 721
Lipid A
E5531, 2824
Lipopolysaccharides
CAP18, 3269
P. aeruginosa, 3269
Lipoproteins
nystatin, 1878
Liposomal agents
pharmacokinetics
blood clearance capacity of the mononuclear phagocyte system, 1677

- Liposomes 1253
gentamicin, 2511
- Lipoteichoic acid
S. aureus, 3073
- Listeria monocytogenes*
gentamicin, 2511
- LL-37
 antimicrobial activities, 2206
- Lobucavir
 hepadnaviruses, 3200
 triphosphate form, 3200
- Lomefloxacin
 photosensitivity, 3141
- Loratadine
 electrocardiographic pharmacodynamics
 after individual or concomitant administration with clarithromycin, 1176
 pharmacokinetics, steady state
 after individual or concomitant administration with clarithromycin, 1176
- Loviride
 HIV reverse transcriptase, 3123
- Luciferase
S. mutans, 1906
- Lumefantrine
P. falciparum, 2347
- LY303366
A. fumigatus, 2898
A. fumigatus, amphotericin B susceptible and resistant
 efficacy in murine model of invasive aspergillosis, 873
- Aspergillus* spp., 2726
- Candida*, 2446
- pharmacokinetics, 2898
 photoaffinity analog
C. albicans, identification of targets in, 1187
 susceptibility testing
 endpoints, evaluation of, 1387
 versus amphotericin B, 2726
 versus itraconazole, 2726
- LY333328
 combination with ampicillin, 2564
E. faecium, 2564
 multidrug resistance, 2452
 postantibiotic effects, 2564
S. aureus, 2427
S. aureus, methicillin resistant
 experimental endocarditis, efficacy against, 981
 vancomycin resistance, 2564
 versus teicoplanin, 2452
 versus vancomycin, 2452
- Lysostaphin
S. aureus, methicillin resistant
 aortic valve endocarditis, treatment of, 1335
- M13
 BLIP, 2893
- Macrolides
 coryneform bacteria, 3290
M. avium resistance
 emergence during experimental chemotherapy, 180
 pneumococci
 postantibiotic effect and postantibiotic sub-MIC effect, comparative evaluation, 1253
 postantibiotic effect and postantibiotic sub-MIC effect
 pneumococci, comparative evaluation,
- Macrophages
 liposomal delivery system, peptide grafted, 348
- Magainin, 3320
- Magainins
 analogs
 MSI-78, in vitro antimicrobial activity, 1213
- Malaria
 ferrocene-chloroquine
 in vitro activity, 540
- P. falciparum*, multidrug resistant
 artesunate-mefloquine versus artemether-benflumetol, 135
- P. falciparum*, sulfadoxine-pyrimethamine resistant
 molecular basis for, 1811
- WR 238605
 prophylaxis in a human challenge model, 1293
- Mannich agents
 disposition, 2410
 malaria, 2410
 pharmacology, 2410
 toxicology, 2410
- marA*
E. coli, 2089
 fluoroquinolone resistance, 2089
- Marvelon
 ciprofloxacin, 3266
- Mathematical modeling
 indinavir
 CD4 lymphocyte count and viral load changes, 358
- MDR1
 HIV, 3157
 indinavir, 3157
 nelfinavir, 3157
 ritonavir, 3157
 saquinavir, 3157
- mec*
S. aureus, introduction in
 alteration of in vitro functional activities of fibrinogen and fibronectin adhesins, 564
- mecA*
 coagulase-negative staphylococci
mecA and *gyrA*, chromosomal relationship, 306
- S. aureus* and *S. epidermidis*, methicillin resistant
 diversity of mutations, analysis of, 717
- mecI*
S. aureus and *S. epidermidis*, methicillin resistant
 diversity of mutations, analysis of, 717
- Megalomicin
Leishmania, 2668
Trypanosoma, 2668
- Meglumine antimonate
 characterization of, 1076
- Membrane-active peptides
cercopin P1, 3320
 indolicin, 3320
 magainin, 3320
 ranalexin, 3320
- Meningitis
 amphotericin B
 alone and with flucytosine with or without fluconazole, 528
- cryptococcal
 amphotericin B, alone and with flucytosine with or without fluconazole, 528
- tosine with or without fluconazole, 528
- pneumococci, penicillin resistant
 moxifloxacin, activity against, 1706
- S. pneumoniae*
 moxifloxacin, activity, 1397
- S. pneumoniae*, penicillin resistant
 meropenem, imipenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
- Meropenem
 bacterial infections in elderly patients
 cefuroxime-gentamicin, comparative evaluation, 1233
- hydrocephalus, 2012
- pharmacokinetics, 2417, 2421
 hemofiltration, 2417, 2421
- S. pneumoniae*, penicillin resistant
 imipenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
- ventriculostomy, 2012
- Mersacidin
 peptidoglycan synthesis
 inhibition by targeting lipid II, 154
- Methadone
 3'-azido-3'-deoxythymidine
 glucuronidation by human liver microsomes, inhibition by, 1592
- pharmacokinetics
 zidovudine, glucuronidation by human liver microsomes, inhibition by, 1592
- Methicillin
 coagulase negative staphylococci, resistance
mecA and *gyrA*, chromosomal relationship, 306
- postantibiotic effect
S. aureus, flow cytometric assessment of, 1195
- S. aureus*, 2817
- S. aureus* resistance
 introduction of *mec* alters in vitro functional activities of fibrinogen and fibronectin adhesins, 564
- letter to the editor, 727
- mecA* and *mecI*, diversity of mutations, analysis of, 717
- selection with ciprofloxacin and trovafloxacin, 727
- S. epidermidis* resistance
mecA and *mecI*, diversity of mutations, analysis of, 717
- 8-Methoxyquinolones
 BAY 12-8039
C. pneumoniae, in vitro activity, 951
- moxifloxacin
 meningitis due to penicillin-resistant pneumococci, efficacy against, 1706
- Metronidazole
H. pylori resistance
 effect on bacterial eradication in infected children, 1334
 risk of development, 1222
- Miconazole
H. pylori
 letter to the editor, 725
 morphological effects of, 725
- Paecilomyces* spp.
 antifungal susceptibilities, 1601
- Micrococci
P. falciparum

- potent inhibition of growth and protein synthesis, 715
- Microdialysis**
rifampin in brain, 2626
- Microspheres**
rifampin, 2682
- Microsporidia**
albendazole, 3301
- Minireviews**
 β -lactamases
kinship and diversification, 1
- HIV, 2775
- P. carinii*
pneumonia, treatment of, 1309
- prevention of infection, 995
- penicillin-binding proteins
kinship and diversification, 1
- protease inhibitors, 2775
- Tn916, 1871
- two-component signal transduction
target for microbial anti-infective therapy, 1529
- Minocycline**
letter to the editor, 3334
- M. leprae*, 3334
combination with ofloxacin, with or without rifampin, 1115
- ofloxacin, with or without rifampin
bactericidal activity in mice and lepromatous patients, 1115
- V. vulnificus*
alone or in combination with cefotaxime, 1319
- experimental murine infection, treatment of, 1319
- MK-826**
S. aureus, 1996
- MK-991**
histoplasmosis
disseminated, murine model, treatment of, 151
- P. carinii*, 1985
- MLS resistance**
H. pylori 23S RNA, 1952
- S. pneumoniae*, 2312, 2425
- Monoclonal antibodies**
C. neoformans capsular polysaccharide candidate for human therapeutic studies, 1437
- Monocytes**
A. fumigatus, 2299
combination with voriconazole, 2299
- novobiocin, 1911
- Monoglycerides**
C. trachomatis, 2290
- Moraxella catarrhalis**
 β -lactamase BRO-1, 2521
- biofilms, 2521
- HMR 3647, 3032
- interaction with *S. pneumoniae*, 2521
- Morganella morganii**
ampR, 2352
- S. enteritidis* DHA-1, 2352
- TEM-21, 2125
- Moxalactam**
K. pneumoniae, decreased susceptibility novel, extended-spectrum, TEM-type β -lactamase, 108
- Moxifloxacin**
M. tuberculosis, 2066
- meningitis
penicillin-resistant pneumococcus, activity against, 1706
- pharmacokinetics, 2060
- coadministration of dexamethasone, effect on penetration into cerebrospinal fluid, 1397
- pneumococci, penicillin resistant activity against, 1706
- S. pneumoniae* meningitis activity against, 1397
- MRP1**
HIV, 3157
- indinavir, 3157
- nefnavir, 3157
- ritonavir, 3157
- saquinavir, 3157
- MSI-78**
in vitro antimicrobial activity
comparative evaluation, 1213
- Multidrug efflux pumps**
P. aeruginosa
 β -lactamase inhibitors, substrates for, 399
expression in multidrug-sensitive *E. coli* strain, 65
resistance to fatty acid biosynthesis inhibitors, novel technique for study, 395
- S. aureus* QacA
comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones, 475
- V. parahaemolyticus* NorM cloning and sequencing, 1778
- Mupirocin**
S. aureus resistance
characterization of isolates from different geographic areas, letter to the editor, 1305
- Murine gamma herpesvirus 68
in vitro and in vivo susceptibilities, 170
- Mycobacteria**
fluoroquinolones, 2978
- gyrA, 2978
- gyrase, 2084
- quinolone resistance, 2084
- Mycobacterium aurum**
norfloxacin
accumulation in, 795
- Mycobacterium avium**
amikacin, 3006
- amikacin, liposome encapsulated prolonged-interval treatment, rationale for and efficacy of, 459
- clarithromycin, 3006
- clofazimine, 3006
- isoniazid
activity in beige mice, 712
- amikacin and/or clarithromycin, activity in beige mice, 712
- macrolide resistance
emergence during experimental chemotherapy, 180
- rifampin, 3006
- TNF- α , 2336
- triple infection with *T. gondii* and *P. carinii* in rat model
drug evaluation, 1068
- Mycobacterium avium complex**
diaminomethylpyridopyrimidines, 3315
- dihydrofolate reductase, 3315
- postantibiotic effect
 CO_2 generation versus viable-count method for determination, 184
- Mycobacterium leprae**
letter to the editor, 3334
- minocycline, 3334
- ofloxacin, 3334
- ofloxacin-minocycline, with or without rifampin
bactericidal activity in mice and lepromatous patients, 1115
- rifampin, 3334
- Mycobacterium smegmatis**
norfloxacin
accumulation in, 795
- tet(V), 1931
- Mycobacterium spp.**
5-chloropyrazinamide
in vitro activity, 462
- isoniazid action
catalase-peroxidase mediated, role of superoxide, 709
- Mycobacterium tuberculosis**
ABT-255, 2674
- amikacin and kanamycin resistance mechanism of, 1295
- β -lactamases
 β -lactam susceptibilities, contribution to, 1524
- recombinant expression and characterization of, 1375
- BM212, 3035
- clinafloxacin, 2066
- isoniazid, 2443, 3047
- katG, 2443
- macrophages, 2682
- moxifloxacin, 2066
- rifalizil, 3047
- rifampin, 2443, 2682
- rifamycin resistance
rpoB mutations, contribution to, 1853
- rifapentine, 3047
- screening of antimycobacterial compounds
fluorescent protein reporter microplate assay, 344
- Mycobacterium ulcerans**
clarithromycin, 2070
- Mycophenolate mofetil**
antiherpesvirus activity of acyclovir, ganciclovir, and penciclovir
potentiation of, 216
- H2G, 3285
- herpesvirus, 3285
- Mycoplasma hominis**
DNA gyrase, 2304
- ofloxacin, 2304
- sparfloxacin, 2304
- topoisomerase IV, 2024, 2304
- Mycoplasma pneumoniae**
quinupristin-dalfopristin
comparative in vitro activity, 698
- RPR 106972
comparative in vitro activity, 698
- Mycoplasma spp.**
BAY 12-8039
in vitro activities, 703
- Nalidixic acid
C. jejuni, 2106
- Neisseria gonorrhoeae**
 β -lactams, 2799
- ciprofloxacin, 2103, 2919
- parC, 2103
- pazufloxacin, reduced clinical efficacy against
high prevalence of quinolone-resistant

- isolates with GyrA mutation, 579
penB porin, 2799
 tetracycline, 2799
- Nelfinavir
 HIV, 2637, 3157
 MDR1, 3157
 MRP1, 3157
- Neuraminidase inhibitors
 influenza A virus resistance
 generation and characterization of resistant mutant, 801
- Neuraminidases
 GS 4071, 3234
 influenza virus, 3234
- Neuropeptide Y
C. albicans, 2745
- Neutropenia
 amphotericin B, 2391
 BMS 181184, 2399
- Neutrophils
A. fumigatus, 2299
 combination with voriconazole, 2299
 LL-37, 2206
- NF- κ B
 ciprofloxacin, 1923
- Nikkomycin Z
H. capsulatum, 2371
- Nitazoxanide
C. parvum, 1959, 2877
H. pylori, 2836
- Nitric oxide
Candida, 2342
 synergy with azoles, 2342
- Nitrofurantoin
Clostridium resistance
 nitroreductase-producing strains, isolation from human intestinal tract, 1121
- NND-502
Trychophyton spp.
 in vitro and in vivo activities, comparative evaluation, 967
- Non-small-cell lung cancer cells
 keto-C-glycosides
 antiproliferative and apoptotic activities, 779
- ketonucleosides
 antiproliferative and apoptotic activities, 779
- NorA
S. aureus, 3317
- Norfloxacin
B. fragilis, 2119
 efflux, 2119
 epileptogenic potential, 2756
- M. aurum*
 accumulation in, 795
- M. smegmatis*
 accumulation in, 795
- V. parahaemolyticus* resistance
 NorM multidrug efflux protein, cloning and sequencing, 1778
- Novobiocin
 monocyte functions, 1911
- Nucleoside analogs
E. coli, 2620
- L-Nucleoside analogs
 unique metabolism, substrate for both thymidine kinase and deoxycytidine kinase, 833
- Nystatin
 free and liposome encapsulated four amphotericin B formulations, com-
- parative evaluation, 1412
 high-density lipoproteins, 1878
- Oflloxacin
Caco-2/TC-7 cells, 2950
 glucose metabolism, 2950
 glutamine metabolism, 2950
 letter to the editor, 3334
M. hominis, 2304
M. leprae, 3334
 combination with minocycline, with or without rifampin, 1115
 minocycline, with or without rifampin bactericidal activity in mice and leprosy patients, 1115
 osteomyelitis prophylaxis with absorbable, ofloxacin-impregnated beads, 840
- pharmacokinetics
 disposition in human head, axillary, and pubic hairs, 1298
 probenecid and cimetidine, effects on renal disposition in rats, 456
- S. typhimurium*, 2950
 urinary tract infection, 2262
- OPC-20011
E. faecalis, 2943
S. aureus, 2943
S. pneumoniae, 2943
- oprM
P. aeruginosa antibiotic resistance contribution to independent of MexAB, 1682
- Orthopedic implants
 susceptibilities of isolates, 3002
- Osteomyelitis
 ofloxacin-impregnated beads, absorbable prophylaxis with, 840
- Otitis media
 acute
 antimicrobial-resistant pathogens in middle ear fluid, prevalence of, 589
- S. pneumoniae*, penicillin resistant amoxicillin versus cefuroxime, 1361
- OXA-16
P. aeruginosa, 3117
- OXA-19
P. aeruginosa, 3113
- OXA-20
P. aeruginosa, 2074
- Oxacillin
S. aureus, methicillin resistant reduction of oxacillin resistance by cibacron blue F3GA, 1278
- Oxazolidinones
 linezolid, 3251
S. aureus resistance biochemical basis and mechanism of action, 947
- Oxfendazole
E. granulosus
 naturally infected animals, treatment of, 601
- hydatid disease, cystic naturally infected animals, treatment of, 601
- OXY-2
K. oxytoca, 2184
- Paclitaxel
T. gondii, 2032
- Paecilomyces spp.
 antifungal susceptibilities, 1601
- Panipenem
 diclofenac, 3136
 valproic acid, 3136
- parC
 ciprofloxacin, 2103
N. gonorrhoeae, 2103
S. pneumoniae, 2193
 sparfloxacin, 2193
- Paromomycin
C. parvum, 1959, 2877
- Pasteurella multocida*
 tetracycline, 2116
 Tn5706, 2116
- Pazufloxacin
 gonorrhea, reduced clinical efficacy against high prevalence of quinolone-resistant isolates with GyrA mutation, 579
- Pefloxacin
 bactericidal activity
 fleroxacin, comparative evaluation, 1659
 epileptogenic potential, 2756
 pharmacokinetics
 concentration in plasma and tissue after administration as surgical prophylaxis, 425
 urinary excretion in healthy volunteers, comparative evaluation, 1659
- penB
N. gonorrhoeae, 2799
- Penciclovir
 hepatitis B virus, 2132
 mycophenolate mofetil potentiation of antiherpesvirus activity, 216
- Penicillanic acid sulfones
 PSE-4, 2319
- Penicillin
 cytokine production induced by heat-killed *S. pneumoniae* effect on, 1605
S. pneumoniae, high-level resistance penicillin-binding protein 1A, alterations in responsible for, 1329
S. pneumoniae PBP 1A, 2262
- S. pyogenes*
 in vitro activity of combinations with clindamycin, 1266
- Penicillin-binding proteins
 IA
 alterations in essential for high-level penicillin resistance in *S. pneumoniae*, 1329
- E. hirae*
 3r gene, borne on plasmid carrying other antibiotic resistance determinants, 534
- minireview
 kinship and diversification, 1
- S. pneumoniae*
 affinity for, 173
 alterations in PBP 1A essential for high-level penicillin resistance, 1329
- Penicillins
E. faecalis
 activities and time-kill studies, 857
- Pentamidine
C. albicans, 2495
C. neoformans, 2495
 structure-activity relationships, 2495
- Pentavalent antimony
L. infantum, 3097

- L. viannia pannensis*, 1990
Pentoxifylline
C. albicans, 2405
 pharmacokinetics, 2405
Peptidoglycan
S. aureus, 3073
Peroxides
 organic, water soluble
 synthesis and antibacterial evaluation, 911
PGG glucan, 545
Staphylococcus spp.
 prophylactic activity in a guinea pig model of wound infection, 545
PGG-glucan
S. aureus, 2449
S. epidermidis, 2449
 synergism with cefazolin, 2449
P-glycoprotein
 sparfloxacin, 2607
Pharmacodynamics
 aminoglycosides
 dosing to obtain pharmacodynamic goals in patients with pneumonia, 1892
 amphotericin B
 assessment of activity against *C. albicans* by dynamic in vitro mycotic infection model, 1382
 ampicillin-sulbactam
 in vitro model against resistant *E. coli*, 231
 antimicrobial pharmacodynamic indices and bacterial killing
 comparisons by the Zhi model, 1731
 azithromycin
 in vitro and in vivo, comparison with those of erythromycin, 377
S. aureus and *E. coli*, postantibiotic and sub-MIC effects, 414
 bacterial resistance, development in acutely ill patients during therapy factors associated with, 521
 ceftazidime-aztreonam
P. aeruginosa, 1610
 co-amoxiclav
S. aureus, in vitro activities at concentrations achieved in human serum, 1574
 combination therapy, prediction of efficacy
 fractional inhibitory concentration kinetics, 744
 erythromycin
 in vitro and in vivo, comparison with those of azithromycin, 377
fluconazole
 assessment of activity against *C. albicans* by dynamic in vitro mycotic infection model, 1382
 murine model of systemic candidiasis, 1105
 fractional inhibitory concentration kinetics combination therapy, prediction of efficacy, 744
 isepamicin
S. aureus and *E. coli*, postantibiotic and sub-MIC effects, 414
 $\Gamma(-)\text{Fd}4\text{C}$
 comparative evaluation, 1805
 trovafloxacin
Enterococci, in vitro dynamic model of infection, 72
Pharmacokinetics
 amikacin
 population pharmacokinetic study in febrile, severely neutropenic adults, 849
 amphotericin B, 2391
 distribution in lung tissue after injection and inhalation, 1597
 unilamellar liposomal vesicle formulation, rats, 263
 ampicillin-sulbactam
 concentrations in tissues after bolus injections versus bolus plus continuous infusion, 1093
 antimicrobial effect, prediction of in vitro dynamic model, quinolones, 659
 artesunate, 2332
 atovaquone, micronized
 human immunodeficiency virus-infected infants and children, phase I safety, 1315
 azithromycin, 2385
 BEA005, 2174
 biapenem
 pharmacokinetics and safety in elderly subjects, 1433
 bis(isopropoxy carbonyloxymethyl)-PMPA mice, 1568
 BMS 181184, 2700
 bronchopulmonary, letter to the editor, 481
 ceftazidime
 hemodialysis patients, 1718
 cefpirome
 concentrations in cerebrospinal fluid of children with bacterial meningitis, 199
 ceftizoxime
 continuous infusion in clinically ill adults, 1783
 cephalixin
 interaction with quinapril, analysis by a nonlinear mixed-effect model, 1463
 ciprofloxacin, 2235, 2841
 cholera toxin, effect on intestinal elimination in rabbits, 473
 fosfomycin, neurotoxicodynamics of interaction in mice, 691
 liposomal encapsulation, effect on, 45
 renal failure in rats, influence on, 289
 ciprofloxacin-fenbufen
 effects on central nervous system, assessment by electroencephalography, 1256
 clarithromycin, 2385
 bronchopulmonary, letter to the editor, 481
 grapefruit juice, effect on, 927
 interactions with rifabutin in human immunodeficiency virus-infected volunteers, 631
 oral cimetidine prolongs absorption, 1578
 clarithromycin and loratadine
 individual or concomitant administration, 1176
 clinafloxacin
 pharmacokinetics and inflammatory fluid penetration, 428
 D0870
 two multiple-dosing regimens in human immunodeficiency virus-positive patients, 903
DA-1131
 rats with uranyl nitrate-induced acute renal failure, 1217
didoanosine
 human immunodeficiency virus-infected outpatients, 821
fleroxacin
 urinary excretion in healthy volunteers, comparative evaluation, 1659
fluconazole
 burn patients, 930
 effect on indinavir pharmacokinetics in human immunodeficiency virus-infected patients, 223
 rabbits and humans, correlation of AUC and peak levels, 1512
foscarnet
 absolute bioavailability, 293
 ciprofloxacin, neurotoxicodynamics of interaction in mice, 691
 human immunodeficiency virus-seropositive patients, 293
gentamicin
 delivery into mammalian cells by *S. flexneri* membrane vesicles, 1476
 initial concentration-time profile determines efficacy against *E. cloacae*, 1370
GS 4104
 oral bioavailability, 647
 human immunodeficiency virus-infected patients, 1788
 (S) -9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S) -HPMPA]
 disposition in liver, 1146
hydroxyvitraconazole
 repeated dose, infants and children, 404
 indinavir, 2784
 fluconazole, effect on, human immunodeficiency virus-infected patients, 223
 single dose, effect of food, 332
itraconazole
 blood-brain barrier, transport across, mediation by P glycoprotein, 1738
 enhanced bioavailability in hydroxypropyl-β-cyclodextrin solution, 1858
 repeated dose, infants and children, 404
KNI-272
 human immunodeficiency virus-infected children after intravenous and oral dosing, 1815
 nonhuman primates after intravenous dosing, 1815
lamivudine, 3187
levofloxacin
 population pharmacokinetics and demographic model for prediction of individual drug clearance, 1098
 safety and pharmacokinetics, double-blind evaluation in healthy volunteers, 885
 $\Gamma(-)\text{Fd}4\text{C}$
 metabolism, 1799, 1805
liposomal agents
 blood clearance capacity of the mononuclear phagocyte system, 1677
Mannich agents, 2410
meropenem, 2417, 2421
moxifloxacin, 2060
 coadministration of dexamethasone, effect on penetration into cerebro-

- spinal fluid, 1397
- new pasteurized human tetanus immunoglobulin
- safety and pharmacokinetic profile, 298
 - ofloxacin
 - disposition in human head, axillary, and pubic hairs, 1298
 - probencid and cimetidine, effects on renal disposition in rats, 456 - pefloxacin
 - concentration in plasma and tissue after administration as surgical prophylaxis, 425
 - urinary excretion in healthy volunteers, comparative evaluation, 1659
- pentoxifylline, 2405
- 9-R-(2-phosphomethoxypropyl)adenine (PMPA)
- pharmacokinetics and bioavailability in dogs, 687
- pleconaril, 2706
- PMPA, 2380
- population
- levofloxacin, 1098
 - positron emission tomography, 2048
 - quinapril
 - interaction with cephalixin, analysis by a nonlinear mixed-effect model, 1463 - rifabutin, 2017
 - interactions with clarithromycin in human immunodeficiency virus-infected volunteers, 631 - ritonavir, 2784, 3107
 - alone and in combination with zidovudine, 1788 - human immunodeficiency virus-infected patients, 1788
 - sparfloxacin
 - chondrotoxicity and toxicokinetics in juvenile rats, 1470
 - physicochemical properties that regulate penetration of quinolones, 1412
 - serum and vitreous humor in rabbits, 1417 - subbenicillin
 - stereoselective disposition in humans, 325 - theophylline, 2359
 - terbinfine, effect on in healthy volunteers, 695 - tobramycin
 - MIC changes alter responses of *P. aeruginosa*, 1365 - tosufloxacin
 - aluminum hydroxide and famotidine, effects on bioavailability, 453 - trovafloxacin, 2048, 2841
 - zalcitabine, 2174
 - application of radioimmunoassay to population pharmacokinetics, 409
 - zidovudine
 - alone and in combination with ritonavir, 1788
 - premature infants exposed to human immunodeficiency virus, 808

Pharyngitis

 - S. pyogenes*
 - cefdinir treatment, 5 day, 1073

Phenylcarbamates

 - β -tubulin, 2171

Phospholipases

 - amphotericin B lipid complex
 - role in antifungal activity, 767

9-R-(2-Phosphomethoxypropyl)adenine (PMPA)

 - human immunodeficiency virus, drug resistant
 - activity against, 1484 - pharmacokinetics and bioavailability
 - dogs, 687 - prodrug
 - human immunodeficiency virus, activity and cellular metabolism, 612

9-R-(2-Phosphomethoxypropyl adenine (PMPA))

 - antiretroviral efficacy in mice, 1568
 - pharmacokinetics in mice, 1568

Photochemotherapy

 - A. viscosus*, 2595
 - P. gingivalis*, 2595

Photosensitivity

 - lomefloxacin, 3141

Piperacillin-tazobactam

 - versus imipenem-cilastatin, 2966

Plasmodium

 - lactacystin, 2731
 - Mannich agents, 2410

Plasmodium falciparum

 - 4-aminoquinolines, 2973
 - artesunate, 2332
 - aspartic protease inhibition, 2254
 - chlorocycloguanil
 - in vitro activity, correlation with point mutations in the dihydrofolate reductase domain, 164 - cysteine inhibition, 2254
 - ferrocene-chloroquine
 - in vitro activity, 540 - heme polymerization, inhibition of, and drug accumulation
 - drug activity, relationship between, 682 - hemoglobin degradation, 2973
 - hydroxamate, 2456
 - lumefantrine, 2347
 - malaria, multidrug resistant
 - artesunate-mefloquine versus artemether-benzflumetol, 135 - megalomicin, 2668
 - micrococci
 - potent inhibition of growth and protein synthesis, 715 - phenanthrene methanols, 2973
 - polyhydroxyphenyl, 2456
 - pyrimethamine
 - in vitro activity, correlation with point mutations in the dihydrofolate reductase domain, 164 - quinoline methanols, 2973
 - sulfadoxine-pyrimethamine resistance
 - molecular basis for, 1811 - thalassemia, 2332
 - WR 238605
 - prophylaxis in a human challenge model, 1293

Platelets

 - S. aureus*, 3169

Pleconaril

 - effect of food, 2706
 - oral solution, 2706
 - pharmacokinetics, 2706

PMEA

 - hepatitis B virus, 3130

PMPA

 - HIV, 2380
 - pharmacokinetics, 2380

PMX-622

 - antimicrobial activity, 2765
 - combinations, 2765

Pneumocandins

 - MK-991, 1985
 - MK-991 (L-743,872)
 - histoplasmosis, murine model, treatment of, 151 - P. carinii*, 1985

Pneumococci

 - grepafloxacin
 - in vitro activity, comparative evaluation, 1263 - HMR 3647 (RU 66647)
 - comparative activity, 624 - levofloxacin
 - postantibiotic effect, comparative evaluation, 1253 - macrolides
 - postantibiotic effect, comparative evaluation, 1253 - penicillin resistant
 - moxifloxacin, activity against, 1706 - quinolones
 - postantibiotic effect, comparative evaluation, 1253
 - trovafloxacin
 - postantibiotic effect, 1503

Pneumocystis carinii

 - echinocandins
 - water soluble, pneumonia in mice, 37 - MK-991, 1985
 - pneumonia
 - echinocandins, water soluble, 37
 - sulfamethoxypyridazine, efficacy in murine model, 934
 - treatment of, minireview, 1309 - prevention of infection
 - minireview, 995 - sordarins, 2863
 - sulfa drugs
 - quantitative structure-activity relationship studies, 1454 - sulfamethoxypyridazine
 - efficacy in murine model, 934
 - triple infection with *T. gondii* and *M. avium* in rat model
 - drug evaluation, 1068

Pneumocystis spp.

 - aromatic diamidoxime prodrugs
 - activities in rats, 666

Pneumonia

 - aminoglycosides
 - dosing to obtain pharmacodynamic goals in patients with pneumonia, 1892 - C. pneumoniae*
 - susceptibilities of isolates from patients with community-acquired pneumonia, 194 - cefepime
 - ceftriaxone, comparative evaluation, 729
 - cefpirome
 - ceftazidime, comparative evaluation, 28
 - ceftazidime
 - cefpiprome, comparative evaluation, 28 - ceftriaxone
 - cefpiprome, comparative evaluation, 729
 - community acquired
 - cefpiprome versus ceftriaxone, compara-

- tive evaluation, 729
- P. carinii*
echinocandins, water soluble, 37
sulfamethoxypyridazine, efficacy in murine model, 934
treatment of, minireview, 1309
- S. pneumoniae*
CS-834, 23
penicillin susceptible and resistant, 23
S. pneumoniae, penicillin susceptible and multiresistant
trovafloxacin, efficacy in mouse pneumonia model, 862
- Pneumonic plague
antibiotic treatments
comparative evaluation, 675
- Pokeweed antiviral protein
TXU anti-CD7 monoclonal antibody
human immunodeficiency virus, potent inhibition, 383
- Poland
K. pneumoniae, 3079
- Polycarbophil
C. albicans, 2434
combination with econazole, 2434
- Polyenes
SPA-S-843, 3012
- Polyhydroxyphenyl
P. falciparum, 2456
- Polymorphonuclear neutrophils
HMR 3647, 1944
- Polymyxin B
covalent conjugate with human immunoglobulin G
antidotoxin reagent, 583
- PMX-622, 2765
- Population pharmacokinetics
HIV, 2017
rifabutin, 2017
- Porins
N. gonorrhoeae penB, 2799
- Porphyromonas gingivalis*
photochemotherapy, 2595
susceptibilities, 3022
- Positron emission tomography
trovafloxacin, 2048
- Postantibiotic effect
azithromycin
S. aureus and *E. coli*, 414
bacterial populations
characteristics and dynamics, determination by flow cytometry, 1005
- CO₂ generation versus viable-count method for determination, 184
- E. coli*
cefotaxime and piperacillin, 78
determination with real-time metabolic monitoring, 78
- E. faecium*, 2188
isepamicin
S. aureus and *E. coli*, 414
levofloxacin
pneumococci, comparative evaluation, 1253
- M. avium* complex
CO₂ generation versus viable-count method for determination, 184
- macrolides
pneumococci, comparative evaluation, 1253
- methicillin
S. aureus, flow cytometric assessment of, 1195
- quinolones
pneumococci, comparative evaluation, 1253
quinupristin-dalfopristin, 2188, 3028
- tobramycin
dosing interval, relation to duration and clinical relevance, 749
- trovafloxacin
gram-positive and -negative organisms, 1503
- Povidone-iodine
Acanthamoeba, 2232
- Pradimicin
A. fumigatus, 2399
BMS 181184, 2399
- Pradimicins
BMS 181184, 2700
- Prediction of effect
ciprofloxacin, 2848
MIC based, 2848
- Prevotella intermedia*
susceptibilities, 3022
- Prevotella nigrescens*
susceptibilities, 3022
- Probenecid
pharmacokinetics
ofloxacin, effects on renal disposition in rats, 456
- Propamidine
Acanthamoeba 18S rRNA, 2144
- Prostheses
S. aureus, 2830
- Protease inhibitors
HIV, 2775
homophthalimides
human rhinovirus 2A and 3C proteases, dual inhibition of, 916
- human immunodeficiency virus type 1 resistance
detection of, rapid method for, 269
estimate of frequency in unselected virus populations in vitro, 478
- KNI-272
pharmacokinetics in nonhuman primates and human immunodeficiency virus-infected children, 1815
- minireview, 2775
zidovudine azido-reductase inhibition by, 1654
- Proteasomes
lactacystin, 2731
Plasmodium, 2731
- Protegrin
H. ducreyi, 2690
- Proteus mirabilis*
β-lactamase
AmpC type, chromosomally encoded, 1110
resistance to expanded-spectrum cephalosporins, 1350
cephalosporins, expanded spectrum, resistance to
β-lactamase, characterization of, 1350
- Providencia stuartii*
aarE mutations
high-level aminoglycoside resistance and reduced expression of the chromosomal aminoglycoside 2'-N-acetyltransferase, 959
- aminoglycoside resistance
aarE mutations, 959
ceftazidime and aztreonam resistance
β-lactamase, TEM derived, extended spectrum, 1459
- PSE-4
ceftazidime, 2576
subbactam, 2319
tazobactam, 2319
- Pseudomonas aeruginosa*
aacC3, 3173
aminoglycosides
diffusion through extracellular polysaccharide, promotion by alginate lyase, 974
- AmpC β-lactamase, 3296
ampD, 3296
biofilm producing
levofloxacin, in vitro and in vivo activities, 1641
- blaIMP*, 2006
- CAP18, 3269
cefepime-aztreonam
activity against, 1610
- cvsC*, 3173
efflux, 2225
endotoxins released after antibiotic treatment
biological characterization, 1015
- fluoroquinolones, 2956
- gut-derived sepsis, 2853
- interleukin-10, 2853
- levofloxacin
determination of activities by checkerboard and time-kill methodology, 953
in vitro and in vivo activities against biofilm-producing isolates, 1641
synergy, 953
- MexC-MexD-OprJ, 1938
- multidrug efflux pumps
β-lactamase inhibitors, substrates for, 399
expression in multidrug-sensitive *E. coli* strain, 65
novel technique for study of, 395
role in resistance to fatty acid biosynthesis inhibitors, 395
- nfxB* mutants, 1938
- oprM*
antibiotic resistance, contribution to independent of MexAB, 1682
- OXA-19 β-lactamase, 3113
- OXA-20 β-lactamase, 2074
- postantibiotic effect
physical and biochemical characteristics and dynamics, determination by flow cytometry, 1005
- SPI-ARGENT II, 2440
tobramycin postantibiotic effect
dosing interval, relation to duration and clinical relevance, 749
- TonB, 2225
- Pyelonephritis
enterococcal
levofloxacin-rifampin, contrast with in vitro and in vivo results, 188
- Pyrimethamine
P. falciparum
in vitro activity, correlation with point mutations in the dihydrofolate reductase domain, 164
- Pyrrole
BM212, 3035
- M. tuberculosis*, 3035

- ORDR**
- C. jejuni*, 3276
 - C. trachomatis*, 2474
 - Enterobacteriaceae*, 2661
 - gyrA*, 2661
 - gyrase, 2472
 - letter to the editor, 3051
 - mycobacteria, 2084
 - S. epidermidis*, 3293
 - S. flexneri*, 3051
 - topoisomerase IV, 2474
 - viridans streptococci, 2792
- Quantitative structure-activity relationship studies**
- sulfa drugs
 - inhibitors of *P. carinii*, 1454
- Quinapril**
- pharmacokinetics
 - interaction with cephalexin, analysis by a nonlinear mixed-effect model, 1463
- Quinolones**
- antimicrobial effect, prediction of in vitro dynamic model, 659
 - ciprofloxacin, 1923
 - clinafloxacin
 - bacterial isolates from 10 North American centers, activity against, 1274
 - disk diffusion interpretive zone diameter criteria, 1274
 - gram-positive and gram-negative bacteria, activity against, 1269
 - DU-6859a
 - theophylline metabolism, effect on, 1751
 - E. faecalis* resistance
 - alterations in *GyrA* subunit of DNA gyrase and *ParC* subunit of DNA topoisomerase IV, 433
 - gatifloxacin, 1917
 - gestational exposure, pregnancy outcome following
 - multicenter prospective controlled study, 1336
 - grlA*, 2109
 - pharmacokinetics
 - physicochemical properties that regulate penetration, 1412
 - pneumococci
 - postantibiotic effect and postantibiotic sub-MIC effect, comparative evaluation, 1253
 - postantibiotic effect and postantibiotic sub-MIC effect
 - pneumococci, comparative evaluation, 1253
 - S. aureus*, 2109
 - S. aureus* resistance
 - grlA* mutations, analysis of, letter to the editor, 1306
 - mutations in topoisomerase IV and DNA gyrase, effect on, 121
 - S. marcescens* resistance
 - DNA gyrase, mutations in, 190
 - sitafloxacin
 - antibacterial activities, 1284
 - type II topoisomerases, inhibitory effects on, 1284
 - Y-688, 1889
- Quinupristin-dalfopristin**
- combination with doxycycline, 2710
 - E. faecium*, 2188, 2710
 - M. pneumoniae*
- comparative in vitro activity, 698
- postantibiotic effect, 2188, 3028
- S. pneumoniae*
- HMR 3647, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 - release of lipoteichoic and teichoic acids as a result of exposure, 277
 - time-kill curve, 2188
- Radioimmunoassays**
- population pharmacokinetics
 - zalcitabine, 409
- Ranalexin, 3320
- Rebamipide
- H. pylori*, 1889
- Resistance studies**
- bacteremia, bacterial pathogens from frequencies of occurrence and antimicrobial susceptibility patterns, 1762
 - SENTRY antimicrobial surveillance program, 1762
- Respiratory infections**
- H. influenzae*
 - dirithromycin, effect on infection of the respiratory mucosa, 772
 - S. pneumoniae*, penicillin resistant amoxicillin-clavulanate, activity in rat model, 813
- Respiratory pathogens**
- HSR-903
 - in vivo activity, 785
- Reverse transcriptase inhibitors**
- human immunodeficiency virus resistance detection of, rapid method for, 269
 - S-1153, inhibition of replication, 1340
 - 1,1,3-trioxo-2*H*-4*H*-thieno[3,4-*e*][1,2,4]thiadiazine derivatives
 - anti-human immunodeficiency virus activity, 618
- Ribonucleotide reductase inhibitors**
- herpes simplex virus, acyclovir resistant BILD 1633, activity of, 1629
- Rickettsia* spp.
- in vitro susceptibilities
 - 13 antimicrobial agents, 1537
- Rickettsia typhi*
- rifampin resistant
 - rpoB*, point mutations in, 1845
- Rifabutin
- Aspergillus* and *Fusarium* spp.
 - synergy with amphotericin B, 509
- HIV, 2017
- pharmacokinetic interactions with clarithromycin
 - human immunodeficiency virus-infected volunteers, 631
- population pharmacokinetics, 2017
- synergy
- amphotericin B, 509
 - Aspergillus* and *Fusarium* spp., 509
- tolerance
- human immunodeficiency virus-infected volunteers, 631
- Rifalizil
- combination with isoniazid, 3047
 - M. tuberculosis*, 3047
- Rifampin
- brain concentrations, 2626
 - CD1b expression by human peripheral blood monocytes
 - cytokine induced, increase of, 550
 - L. pneumophila*, 3153
- Legionella* spp.
- activity in vitro, 1520
 - letter to the editor, 3334
- M. avium*, 3006
- M. leprae*, 3334
- M. tuberculosis*, 2682
- M. tuberculosis katG*, 2443
- microspheres, 2682
- pyelonephritis, enterococcal
- combination with trovafloxacin, contrast with in vitro and in vivo results, 188
- R. typhi* resistance
- rpoB*, point mutations in, 1845
- S. aureus rpoB*, 2590
- trovafloxacin
- enterococcal pyelonephritis, contrast with in vitro and in vivo results, 188
- Rifamycin**
- M. tuberculosis* resistance
 - rpoB* mutations, contribution to, 1853
- Rifamycins**
- S. pneumoniae*
 - release of lipoteichoic and teichoic acids as a result of exposure, 277
- Rifapentine**
- combination with isoniazid, 3047
 - Legionella* spp.
 - activity in vitro, 1520
 - M. tuberculosis*, 3047
- Ritonavir
- ABT-378, 3218
 - fluoxetine, 3107
 - HIV, 3157
 - HIV protease, 3218
 - human immunodeficiency virus-infected patients, 1788
 - interaction with indinavir, 2784
 - MDRI, 3157
 - MRPI, 3157
 - pharmacokinetics, 3107
 - alone and in combination with zidovudine, 1788
- Roxithromycin**
- cytokine production by and neutrophil attachment to bronchial epithelial cells
 - inhibition of, 1499
- rpoB*
- rifampin resistance, 2590
 - S. aureus*, 2590
- RPR 106972
- M. pneumoniae*
 - comparative in vitro activity, 698
- Rufloxacin
- interaction with theophylline, 2359
- S-1153
- human immunodeficiency virus, drug resistant
 - inhibition of replication, 1340
- S-4661
- in vitro and in vivo activities, 94
- Saccharomyces*
- SPA-S-843, 3012
- Saccharomyces cerevisiae*
- aureobasidin A resistance
 - role of ABC transporters, 755
- dermaseptin s3, 2160
- EF2, 2694
- quinoline-ring containing antimalarial drugs

- resistance genes, identification of, 1034
sordarins, 2694
- Salmonella enterica*
IncF1 plasmid, 3053
IncL/M plasmid, 3053
tetracycline resistance
subsp. *enterica* serovar Dublin, 1288
- Salmonella enteritidis*
DHA-1, 2352
M. morganii ampR, 2352
- Salmonella typhi*
lipopolysaccharide release, antibiotic induced
delay between killing by ceftazidime and imipenem and release, 739
- Salmonella typhimurium*
Caco-2/TC-7 cells, 2950
CTX-M-5, 1980
gentamicin, 2511
glucose metabolism, 2950
glutamine metabolism, 2950
ofloxacin, 2950
- Salvage kinases
E. coli, 2620
- Sanfetinrem
β-lactamases, interaction with
comparison with interactions with imipenem and oral β-lactams, 1168
polymorphonuclear granulocytes, entry into, 1745
prodrugs
sanfetinrem cilexetil, in vivo activities, 1858
- S. pneumoniae*
in vitro activity and affinity for penicillin-binding proteins, 173
- S. pneumoniae*, penicillin resistant intracellular, activity against, 1745
- Sanfetinrem cilexetil
in vivo activities, comparative evaluation, 1858
- Saquinavir
HIV, 3157
MDRI, 3157
MRP1, 3157
- SCH 56592
A. fumigatus, 2467
T. cruzi
antiproliferative effects and mechanism of action, 1771
- Screening
combinatorial chemical libraries
two-dimensional agar format, 1447
- SENTRY antimicrobial surveillance program
bacteremia, bacterial pathogens from frequencies of occurrence and antimicrobial susceptibility patterns, 1762
- Serratia marcescens*
β-lactamases
homologous, sequences of, 176
- bla*_{IMP}, 2006
- DNA gyrase
cloning and nucleotide sequence, 190
mutations in quinolone-resistant isolates, characterization of, 190
- Serum
ceftriaxone concentrations, 2259
- Shigella flexneri*
antimicrobial resistance
Hong Kong, 1986 to 1995, 440
gentamicin
delivery into mammalian cells by *S. flex-*
- neri* membrane vesicles, 1476
gyrase, 3051
letter to the editor, 3051
topoisomerase IV, 3051
- Shigella sonnei*
antimicrobial resistance
Hong Kong, 1986 to 1995, 440
- Silver
SPI-ARGENT II, 2440
- Single-strand conformation polymorphism-PCR
β-lactamases, inhibitor resistant discriminatory detection, 879
- SPII 1029
T. brucei, 2718
- Sitafoxacin
antibacterial activities, 1284
type II topoisomerases
inhibitory effects on, 1284
- Sodium stibogluconate
L. donovani, 2722
L. tarentolae resistance
gene amplification, 1689
versus amphotericin B, 2722
- Sordarins
Candida, 2274, 2279
fungi, 2863
P. carinii, 2863
S. cerevisiae EF2, 2694
yeasts, 2863
- Sorivudine
dermatomal herpes zoster
acyclovir, comparative evaluation, 1139
human immunodeficiency virus-infected patients, 1139
- South Africa
Enterococcus, 2752
- soxS
E. coli, 2089
fluoroquinolone resistance, 2089
- Spain
P. gingivalis, 3022
P. intermedia, 3022
P. nigrescens, 3022
- Sparfloxacin
M. hominis, 2304
P-glycoprotein, 2607
- pharmacokinetics
chondrotoxicity and toxicokinetics in juvenile rats, 1470
physicochemical properties that regulate penetration of quinolones, 1412
serum and vitreous humor in rabbits, 1417
- photodegradation
defluorinated sparfloxacin as a photoproduct, 1151
liquid chromatography coupled with UV detection and tandem mass spectrometry, 1151
- S. pneumoniae*, 2193
secretion from Caco-2 cells, 2607
urinary tract infection, 2262
- SPA-S-843
Candida, 3012
Cryptococcus, 3012
Saccharomyces, 3012
versus amphotericin B, 3012
- SPI-ARGENT II
C. albicans, 2440
E. coli, 2440
P. aeruginosa, 2440
- S. aureus*, 2440
silver, 2440
- Spiramycin
S. ambofaciens *gimA*, 2612
- St. Petersburg
M. tuberculosis, 2443
- Staphylococcus*
co-trimoxazole, 3086
orthopedic implants, 3086
- Staphylococcus aureus*
alpha-toxin, 2817
ampicillin-subactam, 3325
antibiotic susceptibility
increase overall in *femAB* null mutants, 936
azithromycin
postantibiotic and sub-MIC effects, 414
cefazolin, 2449
ciprofloxacin sensitive, 3325
co-amoxiclav
in vitro activities at concentrations achieved in human serum, 1574
coumarins, 2109
- DNA gyrase
mutations in, novel pleiotropic effects on quinolone and coumarin activity, 121
- endocarditis
trovalfoxacin, 1837
trovalfoxacin, efficacy of, 254
endocarditis, aortic valve
lysostaphin, treatment of experimental infection, 1335
- eperezolid and linezolid
comparative activity and postantibiotic effect, 721
- eperezolid resistance
conferred by ribosomes from an oxazolidinone-resistant mutant, 947
- erythromycin, 3024
- femAB* null mutants
increased overall antibiotic susceptibility, 936
- fluoroquinolone and methicillin resistant letter to the editor, 727
selection with ciprofloxacin and trovafloxacin, 727
- fluoroquinolone resistance, 3317
- fluoroquinolone resistant, methicillin susceptible and resistant
topoisomerase mutations, 197
- gatifloxacin, 1917
- grlA*, 2109
- grlA*, *grlB*, *gyrA*, and *gyrB* mutations
characterization of and effect on ciprofloxacin MIC, 1249
- grlA* and *gyrA*
mutations in, detection in 344 strains, 236
- GrlB*, 3044
- isepramycin
postantibiotic and sub-MIC effects, 414
joint prostheses, 2830
- linezolid, 3251
- lipotichoic acid, 3073
- LY333328, 2427
- lysostaphin
aortic valve endocarditis, treatment of, 1335
- mec* element, introduction of
alteration of in vitro functional activities of fibrinogen and fibronectin adhesins, 564

- methicillin, 2817
 postantibiotic effect, flow cytometric assessment of, 1195
 methicillin resistance, 3317
 methicillin resistant, 3325
 LY333328, efficacy against, 981
mecA and *mecI*, diversity of mutations, analysis of, 717
 triazone dye cibacron blue F3GA decreases oxacillin resistance, 1278
 C-8-methoxy fluoroquinolones killing by, 956
 MK-826, 1996
 multidrug efflux pump
 QacA, comparative analysis of resistance to diamidines, biguanides, and guanylhydrazones, 475
 mupirocin resistant
 characterization of isolates from different geographic areas, letter to the editor, 1305
norA, 1917, 3317
 OPC-20011, 2943
 osteomyelitis
 prophylaxis with absorbable, ofloxacin-impregnated beads, 840
 oxacillin resistant
 trovafloxacin, activity in experimental endocarditis, 1837
 oxazolidinone resistance
 biochemical basis and mechanism of action, 947
 peptidoglycan, 3073
 PGG-glucan, 2449
 platelets, 3169
 quinolone resistant
 $gyrA$ mutations, analysis of, letter to the editor, 1306
 quinolones, 2109
 rifampin, 2590
rpoB, 2590
 SPI-ARGENT II, 2440
 teicoplanin, 2830
 tobramycin postantibiotic effect
 dosing interval, relation to duration and clinical relevance, 749
 topoisomerase, 2109, 2122
 topoisomerase IV
 mutations in, novel pleiotropic effects on quinolone and coumarin activity, 121
 trovafloxacin, 2122, 3325
 experimental endocarditis, efficacy of, 254
 type B β -lactamase, 3163
 vancomycin, 3325
 vancomycin pharmacodynamics, 2739
 Y-688, 1889
Staphylococcus epidermidis
 biofilm formation
 antibiotic activity in vitro and in vivo, impact on, 895
 cefazolin, 2449
 methicillin resistant
 mecA and *mecI*, diversity of mutations, analysis of, 717
 PGG-glucan, 2449
 QRDR, 3293
 slime production
 effect on activities of various agents, 939
 vancomycin pharmacodynamics, 2739
- Staphylococcus* spp.
 coagulase negative
 eperezolid and linezolid, comparative activity and postantibiotic effect, 721
 slime production, effect on activities of various agents, 939
 coagulase negative, methicillin resistant decreased susceptibilities to teicoplanin and vancomycin, 100
 mecA and *gyrA*, chromosomal relationship, 306
 streptogramin A and B resistance plasmid carrying two resistance genes, characterization of, 1788
 trovafloxacin
 postantibiotic effect, 1503
 Stavudine
 bioavailability, 2295
 effect of food, 2295
 HIV, 2295
Stenotrophomonas maltophilia
 cephalosporins, 2002
 gentamicin, 2002
 metallo- β -lactamase L-1
 molecular heterogeneity, 1245
 overexpression, purification, and characterization, 921
 quinolones, 2002
 Stepwise mutations
 S. aureus NorA, 3317
 Sterol methyltransferase genes
 C. albicans
 sequencing, disruption, and characterization, 1160
Streptococcus mutans
 bioluminescence, 1906
Streptococcus pneumoniae
 acute otitis media
 antimicrobial-resistant pathogens in middle ear fluid, prevalence of, 589
 amoxicillin, 2375
 amoxicillin-clavulanate, 2375, 3193
 azithromycin, 2914, 3193
 β -lactams, 1973, 2914
 biofilms, 2521
 cefodizime, 2527
 cefotaxime, 2768
 bactericidal activity, letter to the editor, 1869
 ceftizoxime
 bactericidal activity, letter to the editor, 1869
 cephalosporin resistant, 2650
 clarithromycin, 3193
 clinafloxacin, 2810
 clindamycin
 HMR 3647, quinupristin-dalfopristin, and erythromycin, comparative activities of and cross-resistance to, 945
 erythromycin, 2312, 3193
 quinupristin-dalfopristin, HMR 3647, and clindamycin, comparative activities of and cross-resistance to, 945
 fluoroquinolones, 2032, 2956
 gatifloxacin pharmacodynamics, 2650
 grepafloxacin
 in vitro activity, comparative evaluation, 1263
 $gyrA$, 2193
 gyrase, 2810
- HMR 3004, 3309
 HMR 3004 (RU 64004)
 German isolates, activity against, 1509
 HMR 3647 (RU 66647)
 German isolates, activity against, 1509
 quinupristin-dalfopristin, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 interaction with *M. catarrhalis*, 2521
 meningitis
 moxifloxacin, activity, 1397
 MLS resistance, 2312, 2425
 OPC-20011, 2943
 otitis media, acute
 amoxicillin versus cefuroxime, 1361
parC, 2193
 PBP 1A, 2262
 penicillin resistance, high level
 penicillin-binding protein 1A, alterations in responsible for, 1329
 penicillin, resistant
 acute otitis media, amoxicillin versus cefuroxime, 1361
 amoxicillin-clavulanate, activity in rat respiratory infection model, 813
 meropenem, imipenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
 penicillin-resistant, intracellular sanfetrinem, activity against, 1745
 penicillin susceptible and resistant CS-834, treatment of experimental pneumonia, 23
 trovafloxacin, efficacy in mouse pneumonia model, 862
 penicillin-binding protein 1A
 high-level penicillin resistance, alterations responsible for, 1329
 quinupristin-dalfopristin
 HMR 3647, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 release of lipoteichoic and teichoic acids drug exposure, result of, 277
 sanfetrinem
 in vitro activity and affinity for penicillin-binding proteins, 173
 sparfloxacin, 2193
 susceptibilities in China, 2633
 Thr-371, 2267
 Tn917, 2312
 topoisomerase IV, 2810
 trovafloxacin
 efficacy in mouse pneumonia model, 862
 synergistic activity with ceftriaxone or vancomycin, letter to the editor, 991
Streptococcus pyogenes
 CD15s-related antigen expression
 reduction of after treatment with fosfomycin, 1083
 erythromycin resistance
 novel methylase gene (*ermTR*), 257
 erythromycin resistant, clindamycin susceptible isolates
 emergence in Madrid, letter to the editor, 989
 fosfomycin
 CD15s-related antigen expression, reduction of, 1083
 penicillin-clindamycin

- in vitro activity by E test, broth microdilution, and time-kill studies, 1266
- pharyngitis**
cefdinir treatment, 5 day, 1073
- sulfonamide resistance**
chromosomal dihydropteroate synthase, differences in amino acid sequence, 1062
- Streptococcus spp.**
group B
susceptibilities of isolates from patients with bacteremia or meningitis, 1517
- group C and G
erythromycin resistance mechanisms, analysis of different, 1493
- HMR 3004 (RU 64004)
activity against strains inducibly resistant to erythromycin, 1392
- Streptogramins**
RPR 106972
M. pneumoniae, comparative in vitro activity, 698
- staphylococcal resistance
plasmid carrying two resistance genes, characterization of, 1788
- Streptomyces ambofaciens**
ginA, 2612
glycosyl transferase inactivation, 2612
- spiramycin**, 2612
- Streptomyces rimosus**
letter to the editor, 3050
- OtrB, 3050
- Tet347, 3050
- tetracycline efflux, 3050
- Streptomyces virginiae**
virginiamycin M₁ reductase, 2985
- Streptomycin**
biosynthesis, 2041
- Sulbactam**
combinations
ampicillin, pharmacodynamics in in vitro infection model, 231
- pharmacodynamics
with ampicillin, in vitro infection model against resistant *E. coli*, 231
- PSE-4, 2319
- Sulbenicillin**
pharmacokinetics
stereoselective disposition in humans, 325
- stereoselective disposition
humans, 325
- Sulfa drugs**
P. carinii
quantitative structure-activity relationship studies, 1454
- Sulfadoxine-pyrimethamine**
P. falciparum resistance
molecular basis for, 1811
- Sulfamethoxypyridazine**
P. carinii pneumonia
efficacy in murine model, 934
- Sulfanilyl fluoroquinolones**
mode of action, 1495
- Sulfathiazole**
E. coli resistance
mutations contributing to, characterization of, 88
- Sulfonamides**
S. pyogenes resistance
chromosomal dihydropteroate synthase, differences in amino acid sequence, 1062
- Susceptibility testing
ATP-bioluminescence method
novel test using filamentous cell treatment, 1406
- C. fetus* subsp. *fetus*, 1847
- clinafloxacin**
disk diffusion interpretive zone diameter criteria, 1274
- continuous-biofilm system
G. vaginalis, 1428
L. acidophilus, 1428
- G. vaginalis*
continuous-culture biofilm system, 1428
- L. acidophilus*
continuous-culture biofilm system, 1428
- LY303366
endpoints, evaluation of, 1387
- U. urealyticum*
neonatal respiratory isolates, 1290
- TAK-187**
C. neoformans, 2630
- Tazobactam**
PSE-4, 2319
- Teicoplanin**
S. aureus, 2830
versus LY333328, 2452
- TEM-21**
M. morganii, 2125
- TEM-41**
letter to the editor, 2771
- TEM-61** β -lactamase
letter to the editor, 3329
- Temacrazine**
human immunodeficiency virus type I
selective inhibition of replication, 487
- Terbinafine**
C. albicans
in vitro activities, 1057
pathogenic yeasts
in vitro activities, 1057
- Tet(M)**
tetracycline resistance
host mutations reduce resistance, 59
- Tet(O)**
tetracycline resistance
host mutations reduce resistance, 59
- Tetanus**
new pasteurized immunoglobulin
safety and pharmacokinetic profile, 298
- Tetracycline**
C. jejuni, 2106
efflux, 3050
letter to the editor, 3050
- N. gonorrhoeae penB*, 2799
- P. multocida* Tn5706, 2116
- resistance in *M. smegmatis*, 1931
- resistance, Tet(O) mediated
host mutations reduce resistance, 59
- S. rimosus* OtrB, 3050
- Tetracyclines**
resistance in a gram-positive bacterium
16S rRNA mutation, association with, 1702
- S. enterica* subsp. *enterica* serovar Dublin
resistance in, 1288
- Thalassemia**
artesunate, 2332
- P. falciparum*, 2332
- Theophylline**
DU-6859a
- metabolism, effect on**, 1751
- interaction with rufloxacin**, 2359
- pharmacokinetics**, 2359
- terbinafine, effect on in healthy volunteers**, 695
- Thiamphenicol**
rickettsiae
in vitro susceptibilities, 1537
- Thiazolidines**
H. pylori, 2836
nitazoxanide, 2836
- Thiolactomycin**
P. aeruginosa resistance
role of efflux systems, novel technique for study, 395
- Thymidine kinase**
acyclovir, 2923
- Epstein-Barr virus, 2923
- ganciclovir, 2923
- herpes simplex virus, 2923
- Time-kill curve**
E. faecium, 2188
quinupristin-dalfopristin, 2188
- Time-kill studies**
antifungal
influence of test conditions on results, 1207
- grepafloxacin
antipseudomococcal activity, comparative evaluation, 1263
- penicillin-clindamycin
S. pyogenes, antimicrobial effect, 1266
- Tn916
minireview, 1871
- Tn5706
P. multocida, 2116
tetracycline, 2116
- TNF- α**
M. avium, 2336
- Tobramycin**
pharmacokinetics
MIC changes alter responses of *P. aeruginosa*, 1365
postantibiotic effect
dosing interval, relation to duration and clinical relevance, 749
- TonB**
P. aeruginosa, 2225
- Topoisomerase**
grlA, 2109
S. aureus, 2109, 2122
- Topoisomerase II**
gatifloxacin, 2678
HeLa cells, 2678
- Topoisomerase IV**
C. trachomatis, 2474
clinafloxacin, 2810
gatifloxacin, 2678
letter to the editor, 3051
- M. hominis*, 2024, 2304
- parC*, 2024
- parE*, 2024
- QRDR, 2474
- S. aureus*, 2678
- S. aureus* GrIb, 3044
- S. flexneri*, 3051
- S. pneumoniae*, 2810
- Topoisomerases**
E. faecalis resistance
alterations in ParC subunit, association with, 433
- inhibitors
rapid throughput in vivo screen for, 889

- S. aureus*
mutations, novel pleiotropic effects on quinolone and coumarin activity, 121
S. aureus, fluoroquinolone resistant, methicillin susceptible and resistant mutations, 197
type II
 sulfloxacin, inhibitory effects on, 1284
- Tosufloxacin
pharmacokinetics
 aluminum hydroxide and famotidine, effects on bioavailability, 453
- Toxicity
 sparfloxacin
 chondrotoxicity and toxicokinetics in juvenile rats, 1470
- Toxocariasis
 ivermectin, 2770
 letter to the editor, 2770
- Toxoplasma gondii*
encephalitis
 trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine, 1346
- NSC 113452, 2284
NSC 113455, 2284
paclitaxel, 2032
triple infection with *P. carinii* and *M. avium* in rat model
drug evaluation, 1068
- Transcription termination factor Rho
bicyclomycin
 effects on RNA- and ATP-binding activities, 571
- Transplant patients
 amphotericin B nephrotoxicity, 3103
- Triazine dyes
 cibacron blue F3GA
 reduction of oxacillin resistance in methicillin-resistant *S. aureus*, 1278
- Triazines
 SIP 1029, 2718
 T. brucei, 2718
- Triazoles
 A. fumigatus, 2467
 BMS-207147
 in vitro activity, 313
 C. neoformans, 2630
 D0870
 pharmacokinetics of two multiple-dosing regimens in human immunodeficiency virus-positive patients, 903
- SCH 56592
 T. cruzi, antiproliferative effects and mechanism of action, 1771
- SCH56592, 2467
TAK-187, 2630
- Trimethoprim
 C. jejuni dfr, 3059
 dihydrofolate reductase, 2221
- Trimethoprim-sulfamethoxazole
toxoplasmic encephalitis
 patients with AIDS, randomized trial, 1346
 pyrimethamine-sulfadiazine, comparative evaluation, 1346
- 1,1,3-Trioxo-2*H,4H*-thieno[3,4-*c*][1,2,4]thiadiazine (TTD) derivatives
anti-human immunodeficiency virus activity, 618
- Trovafloxacin
 B. parapertussis
 susceptibilities to, letter to the editor, 1868
- B. pertussis*
susceptibilities to, letter to the editor, 1868
- C. burnetti*, 2747
combination with gentamicin, 2002
combinations with cephalosporins, 2002
cytokine production by human monocytes effect on, 1713
endocarditis
 S. aureus, oxacillin resistant, activity against, 1837
- enterococci
 activity in an in vitro dynamic model of infection, 72
- pharmacodynamics
 in vitro dynamic model of infection, 72
pharmacokinetics, 2048, 2841
postantibiotic effect
 gram-positive and -negative organisms, 1503
- pyelonephritis, enterococcal
 combination with rifampin, contrast with in vitro and in vivo results, 188
- rifampin
 enterococcal pyelonephritis, contrast with in vitro and in vivo results, 188
- S. aureus*, 2122, 3325
S. aureus endocarditis
 experimental, efficacy of, 254
S. aureus, oxacillin resistant
 endocarditis, 1837
- S. maltophilia*, 2002
- S. pneumoniae*
 release of lipoteichoic acid as a result of exposure, 277
 synergistic activity with ceftriaxone or vancomycin, letter to the editor, 991
- S. pneumoniae*, penicillin susceptible and multiresistant
 efficacy in mouse pneumonia model, 862
- topoisomerase, 2122
- Trybizine hydrochloride
trypanosomes, 2858
- Trychophyton* spp.
NND-502
 lanoconazole and terbinfine, comparative evaluation, 967
- Trypanosoma brucei*
 megalomicin, 2668
 SIP 1029, 2718
- Trypanosoma cruzi*
 azole resistance, 3245
 benznidazole, 2549
 IL-12, 2549
 megalomicin, 2668
 SCH 56592
 antiproliferative effects and mechanism of action, 1771
- Trypanosomes
 trybizine hydrochloride, 2858
- Trypanosomiasis
 isometamidium, sustained-release device prophylactic effect, 1012
- Turkey
 P. aeruginosa ONA-16, 3117
- Two-component signal transduction
target for microbial anti-infective therapy minireview, 1529
- TXU (anti-CD7)- pokeweed antiviral protein human immunodeficiency virus type I potent inhibition, comparative evaluation, 383
- U937 cells
 uptake of *L. pneumophila*, 2870
- Ureaplasma urealyticum*
susceptibility testing
 neonatal respiratory isolates, 1290
- Urinary tract infection
community acquired, 2262
ofloxacin, 2262
sparfloxacin, 2262
- Valaciclovir
herpes simplex virus type I
latency, prevention of, quantitative comparison with famciclovir, 1555
- Valproic acid
3'-azido-3'-deoxythymidine
 glucuronidation by human liver microsomes, inhibition by, 1592
- panipenem, 3136
- pharmacokinetics
 zidovudine, glucuronidation by human liver microsomes, inhibition by, 1592
- VanA
glycopeptide resistance elements
 diversity, human and nonhuman sources, 502
- vanB
glycopeptide resistance
 E. faecium, transferable, plasmid mediated, 963
- Vancomycin
 B. cirulans, 2055
combinations
 ciprofloxacin, prophylaxis in bone marrow transplant recipients, 1402
- E. faecium*, 2150, 2564, 2710
- E. faecium* resistance
characterization of isolates from United States, 1088
dallopristin-quinupristin susceptibility in vitro, 1088
- enterococci, 2215
- Enterococcus* resistance
 van genes, DNA sequence variation, 202
- glycopeptides, 2215
- historical yearly usage
 letter to the editor, 1303
letter to the editor, 2463
- LY333328, 2564
- orthopedic implants, 3002
- pharmacodynamics, 2739
- resistant enterococci, 2463
- S. aureus*, 2739, 3325
- S. epidermidis*, 2739
- versus LY333328, 2452
- Varicella-zoster virus
A-5021, 2095
- acyclovir
 human immunodeficiency virus-infected patients, 1139
- sorivudine, comparative evaluation, 1139
- sorivudine
 acyclovir, comparative evaluation, 1139
 human immunodeficiency virus-infected patients, 1139

- Venovenous hemofiltration
meropenem, 2417
- Ventriculostomy
meropenem, 2012
- Vibrio cholerae*
fluoroquinolone resistance
letter to the editor, 206
patients with acute diarrhea in Calcutta,
India, 206
- Vibrio parahaemolyticus*
NorM multidrug efflux protein
cloning and sequencing, 1778
- Virginiamycin M₁
S. virginiae reductase, 2985
- Viridans streptococci
ciprofloxacin, 2792
QRDR, 2792
- Voriconazole
A. fungatus, 2299
Aspergillus, 3018
C. albicans
neutrophils or monocytes, combination
with, 907
C. neoformans, fluconazole susceptible
and resistant
- comparative efficacy, itraconazole, 471
Candida, 3018
Candida spp.
comparative in vitro activities, 161
G-CSF, 2299
GM-CSF, 2299
in combination with monocytes, 2299
in combination with neutrophils, 2299
neutrophils or monocytes, combination with
C. albicans, 907
versus amphotericin B, 3018
versus itraconazole, 3018
- Woodchucks
hepatitis B virus, 3209
- WR 238605
P. falciparum malaria
prophylaxis in a human challenge
model, 1293
- Y-688
anaerobic bacteria
in vitro activities, 419
S. aureus, 1889
- Yeast
terbinafine
- in vitro activities, 1057
- Yersinia enterocolitica*
amikacin, 3009
ceftriaxone, 3009
ciprofloxacin, 3009
O9, 3009
- Yersinia pestis*
pneumonic plague, experimental
antibiotic treatments, comparative eval-
uation, 675
- Zalcitabine
pharmacokinetics, 2174
application of radioimmunoassay to
population pharmacokinetics, 409
- Zidovudine
foscarnet coresistance, 3038
HIV, 3038
pharmacokinetics
premature infants exposed to human
immunodeficiency virus, 808
- Zinc-finger-active drugs
G. lamblia
efficacy of, 1488

